

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

23 December 2021 (23.12.2021)



(10) International Publication Number

WO 2021/255263 A3

(51) International Patent Classification:

C12Q 1/6813 (2018.01)

(21) International Application Number:

PCT/EP2021/066668

(22) International Filing Date:

18 June 2021 (18.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2020/067010

18 June 2020 (18.06.2020) EP

63/127,910 18 December 2020 (18.12.2020) US

63/129,942 23 December 2020 (23.12.2020) US

(71) Applicant: **RESOLVE BIOSCIENCES GMBH**

[DE/DE]; Alfred-Nobel-Str. 10, 40789 Monheim am Rhein (DE).

(72) Inventors: **GEIPEL, Andreas**; Weimarer Str. 47, 40822

Mettmann (DE). **REINECKE, Frank**; Heidehang 9, 45134

Essen (DE). **KORFHAGE, Christian**; Sepp-Herberger Str.

6c, 40764 Langenfeld (DE).

(74) Agent: **ROTH, Andy Stefan**; Kaistr. 5, 40221 Düsseldorf

(DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MULTIPLEX METHOD FOR DETECTING DIFFERENT ANALYTES AND DIFFERENT SUBGROUPS/VARIATIONS OF AN ANALYTE IN A SAMPLE

(57) Abstract: The technology provided herein relates to multiplex methods and kits for detecting different analytes and different subgroups/variations of an analyte in a sample, as well as in vitro methods for screening, identifying and/or testing a substance and/or drug and in vitro methods for diagnosis of a disease, and an optical multiplexing system.



WO 2021/255263 A3

MULTIPLEX METHOD FOR DETECTING DIFFERENT ANALYTES AND DIFFERENT SUBGROUPS/VARIATIONS OF AN ANALYTE IN A SAMPLE

FIELD OF THE DISCLOSURE

5 The technology provided herein relates to multiplex methods and kits for detecting different analytes and different subgroups/variations of an analyte in a sample in parallel by sequential signal-encoding of said analytes, as well as *in vitro* methods for screening, identifying and/or testing a substance and/or drug and *in vitro* methods for diagnosis of a disease, and an optical multiplexing system.

10

BACKGROUND

The analysis and detection of small quantities of analytes in biological and non-biological samples has become a routine practice in the clinical and analytical environment. Numerous analytical methods have been established for this purpose. Some of them use encoding techniques assigning a particular
15 readable code to a specific first analyte which differs from a code assigned to a specific second analyte.

One of the prior art techniques in this field is the so-called 'single molecule fluorescence in situ hybridization' (smFISH) essentially developed to detect mRNA molecules in a sample. In Lubeck et al. (2014), Single-cell in situ RNA profiling by sequential hybridization, Nat. Methods 11(4), p. 360-361, the
20 mRNAs of interest are detected via specific directly labeled probe sets. After one round of hybridization and detection, the set of mRNA specific probes is eluted from the mRNAs and the same set of probes with other (or the same) fluorescent labels is used in the next round of hybridization and imaging to generate gene specific color-code schemes over several rounds. The technology needs several differently tagged probe sets per transcript and needs to denature these probe sets after every
25 detection round.

A further development of this technology does not use directly labeled probe sets. Instead, the oligonucleotides of the probe sets provide nucleic acid sequences that serve as initiator for hybridization chain reactions (HCR), a technology that enables signal amplification; see Shah et al.
30 (2016), In situ transcription profiling of single cells reveals spatial organization of cells in the mouse hippocampus, Neuron 92(2), p. 342-357.

Another technique referred to as 'multiplexed error robust fluorescence in situ hybridization' (merFISH) is described by Chen et al. (2015), RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells, *Science* 348(6233):aaa6090. There, the mRNAs of interest are detected via specific probe sets that provide additional sequence elements for the subsequent specific hybridization of fluorescently labeled oligonucleotides. Each probe set provides four different sequence elements out of a total of 16 sequence elements. After hybridization of the specific probe sets to the mRNAs of interest, the so-called readout hybridizations are performed. In each readout hybridization one out of the 16 fluorescently labeled oligonucleotides complementary to one of the sequence elements is hybridized. All readout oligonucleotides use the same fluorescent color. After imaging, the fluorescent signals are destroyed via illumination and the next round of readout hybridization takes place without a denaturing step. As a result, a binary code is generated for each mRNA species. A unique signal signature of 4 signals in 16 rounds is created using only a single hybridization round for binding of specific probe sets to the mRNAs of interest, followed by 16 rounds of hybridization of readout oligonucleotides labeled by a single fluorescence color.

A further development of this technology improves the throughput by using two different fluorescent colors, eliminating the signals via disulfide cleavage between the readout-oligonucleotides and the fluorescent label and an alternative hybridization buffer; see Moffitt et al. (2016), High-throughput single-cell gene-expression profiling with multiplexed error-robust fluorescence in situ hybridization, *Proc. Natl. Acad. Sci. U S A.* 113(39), p. 11046-11051.

A technology referred to as 'intron seqFISH' is described in Shah et al. (2018), Dynamics and spatial genomics of the nascent transcriptome by intron seqFISH, *Cell* 117(2), p. 363-376. There, the mRNAs of interest are detected via specific probe sets that provide additional sequence elements for the subsequent specific hybridization of fluorescently labeled oligonucleotides. Each probe set provides one out of 12 possible sequence elements (representing the 12 'pseudo colors' used) per color-coding round. Each color-coding round consists of four serial hybridizations. In each of these serial hybridizations, three readout probes, each labeled with a different fluorophore, are hybridized to the corresponding elements of the mRNA-specific probe sets. After imaging, the readout probes are stripped off by a 55% formamide buffer and the next hybridization follows. After 5 color-coding rounds with 4 serial hybridizations each, the color-codes are completed.

EP 0 611 828 discloses the use of a bridging element to recruit a signal generating element to probes that specifically bind to an analyte. A more specific statement describes the detection of nucleic acids via specific probes that recruit a bridging nucleic acid molecule. This bridging nucleic acids eventually recruit signal generating nucleic acids. This document also describes the use of a bridging element with more than one binding site for the signal generating element for signal amplification like branched DNA.

Player et al. (2001), Single-copy gene detection using branched DNA (bDNA) in situ hybridization, J. Histochem. Cytochem. 49(5), p. 603-611, describe a method where the nucleic acids of interest are detected via specific probe sets providing an additional sequence element. In a second step, a preamplifier oligonucleotide is hybridized to this sequence element. This preamplifier oligonucleotide comprises multiple binding sites for amplifier oligonucleotides that are hybridized in a subsequent step. These amplifier oligonucleotides provide multiple sequence elements for the labeled oligonucleotides. This way a branched oligonucleotide tree is build up that leads to an amplification of the signal.

A further development of this method referred to as is described by Wang et al. (2012), RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues, J. Mol. Diagn. 14(1), p.22-29, which uses another design of the mRNA-specific probes. Here two of the mRNA-specific oligonucleotides have to hybridize in close proximity to provide a sequence that can recruit the preamplifier oligonucleotide. This way the specificity of the method is increased by reducing the number of false positive signals.

Choi et al. (2010), Programmable in situ amplification for multiplexed imaging of mRNA expression, Nat. Biotechnol. 28(11), p. 1208-1212, disclose a method known as 'HCR-hybridization chain reaction'. The mRNAs of interest are detected via specific probe sets that provide an additional sequence element. The additional sequence element is an initiator sequence to start the hybridization chain reaction. Basically, the hybridization chain reaction is based on metastable oligonucleotide hairpins that self-assemble into polymers after a first hairpin is opened via the initiator sequence.

A further development of the technology uses so called split initiator probes that have to hybridize in close proximity to form the initiator sequence for HCR, similarly to the RNAscope technology, this

reduces the number of false positive signals; see Choi et al. (2018), Third-generation in situ hybridization chain reaction: multiplexed, quantitative, sensitive, versatile, robust. Development 145(12).

- 5 Mateo et al. (2019), Visualizing DNA folding and RNA in embryos at single-cell resolution, Nature Vol, 568, p. 49ff., disclose a method called 'optical reconstruction of chromatin structure (ORCA). This method is intended to make the chromosome line visible.

10 EP 2 992 115 B1 describes a method of sequential single molecule hybridization and provides technologies for detecting and/or quantifying nucleic acids in cells, tissues, organs or organisms through sequential barcoding.

The methods known in the art, however, have numerous disadvantages. In particular, they are inflexible, expensive, complex, time consuming and quite often provide non-accurate results. In particular, the encoding capacities of the existing methods are low and do not meet the requirements of modern molecular biology and medicine.

Against this background, it is an object underlying the present disclosure to provide a method by means of which the disadvantages of the prior art methods can be reduced or even avoided.

20

SUMMARY OF THE DISCLOSURE

25 The present disclosure pertains to novel multiplex method for detecting different analytes and different subgroups/variations of an analyte in a sample in parallel by sequential signal-encoding of said analytes and variations.

In particular, the present disclosure pertains multiplex method for detecting different analytes and different subgroups/variations of an analyte in a sample comprising:

30

(A) contacting the sample with at least twenty (20) different sets of analyte-specific probes for encoding of at least 20 different analytes, each set of analyte-specific probes interacting with a

different analyte, wherein if the analyte is a nucleic acid each set of analyte-specific probes comprises at least five (5) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each analyte-specific probe comprising

(aa) a binding element (S) that specifically interacts with one of the different analytes to be encoded,
5 and

(bb) an identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

wherein the analyte-specific probes of a particular set of analyte-specific probes differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the
10 identifier element (T),

wherein the analyte-specific probes in each set of analyte-specific probes binds to the same analyte and comprises the same nucleotide sequence of the identifier element (T) which is unique to said analyte; and

contacting the sample with at least two different sets of analyte-specific probes for at least one analyte
15 and a variation thereof,

wherein the analyte-specific probes comprised in these different sets interacting with the same analyte, but specifically interact with different sub-structures of the same analyte,

wherein the analyte-specific probes of the first set of analyte-specific probes interacts with a sub-structure which is comprised in all variations of an analyte,

20 wherein the analyte-specific probes of the second set of analyte-specific probes (subgroup-specific probes) interacts with a sub-structure which is comprised only in a specific variation of the analyte,

wherein the analyte-specific probes of the first set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence), and

25 wherein the analyte-specific probes of the second set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

wherein the identifier elements (T) of the analyte-specific probes of the first set of analyte-specific probes and the identifier elements (T) of the analyte-specific probes of the second set of analyte-specific probes are different for binding different decoding oligonucleotides and/or non-signal decoding oligonucleotides.

5

(B) contacting the sample with at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding oligonucleotides for an individual analyte each decoding oligonucleotide comprises:

10 (aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

(bb) a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

15 wherein the decoding oligonucleotides of a set for an individual analyte differ from the decoding oligonucleotides of another set for a different analyte in the first connect element (t); and

(C) contacting the sample with at least a set of signal oligonucleotides, each signal oligonucleotide comprising:

20 (aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide, and

(bb) a signal element.

(D) Detecting the signal caused by the signal element;

25 (E) selectively removing the decoding oligonucleotides and signal oligonucleotides from the sample, thereby essentially maintaining the specific binding of the analyte-specific probes to the analytes to be encoded;

(F) Performing at least three (3) further cycles comprising steps B) to E) to generate an encoding scheme with a codeword per analyte,

(G) Performing at least one (1) further cycle comprising steps B) to E) to identify the subgroup-specific probes, wherein in particular the cycle may stop with step (D).

Furthermore, the present disclosure pertains to the use of improved decoding-oligonucleotides to increase the efficiency of the encoding scheme. The so called "multi-decoders" allows the recruiting of more than just one signal oligonucleotide and therefore can generate new signal types by utilizing the combination of two or more different signal-oligonucleotides without decreasing the brightness of the signals.

In a further aspect, embodiments of the disclosure in particular to a multiplex method for detecting different analytes in a sample by sequential signal-encoding of said analytes, comprising:

(A) contacting the sample with at least twenty (20) different sets of analyte-specific probes for encoding of at least 20 different analytes, each set of analyte-specific probes interacting with a different analyte, wherein if the analyte is a nucleic acid each set of analyte-specific probes comprises at least five (5) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each analyte-specific probe comprising

(aa) a binding element (S) that specifically interacts with one of the different analytes to be encoded, and

(bb) an identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

wherein the analyte-specific probes of a particular set of analyte-specific probes differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T),

wherein the analyte-specific probes in each set of analyte-specific probes binds to the same analyte and comprises the same nucleotide sequence of the identifier element (T) which is unique to said analyte; and

(B) contacting the sample with at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding oligonucleotides for an individual analyte each decoding oligonucleotide comprises:

(aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

(bb) a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

wherein the decoding oligonucleotides of a set for an individual analyte differ from the decoding oligonucleotides of another set for a different analyte in the first connect element (t); and

5 (C) contacting the sample with at least a set of signal oligonucleotides, each signal oligonucleotide comprising:

(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide, and

10 (bb) a signal element.

(D) Detecting the signal caused by the signal element;

(E) selectively removing the decoding oligonucleotides and signal oligonucleotides from the sample, thereby essentially maintaining the specific binding of the analyte-specific probes to the analytes to be encoded;

15 (F) Performing at least three (3) further cycles comprising steps B) to E) to generate an encoding scheme with a codeword per analyte, wherein in particular the last cycle may stop with step (D).

In a further aspect, embodiments of this disclosure relate to kits for multiplex analyte encoding, comprising

20 (A) at least twenty (20) different sets of analyte-specific probes for encoding of at least 20 different analytes, each set of analyte-specific probes interacting with a different analyte, wherein if the analyte is a nucleic acid each set of analyte-specific probes comprises at least five (5) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each analyte-specific probe comprising

25 (aa) a binding element (S) that specifically interacts with one of the different analytes to be encoded, and

(bb) an identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

30 wherein the analyte-specific probes of a particular set of analyte-specific probes differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T),

wherein the analyte-specific probes in each set of analyte-specific probes binds to the same analyte and comprises the same nucleotide sequence of the identifier element (T) which is unique to said analyte; and

(B) at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding oligonucleotides for an individual analyte each decoding oligonucleotide comprises:

(aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

(bb) a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

wherein the decoding oligonucleotides of a set for an individual analyte differ from the decoding oligonucleotides of another set for a different analyte in the identifier connect element (t); and

(C) a set of signal oligonucleotides, each signal oligonucleotide comprising:

(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide, and

(bb) a signal element.

In a further aspect, embodiments of this disclosure relate to *in vitro* methods for diagnosis of a disease selected from the group comprising cancer, neuronal diseases, cardiovascular diseases, inflammatory diseases, autoimmune diseases, diseases due to a viral or bacterial infection, skin diseases, skeletal muscle diseases, dental diseases and prenatal diseases comprising the use of the multiplex method according to the present disclosure.

In a further aspect, embodiments of this disclosure provide *in vitro* methods for diagnosis of a disease in plants selected from the group comprising: diseases caused by biotic stress, preferably by infectious and/or parasitic origin, or diseases caused by abiotic stress, preferably caused by nutritional deficiencies and/or unfavorable environment, said method comprising the use of the multiplex method according to the present disclosure.

In a further aspect, some embodiments of this disclosure relate to optical multiplexing systems suitable for the method according to the present disclosure, comprising at least:

- at least one reaction vessel for containing the kits or part of the kits according to the present disclosure;
- a detection unit comprising a microscope, in particular a fluorescence microscope
- a camera
- 5 - a liquid handling device.

In a further aspect, some embodiments of this disclosure relates to a kit for multiplex analyte encoding, comprising

(A) at least twenty (20) different sets of analyte-specific probes for encoding of at least 20 different
10 analytes, each set of analyte-specific probes interacting with a different analyte, wherein if the analyte is a nucleic acid each set of analyte-specific probes comprises at least five (5) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each analyte-specific probe comprising

(aa) a binding element (S) that specifically interacts with one of the different analytes to be encoded,
15 and

(bb) an identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

wherein the analyte-specific probes of a particular set of analyte-specific probes differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the
20 identifier element (T),

wherein the analyte-specific probes in each set of analyte-specific probes binds to the same analyte and comprises the same nucleotide sequence of the identifier element (T) which is unique to said analyte; and

(B) at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding
25 oligonucleotides for an individual analyte each decoding oligonucleotide comprises:

(aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

(bb) a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

wherein the decoding oligonucleotides of a set for an individual analyte differ from the decoding oligonucleotides of another set for a different analyte in the identifier connect element (t); and

5 (C) a set of signal oligonucleotides, each signal oligonucleotide comprising:

(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide, and

(bb) a signal element,

10 wherein the kit comprises at least two different sets of analyte-specific probes for an analyte,

wherein the analyte-specific probes comprised in these different sets interacting with the same analyte, but specifically interact with different sub-structures of the same analyte,

wherein the analyte-specific probes of the first set of analyte-specific probes interacts with a sub-structure which is comprised in all variations of an analyte,

15 wherein the analyte-specific probes of the second set of analyte-specific probes (subgroup-specific probes) interacts with a sub-structure which is comprised only in a specific variation of the analyte,

wherein the analyte-specific probes of the first set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence), and

20 wherein the analyte-specific probes of the second set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

wherein the identifier elements (T) of the analyte-specific probes of the first set of analyte-specific probes and the identifier elements (T) of the analyte-specific probes of the second set of analyte-specific probes are different.

25

Further, some embodiments pertain to kits for multiplex analyte encoding, comprising

- (A) optionally at least twenty (20) different sets of analyte-specific probes for encoding of at least 20 different analytes, each set of analyte-specific probes interacting with a different analyte, wherein if the analyte is a nucleic acid each set of analyte-specific probes comprises at least five (5) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each
5 analyte-specific probe comprising
- (aa) a binding element (S) that specifically interacts with one of the different analytes to be encoded, and
- (bb) an identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),
- 10 wherein the analyte-specific probes of a particular set of analyte-specific probes differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T),
- wherein the analyte-specific probes in each set of analyte-specific probes binds to the same analyte and comprises the same nucleotide sequence of the identifier element (T) which is unique to said
15 analyte; and
- (B) at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding oligonucleotides for an individual analyte each decoding oligonucleotide comprises:
- (aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of
20 the corresponding analyte-specific probe set, and
- (bb) a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;
- wherein the decoding oligonucleotides of a set for an individual analyte differ from the decoding oligonucleotides of another set for a different analyte in the identifier connect element (t); and
- 25 (C) a set of signal oligonucleotides, each signal oligonucleotide comprising:
- (aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide, and

(bb) a signal element.

In a further aspect, some embodiments provide *in vitro* methods for screening, identifying and/or testing a substance and/or drug comprising:

(a) contacting a test sample comprising a sample with a substance and/or drug

5 (b) detecting different analytes in a sample by sequential signal-encoding of said analytes with a method according to the present disclosure.

In a further aspect, embodiments of the disclosure extend the multiplex method for detecting different analytes (described in the first aspect) by targeting subgroups of targets in a sample. Sequential signal-encoding of one set of probes if performed as described and at least one additional set of probes is
10 added to discriminate target subgroups.

Decoding of the main analyte (multiple rounds) is performed as described (A to I of aspect one). To identify subgroups of said analytes, additional signals are generated and analyzed in combination with the main analyte's encode. The method comprises:

(A1) contacting the sample with at least twenty (20) different sets of analyte-specific probes for
15 encoding of at least 20 different analytes, each set of analyte-specific probes interacting with a different analyte, wherein if the analyte is a nucleic acid each set of analyte-specific probes comprises at least five (5) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each analyte-specific probe comprising

20 (aa) a binding element (S) that specifically interacts with one of the different analytes to be encoded, and

(bb) an identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

25 wherein the analyte-specific probes of a particular set of analyte-specific probes differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T),

wherein the analyte-specific probes in each set of analyte-specific probes binds to the same analyte and comprises the same nucleotide sequence of the identifier element (T) which is unique to said analyte; and,

(A2) contacting a subgroup of at least one analyte with a set of at least five (5) subgroup-specific probes

which differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T),

(B) contacting the sample with at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding oligonucleotides for an individual analyte each decoding oligonucleotide comprises:

(aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

(bb) a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

wherein the decoding oligonucleotides of a set for an individual analyte differ from the decoding oligonucleotides of another set for a different analyte in the first connect element (t); and

(C) contacting the sample with at least a set of signal oligonucleotides, each signal oligonucleotide comprising:

(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide, and
(bb) a signal element.

(G) Detecting the signal caused by the signal element;

(H) selectively removing the decoding oligonucleotides and signal oligonucleotides from the sample, thereby essentially maintaining the specific binding of the analyte-specific probes to the analytes to be encoded;

(I) Performing at least three (3) further cycles comprising steps B) to E) to generate an encoding scheme with a codeword per analyte.

(J) Performing at least one (1) further cycle comprising steps B) to E) to identify the subgroup-specific probes contacted in step A2), wherein in particular the last cycle may stop with step (D).

According to the present disclosure, unique tags (identifier) are used per target (e.g. mRNA of one single gene) or for a target group. Groups can be formed to be indicative for a certain identity, process, biological function or disease (examples: cell type, inflammation, signal processing, cancer).

Surprisingly, the methods and kits according to the present disclosure lead to the reduction of complexity. Many different probes with different binding sequences share the same (one per target) unique tag. These tags have reduced the sequence complexity (to one per target) and also have predetermined constant properties (e.g. thermodynamic stability).

5 Advantages of the methods and kits according to the present disclosure are:

a) Full flexibility of the process to determine the identity of the tag, e.g. use more or less signals and/or rounds, varying numbers of fluorophores, number of total signals per tag → lower numbers of targets (e.g. 20) can be identified with high confidence in less rounds (e.g. 4) than a large number of targets (e.g. 100, these need 8 rounds for the same level of confidence), even if in both cases the exact
10 same unique tags are used.

b) All unique tags are used (recycled) in many consecutive rounds of hybridization and all primary probes contribute (provide information about their identity) in every round of identification.

c) As all tags share the same predefined properties (e.g. thermodynamic stability which allows for selective denaturing).

15 d)

In some advantageous embodiments, the unique tags are design as follow:

- No cross-hybridization between all oligonucleotides of the process (probes, decoders, readout), so that all tag sequences are usable together (compatible)
- No cross-hybridization between connector elements (bridges) of different unique tags
- 20 - Stability of hybridization of the unique tags should be in a narrow range: as stable as possible (fast hybridization, i.e. short cycle times) but significantly different (in this case less stable) than the primary probe (for differential denaturation, without removing primary probes)

Therefore, the present description pertains in particular to the usage of a set of labeled and unlabeled nucleic acid sequences for specific quantitative and/or spatial detection of different analytes in parallel
25 via specific hybridization. The technology allows the discrimination of more different analytes than different detection signals are available. The discrimination is realized via sequential signal-coding of the analytes achieved by several cycles of specific hybridization, detection of signals and selective elution of the hybridized nucleic acid sequences. In contrast to other state-of-the-art methods, the oligonucleotides providing the detectable signal are not directly interacting with sample-specific
30 nucleic acid sequences but are mediated by so called “decoding-oligonucleotides”. This mechanism decouples the dependency between the analyte-specific oligonucleotides and the signal

oligonucleotides. The use of decoding-oligonucleotides allows a much higher flexibility while dramatically decreasing the number of different signal oligonucleotides needed which in turn increases the coding capacity achieved with a certain number of detection rounds. The utilization of decoding-oligonucleotides leads to a sequential signal-coding technology that is e.g. more flexible, cheaper, simpler, faster and/or more accurate than other methods.

Examples for the use of the kits and method according to the present disclosure comprising subgroup-specific probes are:

1.) Fusion-transcript detection in cancer research

Gene fusion events that generate a chimeric protein are causative for several cancer types, accounting for approximately 20% of tumors overall (Mitelman 2007). Detection of RNA fusions has facilitated the molecular characterization and diagnosis of various tumors (reviewed by Neckles 2020). The recent approval molecules that target oncogenic fusion transcripts for degradation suggests that these are promising therapeutic targets. However, the inter- and intra-tumoral diversity of oncogenic fusion transcripts needs to be understood in more detail, ideally on the cellular level or even with subcellular resolution.

- Mitelman, F., Johansson, B., & Mertens, F. (2007): The impact of translocations and gene fusions on cancer causation. *Nature Reviews. Cancer*, 7(4), 233–245.
- Neckles, C, Sundara Rajan, S, Caplen, NJ. (2020): Fusion transcripts: Unexploited vulnerabilities in cancer? *WIREs RNA*; 11:e1562. <https://doi.org/10.1002/wrna.1562>

2.) RNA subgroups (alternative splicing)

RNA splicing is a fundamental process of gene expression and alternative splicing plays an important role in transcriptome complexity, cell-type differentiation, and organism development. The detection of splicing products is important because aberrant splicing can lead to numerous diseases, including cancer and neurodegeneration. Splicing variability between individual cells is primarily responsible for gene expression heterogeneity. Investigations of RNA splicing variants on a single cell level will help to decipher regulatory circuits, and to classify and understand cell types and subtypes (Walks 2011).

Single-molecule FISH (smFISH) was applied to detect RNA splicing variants before. Vargas (2011) was able to detect unspliced pre-mRNA, spliced introns, and spliced mRNA are detected simultaneously in a single cell, but this does not allow any multiplexing.

- T. Maniatis, B. Tasic. (2002): Alternative pre-mRNA splicing and proteome expansion in metazoans. *Nature*, 418, pp. 236-243
- Z. Waks, A.M. Klein, P.A. Silver. (2011): Cell-to-cell variability of alternative RNA splicing. *Mol. Syst. Biol.*, 7, p. 506
- D.Y. Vargas, K. Shah, M. Batish, M. Levandoski, S. Sinha, S.A. Marras, P. Schedl, S. Tyagi. (2011): Single-molecule imaging of transcriptionally coupled and uncoupled splicing. *Cell*, 147, pp. 1054-1065

3.) Viral transcript length

Many virus genomes harbor multiple promoters which can lead to mRNA species of various lengths, some of which have some parts in common. Detecting the exact length and composition is crucial in understanding the current phase of viral infection. For example, the HBV genome serves as the template for synthesis of multiple genomic and sub-genomic viral mRNA transcripts: Four viral promoters, Core, Pre S1, Pre S2, and X, and two enhancers, enhancer I and enhancer II, control the transcription of HBV (Zheng 2004). The quantification of each of these sub-genomic mRNA transcripts is key to understand the phase of infection and replication status.

- Zheng, Y., Li, J. & Ou, J. (2004): Regulation of Hepatitis B Virus Core Promoter by Transcription Factors HNF1 and HNF4 and the Viral X Protein Regulation of Hepatitis B Virus Core Promoter by Transcription Factors HNF1 and HNF4 and the Viral X Protein. 78, 6908–6914

Before the disclosure is described in detail, it is to be understood that this disclosure is not limited to the particular component parts of the steps of the methods described. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and is not intended to be limiting. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include singular and/or plural referents unless the context clearly dictates otherwise. It is moreover to be understood that, in case parameter ranges are given which are delimited by numeric values, the ranges are deemed to include these limitation values.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1: Embodiment where the analyte is a nucleic acid and the probe set comprises oligonucleotides specifically binding to the analyte. The probes comprise a unique identifier sequence allowing hybridization of decoding oligonucleotides.

Fig. 2: Embodiment where the analyte is a protein and the probe set comprises proteins (here: antibodies) specifically binding to the analyte. The probes comprise a unique identifier sequence allowing hybridization of decoding oligonucleotides.

Fig. 3: Flowchart of the method according to the disclosure.

Fig. 4: Alternative options for the application of decoding and signal oligonucleotides.

Fig. 5: Example for signal encoding of three different nucleic acid sequences by two different signal types and three detection rounds; in this example, the encoding scheme includes error detection.

Fig. 6: Number of generated codewords (logarithmic scale) against number of detection cycles.

Fig. 7: Calculated total efficiency of a 5-round encoding scheme based on single step efficiencies.

Fig. 8: Comparison of relative transcript abundances between different experiments.

Fig. 9: Correlation of relative transcript abundances between different experiments.

Fig. 10: Comparison of intercellular distribution of signals.

Fig. 11: Comparison of intracellular distribution of signals.

Fig. 12: Distribution pattern of different cell cycle dependent transcripts.

Fig. 13: Detection of multiple targets using a 8 round code with 2 labels (A and B) and no label (-). The targets 1, 2, 3, 4, 5, 20, and n are represented. The rounds 1, 2, 3, and 8 of the coding scheme are represented.

5

Fig. 14: Detection of multiple targets can be performed by an encoding scheme using a detectable marker. The ending scheme may comprise also the „0“ as a marker. That means that at a specific position the transcript is not detected. Consequently, the encoding scheme may be represented by the following constructs using only two gene specific probes:

10

- 1) With detectable label F: detectable during imaging
- 2) With detectable label F and quencher Q: not detectable during imaging
- 3) With quencher Q: not detectable during imaging
- 4) Without label F: not detectable during imaging
- 15 5) Without signaling oligonucleotide: not detectable during imaging
- 6) With a decoder oligonucleotide that cannot recruit a signaling oligonucleotide
- 7) Without decoder oligonucleotide: not detectable during imaging

Fig. 15: Detection of subgroups of different targets (Round 0) using additional, subgroup-specific probe sets. The procedure comprises contacting the analyte-specific probe sets in common (shared) parts and, in addition, contacting subgroup-specific probe sets to subgroup-determining (exclusive) parts (see Round 1; description, A2). Detection of the analytes using the probe sets bound to the shared parts (Round 1 through 4), using the decoding schema also described. Round 5: In at least one dedicated round, only the subgroup-specific probe sets are detected. The presence of the exclusive part of the target is then combined with the results from the previous rounds, allowing to discriminate subgroup 1' within group 1 and subgroup 2' within group 2.

20

25

Fig. 16: Possible structures of a multi-decoder. The numbers depict the examples. (A) is the unique identifier sequence, (a) is the corresponding sequence of the decoding oligonucleotide or multi-decoder and (c1) to (c3) are different sequence elements, that specifically bind to different signal oligonucleotides. Examples 2 to 5 show different versions of multi decoders.

30

The order of the different sequence elements as well as the number of signal oligonucleotide binding elements is not fixed. Example 1 shows a normal decoding oligonucleotide since there is only one signal oligonucleotide binding element (c1).

- 5 Fig. 17: Example for signal encoding of three different nucleic acid sequences by using multi-decoders and two different signal oligonucleotides creating three different signal types and three detection rounds. In this example, the encoding scheme includes error detection and correction.
- 10 Fig. 18: Number of generated codewords (logarithmic scale) against number of detection cycles. The number of codewords for merFISH does not exponentially increase with the number of detection cycles but gets less effective with each added round. In contrast, the number of codewords for intronSeqFISH, the method of the present disclosure without using multi-decoders, the method with multi-decoders increases exponentially. The slope of the curve for
- 15 the method using multi-decoders is much higher than that of the prior invention, leading to more than 20 000 000 times more codewords usable after 20 rounds of detection.

DETAILED DESCRIPTION OF THE DISCLOSURE

- 20 Disclosed herein are novel multiplex methods and kits for detecting different analytes and different subgroups/variations of an analyte in a sample.

The present disclosure describes the usage of a set of labeled and unlabeled nucleic acid sequences for specific quantitative and/or spatial detection of different analytes in parallel via specific hybridization. The technology allows the discrimination of more different analytes than different

25 detection signals are available. The discrimination may be realized via sequential signal-coding of the analytes achieved by several cycles of specific hybridization, detection of signals and selective elution of the hybridized nucleic acid sequences.

In contrast to other state-of-the-art methods, the oligonucleotides providing the detectable signal are not directly interacting with sample-specific nucleic acid sequences but are mediated by so called

30 “decoding-oligonucleotides”. This mechanism decouples the dependency between the analyte-specific oligonucleotides and the signal oligonucleotides. The use of decoding-oligonucleotides allows

a much higher flexibility while dramatically decreasing the number of different signal oligonucleotides needed which in turn increases the coding capacity achieved with a certain number of detection rounds.

The utilization of decoding-oligonucleotides leads to a sequential signal-coding technology that is more flexible, cheaper, simpler, faster and/or more accurate than other methods.

A. Definitions

According to the present disclosure an "analyte" is the subject to be specifically detected as being present or absent in a sample and, in case of its presence, to encode it. It can be any kind of entity, including a protein, polypeptide, protein or a nucleic acid molecule (e.g. RNA, PNA or DNA) of interest. The analyte provides at least one site for specific binding with analyte-specific probes. Sometimes herein the term "analyte" is replaced by "target". An "analyte" according to the disclosure includes a complex of subjects, e.g. at least two individual nucleic acid, protein or peptides molecules. In an embodiment of the disclosure an "analyte" excludes a chromosome. In another embodiment of the disclosure an "analyte" excludes DNA. The term "analyte" according to the present disclosure may include a group of different variations/embodiments of the same analyte e.g. splice variants of an analyte, variations comprising different introns and/or exons, sequences comprising an UTR and/or sequences having different length. In particular, the basic sequence and the variations having a sequence identity of at least 50, %, at least 75%, at least 80%, at least 85%, at least 90 %, or at least 95 %.

In some embodiments, an analyte may be a "coding sequence", "encoding sequence", "structural nucleotide sequence" or "structural nucleic acid molecule" which refers to a nucleotide sequence that is translated into a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include, but is not limited to, genomic DNA, cDNA, EST and recombinant nucleotide sequences.

A "sample" as referred to herein is a composition in liquid or solid form suspected of comprising the analytes to be encoded. In particular, the sample is a biological sample, preferably comprising biological tissue, further preferably comprising biological cells and/or extracts and/or part of cells. For

example, the cell is a prokaryotic cell or a eukaryotic cell, in particular a mammalian cell, in particular a human cell. In some embodiments, the biological tissue, biological cells, extracts and/or part of cells are fixed. In particular, the analytes are fixed in a permeabilized sample, such as a cell-containing sample.

5

As used in the present disclosure, "cell", "cell line", and "cell culture" can be used interchangeably and all such designations include progeny. Thus, the words "transformants" or "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or
10 inadvertent mutations. Mutant progeny that have the same functionality as screened for in the originally transformed cell are included.

15

An "encoding scheme" may describe a set of codewords that are associated with the analytes to be detected. Each codeword refers to one of the analytes and can be distinguished from all other
15 codewords. A codeword hereby is a sequence of signs provided by the detection cycles of the method. A sign within a codeword is a detectable signal or the absence of a signal. A codeword does not need to comprise of all different signals used in the method. The number of signs in a codeword is defined by the number of detection cycles.

20

An "oligonucleotide" as used herein, refers to a short nucleic acid molecule, such as DNA, PNA, LNA or RNA. The length of the oligonucleotides is within the range 4-200 nucleotides (nt), preferably 6-80 nt, more preferably 8-60 nt, more preferably 10-50 nt, more preferably 12 to 35 depending on the number of consecutive sequence elements. The nucleic acid molecule can be fully or partially single-stranded. The oligonucleotides may be linear or may comprise hairpin or loop structures. The oligonucleotides
25 may comprise modifications such as biotin, labeling moieties, blocking moieties, or other modifications.

30

The "analyte-specific probe" consists of at least two elements, namely the so-called binding element (S) which specifically interacts with one of the analytes, and a so-called identifier element (T) comprising the 'unique identifier sequence'. The binding element (S) may be a nucleic acid such as a hybridization sequence or an aptamer, or a peptidic structure such as an antibody.

In particular, in some embodiments the binding element (S) comprises moieties which are affinity moieties from affinity substances or affinity substances in their entirety selected from the group consisting of antibodies, antibody fragments, receptor ligands, enzyme substrates, lectins, cytokines, lymphokines, interleukins, angiogenic or virulence factors, allergens, peptidic allergens, recombinant allergens, allergen-idiotypical antibodies, autoimmune-provoking structures, tissue-rejection-inducing structures, immunoglobulin constant regions and their derivatives, mutants or combinations thereof. In further advantageous embodiments, the antibody fragment is a Fab, an scFv; a single domain, or a fragment thereof, a bis scFv, Fab2, Fab3, minibody, maxibody, diabody, triabody, tetrabody or tandab, in particular a single-chain variable fragment (scFv).

The "unique identifier sequence" as comprised by the analyte-specific probe is unique in its sequence compared to other unique identifiers. "Unique" in this context means that it specifically identifies only one analyte, such as Cyclin A, Cyclin D, Cyclin E etc., or, alternatively, it specifically identifies only a group of analytes, independently whether the group of analytes comprises a gene family or not. Therefore, the analyte or a group of analytes to be encoded by this unique identifier can be distinguished from all other analytes or groups of analytes that are to be encoded based on the unique identifier sequence of the identifier element (T). Or, in other words, there is only one 'unique identifier sequence' for a particular analyte or a group of analytes, but not more than one, i.e. not even two. Due to the uniqueness of the unique identifier sequence the identifier element (T) hybridizes to exactly one type of decoding oligonucleotides. The length of the unique identifier sequence is within the range 8-60 nt, preferably 12-40 nt, more preferably 14-20 nt, depending on the number of analytes encoded in parallel and the stability of interaction needed. A unique identifier may be a sequence element of the analyte-specific probe, attached directly or by a linker, a covalent bond or high affinity binding modes, e.g. antibody-antigen interaction, streptavidin-biotin interaction etc. It is understood that the term "analyte specific probe" includes a plurality of probes which may differ in their binding elements (S) in a way that each probe binds to the same analyte but possibly to different parts thereof, for instance to different (e.g. neighboring) or overlapping sections of the nucleotide sequence comprised by the nucleic acid molecule to be encoded. However, each of the plurality of the probes comprises the same identifier element (T).

A "decoding oligonucleotide" consists of at least two sequence elements. One sequence element that can specifically bind to a unique identifier sequence, referred to as an "identifier connector element

“(t) or "first connector element" (t), and a second sequence element specifically binding to a signal oligonucleotide, referred to as "translator element" (c). The length of the sequence elements is within the range 8-60 nt, preferably 12-40 nt, more preferably 14-20 nt, depending on the number of analytes to be encoded in parallel, the stability of interaction needed and the number of different signal oligonucleotides used. The length of the two sequence elements may or may not be the same.

In some advantageous embodiments, the decoding oligonucleotide in the kits and/or methods of the present disclosure may be a “multi-decoder”. A “multi-decoder” is a decoding oligonucleotide that consists of at least three sequence elements. One sequence element (the identifier connector element (t)) can specifically bind to a unique identifier sequence (identifier element (T)) and at least two other sequence elements (translator elements (c)) specifically bind different signal oligonucleotides (each of these sequence elements specifically binds a signal oligonucleotide that differs to all other signal oligonucleotides recruited by other elements of the multi-decoder). The length of the sequence elements is within the range 8-60 nt, preferably 12-40 nt, more preferably 14-20 nt, depending on the number of analytes detected in parallel, the stability needed and the number of different signal oligonucleotides used. The length of the sequence elements may or may not be the same.

Therefore, in some advantageous embodiments, the decoding oligonucleotide is a multi-decoder comprising

- an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and
- at least two translator elements (c) comprising each a nucleotide sequence allowing a specific hybridization of a different signal oligonucleotide.

Therefore, the first translator element binds a different signal oligonucleotide as the second translator element. In particular, the signal oligonucleotides differ in the signal element comprised in the signal oligonucleotide, e.g. in the kind of the fluorophore.

A "signal oligonucleotide" as used herein comprises at least two elements, a so-called “translator connector element” (C) or "second connector element" (C) having a nucleotide sequence specifically hybridizable to at least a section of the nucleotide sequence of the translator element (c) of the decoding oligonucleotide, and a "signal element" which provides a detectable signal. This element can either actively generate a detectable signal or provide such a signal via manipulation, e.g. fluorescent

excitation. Typical signal elements are, for example, enzymes that catalyze a detectable reaction, fluorophores, radioactive elements or dyes.

A "set" refers to a plurality of moieties or subjects, e.g. analyte-specific probes or decoding oligonucleotides, whether the individual members of said plurality are identical or different from each other. In an analyte specific probe set, the analyte specific probes are identical in the identifier element (T) but may comprise a different binding element (S) for specifically interacting with the same analyte but for specifically interacting with different sub-structures of the same analyte to be encoded.

"Selective denaturation" may be the process of eliminating bound decoding oligonucleotides and signal oligonucleotides with highest efficiency while at the same time the target specific probes have to stay hybridized with the highest efficiency. The total efficiency of these two combined events may to be at least 0.22 for two detection cycles, 0.37 for three detection cycles, 0.47 for four detection cycles, 0.55 for five detection cycles, 0.61 for six detection cycles, 0.65 for seven detection cycles, 0.69 for eight detection cycles, 0.72 for nine detection cycles and 0.74 for 10 detection cycles, 0.76 for 11 detection cycles and 0.78 for 12 detection cycles.

In an embodiment of the disclosure a single set refers to a plurality of oligonucleotides

An "analyte specific probe set" refers to a plurality of moieties or sub-jects, e.g. analyte-specific probes that are different from each other and bind to independent regions of the analyte. A single analyte specific probe set is further characterized at least by the same unique identifier.

A "subgroup specific probe set" may comprise the same characteristics as the "analyte specific probe set", but differs in terms of encoding and decoding information. The "subgroup specific probe sets" are only used to add information (mostly presence/absence) to a code that is already encoded by a "analyte specific probe set".

A "subgroup" or also called "variation" of an analyte refers to an embodiment of an analyte, wherein the variation comprises a common or "shared" element (e.g. identical nucleic acid sequence) comprised in all embodiments (or variations) of the same analyte and at least an additional element discriminating the analyte(target)-subgroups/variations among each other and/or from the basic analyte.

In some embodiments, a subgroup/variation of at least one analyte with a set of at least five (5) is contacted with subgroup-specific probes which differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T).

5 A "decoding oligonucleotide set" refers to a plurality of decoding oligonucleotides specific for a certain unique identifier needed to realize the encoding independent of the length of the codeword. Each and all of the decoding oligonucleotides included in a "decoding oligonucleotide set" bind to the same unique identifier element (T) of the analyte-specific probe.

10 In certain embodiments, this pattern of binding or hybridization of the decoding oligonucleotides may be converted into a "codeword." For example, the codewords could be also "101" and "110" for an analyte, where a value of 1 represents binding and a value of 0 represents no binding. The codewords may also have longer lengths in other embodiments (see Fig. 13). A codeword can be directly related to a specific unique identifier sequence of a analyte-specific probe. Accordingly, different analyte-specific probe may match certain codewords, which can then be used to identify the different analytes of the analyte-specific probe based on the binding patterns of the decoding oligonucleotide. However, 15 if no binding is evident, then the codeword would be "000" in this example.

The values in each codeword can also be assigned in different fashions in some embodiments. For example, a value of 0 could represent binding while a value of 1 represents no binding. Similarly, a value of 1 could represent binding of a secondary nucleic acid probe with one type of signaling entity while a value of 0 could represent binding of a secondary nucleic acid probe with another type of 20 distinguishable signaling entity. These signaling entities could be distinguished, for example, via different colors of fluorescence. In some cases, values in codewords need not be confined to 0 and 1. The values could also be drawn from larger alphabets, such as ternary (e.g., 0, 1, and 2) or quaternary (e.g., 0, 1, 2, and 3) systems. Each different value could, for example, be represented by a different distinguishable signaling entity, including (in some cases) one value that may be represented by the 25 absence of signal.

The codewords for each analyte may be assigned sequentially, or may be assigned at random. For instance, a first analyte may be assigned to 101, while a second nucleic acid target may be assigned to 110. In addition, in some embodiments, the codewords may be assigned using an error-detection system or an error- correcting system, such as a Hamming system, a Golay code, or an extended 30 Hamming system (or a SECDED system, i.e., single error correction, double error detection). Generally

speaking, such systems can be used to identify where errors have occurred, and in some cases, such systems can also be used to correct the errors and determine what the correct codeword should have been. For example, a codeword such as 001 may be detected as invalid and corrected using such a system to 101, e.g., if 001 is not previously assigned to a different target sequence. A variety of different error-correcting codes can be used, many of which have previously been developed for use within the computer industry; however, such error-correcting systems have not typically been used within biological systems. Additional examples of such error-correcting codes are discussed in more detail below.

"Essentially complementary" means, when referring to two nucleotide sequences, that both sequences can specifically hybridize to each other under stringent conditions, thereby forming a hybrid nucleic acid molecule with a sense and an antisense strand connected to each other via hydrogen bonds (Watson-and-Crick base pairs). "Essentially complementary" includes not only perfect base-pairing along the entire strands, i.e. perfect complementary sequences but also imperfect complementary sequences which, however, still have the capability to hybridize to each other under stringent conditions. Among experts it is well accepted that an "essentially complementary" sequence has at least 88% sequence identity to a fully or perfectly complementary sequence.

"Percent sequence identity" or "percent identity" in turn means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The percent identity is then determined according to the following formula: $\text{percent identity} = 100 [1 - (C/R)]$

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence, wherein

(i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and

(ii) each gap in the Reference Sequence and

(iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference and (iiii) the alignment has to start at position 1 of the aligned sequences;

and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

5 If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the herein above calculated percent identity is less than the specified percent identity.

10 In the "incubation" steps as understood herein the respective moieties or subjects such as probes or oligonucleotide, are brought into contact with each other under conditions well known to the skilled person allowing a specific binding or hybridization reaction, e.g. pH, temperature, salt conditions etc. Such steps may therefore, be preferably carried out in a liquid environment such as a buffer system which is well known in the art.

15 The "removing" steps according to the disclosure may include the washing away of the moieties or subjects to be removed such as the probes or oligonucleotides by certain conditions, e.g. pH, temperature, salt conditions etc., as known in the art.

20 It is understood that in an embodiment of the method according to the present disclosure a plurality of analytes can be encoded in parallel. This requires the use of different sets of analyte-specific probes in step (1). The analyte-specific probes of a particular set differ from the analyte-specific probes of another set. This means that the analyte-specific probes of set 1 bind to analyte 1, the analyte-specific probes of set 2 bind to analyte 2, the analyte-specific probes of set 3 bind to analyte 3, etc. In this embodiment also the use of different sets of decoding oligonucleotides is required in the methods according to the present disclosure.

25 The decoding oligonucleotides of a particular set differ from the decoding oligonucleotides of another set. This means, the decoding oligonucleotides of set 1 bind to the analyte-specific probes of above set 1 of analyte-specific probes, the decoding oligonucleotides of set 2 bind to the analyte-specific probes of above set 2 of analyte-specific probes, the decoding oligonucleotides of set 3 bind to the analyte-specific probes of above set 3 of analyte-specific probes, etc.

30 In this embodiment where a plurality of analytes is to be encoded in parallel the different sets of analyte-specific probes may be provided as a premixture of different sets of analyte-specific probes

and/or the different sets of decoding oligonucleotides may be provided as a premixture of different sets of decoding oligonucleotides. Each mixture may be contained in a single vial. Alternatively, the different sets of analyte-specific probes and/or the different sets of decoding oligonucleotides may be provided in steps singularly.

5 A "kit" is a combination of individual elements useful for carrying out the use and/or method of the disclosure, wherein the elements are optimized for use together in the methods. The kits may also contain additional reagents, chemicals, buffers, reaction vials etc. which may be useful for carrying out the method according to the disclosure. Such kits unify all essential elements required to work the method according to the disclosure, thus minimizing the risk of errors. Therefore, such kits also allow
10 semi-skilled laboratory staff to perform the method according to the present disclosure.

The term "quencher" or "quencher dye" or "quencher molecule" refers to a dye or an equivalent molecule, such as nucleoside guanosine (G) or 2'-deoxyguanosine (dG), which is capable of reducing the fluorescence of a fluorescent reporter dye or donor dye. A quencher dye may be a fluorescent dye or non-fluorescent dye. When the quencher is a fluorescent dye, its fluorescence wavelength is
15 typically substantially different from that of the reporter dye and the quencher fluorescence is usually not monitored during an assay. Some embodiments of the present disclosure disclose signal oligonucleotides comprising a quencher and/or a quencher in combination with a signal element (see Fig. 14), and therefore the signal oligonucleotides is not detectable during imaging.

In an embodiment of the disclosure the sample is a biological sample, preferably comprising biological
20 tissue, further preferably comprising biological cells. A biological sample may be derived from an organ, organoids, cell cultures, stem cells, cell suspensions, primary cells, samples infected by viruses, bacteria or fungi, eukaryotic or prokaryotic samples, smears, disease samples, a tissue section.

The method is particularly qualified to encode, identify, detect, count or quantify analytes or single analytes molecules in a biological sample, i.e. such as a sample which contains nucleic acids or proteins
25 as said analytes. It is understood that the biological sample may be in a form as it is in its natural environment (i.e. liquid, semi-liquid, solid etc.), or processed, e.g. as a dried film on the surface of a device which may be re-liquefied before the method is carried out.

In another embodiment of the disclosure prior to step (2) the biological tissue and/or biological cells are fixed. For example, in some embodiments, the cell and/or the tissue is fixed prior to introducing

the probes, e.g., to preserve the positions of the analytes like nucleic acids within the cell. Techniques for fixing cells are known to those of ordinary skill in the art. As non-limiting examples, a cell may be fixed using chemicals such as formaldehyde, paraformaldehyde, glutaraldehyde, ethanol, methanol, acetone, acetic acid, or the like. In one embodiment, a cell may be fixed using Hepes-glutamic acid buffer- mediated organic solvent (HOPE).

This measure has the advantage that the analytes to be encoded, e.g. the nuclei acids or proteins, are immobilized and cannot escape. In doing so, the analytes then prepared for a better detection or encoding by the method according to the disclosure.

In yet a further embodiment within the set of analyte-specific probes the individual analyte-specific probes comprise binding elements (S1, S2, S3, S4, S5) which specifically interact with different sub-structures of one of the analytes to be encoded.

By this measure the method becomes even more robust and reliable because the signal intensity obtained at the end of the method or a cycle, respectively, is increased. It is understood, that the individual probes of a set while binding to the same analyte differ in their binding position or binding site at or on the analyte. The binding elements S1, S2, S3, S4, S5 etc. of the first, second, third fourth, fifth etc. analyte-specific probes therefore bind to or at a different position which, however, may or may not overlap.

In an advantageous embodiment, the present disclosure pertains to kit for multiplex analyte encoding, comprising :

(A) at least twenty (20) different sets of analyte-specific probes for encoding of at least 20 different analytes, each set of analyte-specific probes interacting with a different analyte, wherein if the analyte is a nucleic acid each set of analyte-specific probes comprises at least five (5) analyte-specific probes, and – optionally - also at least a subgroup specific probe set to discriminate targets (analytes/ variations) with shared and exclusive parts of an analyte, which specifically interact with different sub-structures of the same analyte, each analyte-specific probe comprising

(aa) a binding element (S) that specifically interacts with one of the different analytes to be encoded, and

(bb) an identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

5 wherein the analyte-specific probes of a particular set of analyte-specific probes differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T),

 wherein the analyte-specific probes in each set of analyte-specific probes binds to the same analyte and comprises the same nucleotide sequence of the identifier element (T) which is unique to
10 said analyte; and

(B) at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding oligonucleotides for an individual analyte each decoding oligonucleotide comprises:

 (aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element
15 (T) of the corresponding analyte-specific probe set, and

(bb) a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

 wherein the decoding oligonucleotides of a set for an individual analyte differ from the decoding oligonucleotides of another set for a different analyte in the identifier connect element (t);
20 and

(C) a set of signal oligonucleotides, each signal oligonucleotide comprising:

(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide, and

(bb) a signal element.

- 5 A multiplex method or assay allow the simultaneously measurement of multiple analytes according to the present disclosure it may be used to determine the presence or absence of a plurality of predetermined (known) analytes like nucleic acid target sequences in a sample. An analyte may be “predetermined” in that its sequence is known to design a probe that binds to the that target.

10 In some advantageous embodiments according to the present disclosure at least 20, in particular at least 25, in particular at least 30 different analytes are detected and/or quantified in a sample in parallel. For example, there may be at least 5, at least 10, at least 20, at least 50, at least 75, at least 100, at least 300, at least 1,000, at least 3,000, at least 10,000, or at least 30,000 distinguishable analyte-specific probes that are applied to a sample, e.g., simultaneously or sequentially.

15 In some advantageous embodiments for the multiplexing twenty (20) or more different sets of analyte-specific probes for encoding of at least 20 different analytes or more are required, in particular more than 50, more than 100 or more than 200. In the multiplexing methods of the present disclosure, in particular at least 20 different groups of analytes (e.g. mRNA molecules) i.e. tags are targeted.

In an advantageous embodiment, the kit comprises at least two different sets of analyte-specific probes per analyte,

20 wherein the analyte-specific probes comprised in these different sets interacting with the same analyte, but specifically interact with different sub-structures of the same analyte,

wherein the analyte-specific probes of the first set of analyte-specific probes interacts with a sub-structure which is comprised in all variations of an analyte,

wherein the analyte-specific probes of the second set of analyte-specific probes interacts with a sub-structure which is comprised only in a specific variation of the analyte (subgroup specific probe set),

5 wherein the analyte-specific probes of the first set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence), and

wherein the analyte-specific probes of the second set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

10 wherein the identifier elements (T) of the analyte-specific probes of the first set of analyte-specific probes and the identifier elements (T) of the analyte-specific probes of the second set of analyte-specific probes are different for binding different decoding oligonucleotides and/or non-signal decoding oligonucleotides.

In some advantageous embodiments, at least 4 rounds to collect information for identification of the analyte are carried out, wherein multiple readout increases the accuracy of identification and avoids false positives. The unique tag can be identified by various techniques, including hybridization, e.g. with labeled probes, directly or indirectly or by sequencing (by synthesis, ligation). In particular, the identity of the tag can be encoded with one single signal (binary code), two or more signals, wherein the signal can be a fluorescent label (e.g. attached to an oligonucleotide).

20 In some advantageous embodiments according to the present disclosure, the kit does not comprise sets of analyte-specific probes as defined under item A).

Preferably, if the analyte in the kits or methods according to the present disclosure is a nucleic acid, each set of analyte-specific probes comprises at least five (5) analyte-specific probes, in particular at least ten (10) analyte-specific probes, in particular at least fifteen (15) analyte-specific probes, in particular at least twenty (20) analyte-specific probes which specifically interact with different sub-structures of the same analyte. Nucleic acid analyte includes specific DNA molecules, e.g. genomic

DNA, nuclear DNA, mitochondrial DNA, viral DNA, bacterial DNA, extra- or intracellular DNA etc., and specific mRNA molecules, e.g. hnRNA, miRNA, viral RNA, bacterial RNA, extra- or intracellular RNA, etc.

Preferably, if the analyte in the kits or methods according to the present disclosure is a peptide, a polypeptide or a protein, each set of analyte-specific probes comprises at least two (2) analyte-specific probes, in particular at least three (3) analyte-specific probes, in particular at least four (4) analyte-specific probes which specifically interact with different sub-structures of the same analyte.

In some advantageous embodiments according to the present disclosure the kit comprises at least two different sets of signal oligonucleotides, wherein the signal oligonucleotides in each set comprise a different signal element and comprise a different connector element (C).

In particular, the kit may comprise at least two different sets of decoding oligonucleotides per analyte, wherein the decoding oligonucleotides comprised in these different sets comprise the same identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and wherein the decoding oligonucleotides of the different sets per analyte differ in the translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

In some embodiments the kit comprises at least two different sets of decoding oligonucleotides per analyte, wherein the decoding oligonucleotides comprised in these different sets comprise the same identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and wherein the decoding oligonucleotides of the different sets for at least one analyte differ in the translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

In some advantageous embodiments, the number of different sets of decoding oligonucleotides per analyte comprising different translator elements (c) corresponds to the number of different sets of signal oligonucleotides comprising different connector elements (C). However, the decoding oligonucleotides in a particular set of decoding oligonucleotides may interact with identical identifier elements (T) which are unique to a particular analyte. In particular, all sets of decoding oligonucleotides for the different analytes may comprise the same type(s) of translator element(s) (c).

In another aspect, the present disclosure is generally directed to a methods including acts of exposing a sample to a plurality of analyte-specific probes; for each of the analyte-specific probes, determining binding of the analyte-specific probes within the sample; creating codewords based on the binding of the analyte-specific probes, the decoding oligonucleotides and the signal oligonucleotides; and for at least some of the codewords, matching the codeword to a valid codeword. In certain embodiments, this pattern of binding or hybridization of the analyte-specific probes, the decoding oligonucleotides and the signal oligonucleotides may be converted into a "codeword." For example, for instance, the codewords may be "101" and "110" for a first analyte and a second analyte, respectively, where a value of 1 represents binding and a value of 0 represents no binding of decoding oligonucleotides and/or the binding of signal oligonucleotides without and/or quenched signal element. The analyte in the detection round/cycle is therefore not detectable during imaging.

To create such a zero (0) in a codeword for an individual analyte the kit may comprise:

(D) at least a set of non-signal decoding oligonucleotides for binding to a particular identifier element (T) of analyte-specific probes, wherein the decoding oligonucleotides in the same set of non-signal decoding oligonucleotides interacting with the same different identifier element (T),

wherein each non-signal decoding oligonucleotide comprises an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of a unique identifier sequence, and does not comprise a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

To create such a zero (0) in a codeword for an individual analyte the kit may comprise:

(D) at least a set of non-signal decoding oligonucleotides for binding to a particular identifier element (T) of analyte-specific probes, wherein the decoding oligonucleotides in the same set of non-signal decoding oligonucleotides interacting with the same different identifier element (T),

wherein each non-signal decoding oligonucleotide comprises an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of a unique identifier sequence, and comprise a translator element that does not interact/bind to a signal oligonucleotide due to an instable binding sequence and/or due to the translator element is too short (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

In some advantageous embodiments, the kit comprises:

(D) at least two (2) different sets of non-signal decoding oligonucleotides for binding to at least two different identifier elements (T) of analyte-specific probes, each set of non-signal decoding oligonucleotides interacting with a different identifier element (T),

wherein each non-signal decoding oligonucleotide comprises an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of a unique identifier sequence, and does not comprise a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

In some advantageous embodiments, the different sets of non-signal decoding oligonucleotides may be comprised in a pre-mixture of different sets of non-signal decoding oligonucleotides or exist separately.

Furthermore, in some advantageous embodiments the kit may comprise:

(E) a set of non-signal oligonucleotides, each non-signal oligonucleotide comprising:

(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of the translator element (c), and (bb) a quencher (Q), a signal element and a quencher (Q), or does not comprise a signal element.

In some advantageous embodiments, the kit comprises:

(E) at least two sets of non-signal oligonucleotides, each non-signal oligonucleotide comprising:

(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of the translator element (c), and (bb) a quencher (Q), a signal element and a quencher (Q), or does not comprise a signal element.

In some advantageous embodiments, the different sets of non-signal oligonucleotides may be comprised in a pre-mixture of different sets of non-signal oligonucleotides or exist separately.

Further, in some embodiments the decoding oligonucleotides in a particular set of decoding oligonucleotides interacts with identical identifier elements (T) which are unique to a particular analyte.

In some advantageous embodiments, the different sets of decoding oligonucleotides may be comprised in a pre-mixture of different sets of decoding oligonucleotides or exist separately. In some advantageous embodiments, the different sets of analyte-specific probes may be comprised in a pre-mixture of different sets of analyte-specific probes or exist separately. In some advantageous
5 embodiments, the different sets of signal oligonucleotides may be comprised in a pre-mixture of different sets of signal oligonucleotides or exist separately.

In some advantageous embodiments, a mixture of decoding oligonucleotides and/or multi-decoders is provided that specifically hybridize to the unique identifier sequences of the probe sets. In some embodiments, the decoding oligonucleotides comprise of at least two sequence elements, a first
10 element that is complementary to the unique identifier sequences of the corresponding probe set and a second sequence element (translator element) that provides a sequence for the specific hybridization of a signal oligonucleotide, the translator element defines the type of signal that is recruited to the decoding oligonucleotide. In some embodiments multi-decoders comprising at least three sequence elements are used, a first element that is complementary to the unique identifier
15 sequences of the corresponding probe set and at least to additional sequence elements (translator elements) that provide sequences for the specific hybridization of at least two different signal oligonucleotides. The translator elements define the type of signals that are recruited to the multi-decoder. Different possible structures of a multi-decoder can be seen in Fig. 17. Since a multi-decoder does recruit a full signal oligonucleotide per translator element, the brightness of the signals in each
20 channel is not lower than the brightness of signals with decoding oligonucleotides.

The usage of multi-decoders increases further the efficiency of the encoding scheme. Figure 17 shows a possible encoding scheme using multi-decoders based upon the same conditions used for the examples with the decoding oligonucleotide with two sequence elements. One can clearly see that the multi-decoder based encoding scheme can create a higher hamming distance, with the same number
25 of rounds and the same number of different signal oligonucleotides used in the example of Fig. 5.

As mentioned above the analyte to be encoded may be a nucleic acid, preferably DNA, PNA or RNA, in particular mRNA, a peptide, polypeptide, a protein, and/or mixtures thereof.

In some advantageous embodiments, the binding element (S) comprises an amino acid sequence
30 allowing a specific binding to the analyte to be encoded. The binding element (S) may comprise moieties which are affinity moieties from affinity substances or affinity substances in their entirety

selected from the group consisting of antibodies, antibody fragments, anticalin proteins, receptor ligands, enzyme substrates, lectins, cytokines, lymphokines, interleukins, angiogenic or virulence factors, allergens, peptidic allergens, recombinant allergens, allergen-idiotypal antibodies, autoimmune-provoking structures, tissue-rejection-inducing structures, immunoglobulin constant regions and combinations thereof.

In some advantageous embodiments, the binding element (S) may comprise or is an antibody or an antibody fragment selected from the group consisting of Fab, scFv; single domain, or a fragment thereof, bis scFv, F(ab)2, F(ab)3, minibody, diabody, triabody, tetrabody and tandab.

The present disclosure pertains in particular to a multiplex method for detecting different analytes in a sample by sequential signal-encoding of said analytes, comprising the steps of:

(A) contacting the sample with at least twenty (20) different sets of analyte-specific probes for encoding of at least 20 different analytes, each set of analyte-specific probes interacting with a different analyte, wherein if the analyte is a nucleic acid each set of analyte-specific probes comprises at least five (5) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each analyte-specific probe comprising

(aa) a binding element (S) that specifically interacts with one of the different analytes to be encoded, and

(bb) an identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

wherein the analyte-specific probes of a particular set of analyte-specific probes differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T),

wherein the analyte-specific probes in each set of analyte-specific probes binds to the same analyte and comprises the same nucleotide sequence of the identifier element (T) which is unique to said analyte; and

(B) contacting the sample with at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding oligonucleotides for an individual analyte each decoding oligonucleotide comprises:

(aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

(bb) a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

wherein the decoding oligonucleotides of a set for an individual analyte differ from the decoding oligonucleotides of another set for a different analyte in the first connect element (t); and

(C) contacting the sample with at least a set of signal oligonucleotides, each signal oligonucleotide comprising:

(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide, and

(bb) a signal element.

(D) Detecting the signal caused by the signal element;

(E) selectively removing the decoding oligonucleotides and signal oligonucleotides from the sample, thereby essentially maintaining the specific binding of the analyte-specific probes to the analytes to be encoded;

(F) Performing at least three (3) further cycles comprising steps B) to E) to generate an encoding scheme with a codeword per analyte, wherein in particular the last cycle may stop with step (D).

As mentioned above, the method according to the present disclosure comprises selectively removing the decoding oligonucleotides and signal oligonucleotides from the sample, thereby essentially maintaining the specific binding of the analyte-specific probes to the analyte to be encoded. In particular all steps are performed sequentially. However some steps may be performed simultaneously, in particular the contacting steps A) to C), in particular B) and C).

By this measure the requirements for another round/cycle of binding further decoding oligonucleotides to the same analyte-specific probes are established, thus finally resulting in a code or

encoding scheme comprising more than one signal. This step is realized by applying conditions and factors well known to the skilled person, e.g. pH, temperature, salt conditions, oligonucleotide concentration, polymers etc.

5 In another embodiment of the present disclosure, the method may comprise repeating steps (B)-(E) at least three times to generate an encoding scheme. With this measure a code of four signals in case of four cycles/rounds which are carried out by the user, where 'n' is an integer representing the number of rounds. The encoding capacity of the method according to the disclosure is herewith increased depending on the nature of the analyte and the needs of the operator. In an embodiment of the
10 disclosure said encoding scheme is predetermined and allocated to the analyte to be encoded.

However, this measure enables a precise experimental set-up by providing the appropriate sequential order of the employed decoding and signal oligonucleotides and, therefore, allows the correct allocation of a specific analyte to a respective encoding scheme. The decoding oligonucleotides which
15 are used in repeated steps (B)-(D2) may comprise a translator element (c2) which is identical with the translator element (c1) of the decoding oligonucleotides used in previous steps (B)-(E). In another embodiment of the disclosure decoding oligonucleotides are used in repeated steps (B)-(E) comprising a translator element (c2) which differs from the translator element (c1) of the decoding oligonucleotides used in previous steps (B)-(E). It is understood that the decoding elements may or
20 may not be changed from round to round, i.e. in the second round (B)-(E) comprising the translator element c2, in the third round (B)-(E) comprising the translator element c3, in the fourth round (B)-(E) comprising the translator element c4 etc., wherein 'n' is an integer representing the number of rounds.

The signal oligonucleotides which are used in repeated steps (B)-(E) may comprise a signal element
25 which is identical with the signal element of the decoding oligonucleotides used in previous steps (B)-(E). In a further embodiment of the disclosure signal oligonucleotides are used in repeated steps (B)-(E) comprising a signal element which differs from the signal element of the decoding oligonucleotides used in previous steps (B)-(E). In some embodiments no-signal oligonucleotides and/or no-signal decoding oligonucleotides for an individual analyte are used, resulting to the value 0 in the codeword
30 for this cycle/position. In some embodiments in a repeated cycle no decoding oligonucleotides for an individual analyte is contacted with the sample resulting also to the value 0 in the codeword for this cycle/position.

By this measure each round the same or a different signal is provided resulting in an encoding scheme characterized by a signal sequence consisting of numerous different signals. This measure allows the creation of a unique code or codeword which differs from all other codewords of the encoding scheme.

5 In another embodiment of the disclosure, the binding element (S) of the analyte-specific probe comprises a nucleic acid comprising a nucleotide sequence allowing a specific binding to the analyte to be encoded, preferably a specific hybridization to the analyte to be encoded.

10 In another embodiment of the disclosure, subgroups of the same type of analyte (variations) can be detected performing step G) to detect the presence or absence of an exclusive element.

In an advantageous embodiment, the sample is contacted with at least two different sets of analyte-specific probes per analyte,

15 wherein the analyte-specific probes comprised in these different sets interacting with the same analyte, but specifically interact with different sub-structures of the same analyte,

wherein the analyte-specific probes of the first set of analyte-specific probes interacts with a sub-structure which is comprised in all variations of an analyte,

20 wherein the analyte-specific probes of the second set of analyte-specific probes (subgroup-specific probe set) interacts with a sub-structure which is comprised only in a specific variation of the analyte,

wherein the analyte-specific probes of the first set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence), and

25 wherein the analyte-specific probes of the second set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

30 wherein the identifier elements (T) of the analyte-specific probes of the first set of analyte-specific probes and the identifier elements (T) of the analyte-specific probes of the second set of analyte-specific probes are different for binding different decoding oligonucleotides and/or non-signal decoding oligonucleotides.

In some advantageous embodiments, all steps are automated, in particular wherein steps B) to F) are automated, in particular by using a robotic system and/or an optical multiplexing system according to the present disclosure. In some examples, the steps may be performed in a fluidic system.

5 As mentioned above, with the methods according to the present disclosure an encoding scheme with a codeword per analyte is generated. Therefore, each analyte may be associated with a specific codeword, wherein said codeword comprise a number of positions, and wherein each position corresponds to one cycle resulting in a plurality of distinguishable encoding schemes with the plurality of codewords. In particular, said encoding scheme may be predetermined and allocated to the analyte
10 to be encoded.

In some advantageous embodiments, the codewords obtained for the individual analytes in the performed cycles comprise the detected signals and additionally at least one element corresponding to no detected signal like 0,1 or 0,1,2 etc. (see also Fig. 13 and Fig. 14). In particular, no signal is
15 detected for at least one analyte within at least one cycle if using the a non-signal probe according to Figure 14, No. 2 to 4, or a non-signal decoding oligonucleotide as shown in Figure 14 No. 5, or if in one cycle no decoding oligonucleotide is contacted with the corresponding identifier sequence comprised on analyte-specific probe interacting with the corresponding analyte in the sample. In this cycle the position has the value zero (0).

20 In some advantageous embodiments, at least for one individual analyte a position of the codeword is zero (0). In particular, the codeword zero (0) is generated by using no decoding oligonucleotides having an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of
25 a corresponding analyte-specific probe for an individual analyte. As mentioned above, in some embodiments, if at least for one individual analyte a position of the codeword is zero (0) in this cycle no corresponding decoding oligonucleotides having an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of a corresponding analyte-specific probe for an individual
30 analyte are used.

Furthermore, in some advantageous embodiments the sample is contacted with at least two different sets of signal oligonucleotides, wherein the signal oligonucleotides in each set comprise a different signal element and comprise a different connector element (C).

In more particular embodiments, the sample is contacted with at least two different sets of decoding
5 oligonucleotides per analyte,

wherein the decoding oligonucleotides comprised in these different sets comprise the same identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

10 wherein the decoding oligonucleotides of the different sets per analyte differ in the translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

In more particular embodiments, the sample is contacted with at least two different sets of decoding
15 oligonucleotides per analyte,

wherein the decoding oligonucleotides comprised in these different sets comprise the same identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

20 wherein the decoding oligonucleotides of the different sets per analyte differ in the translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

wherein only one set of decoding oligonucleotides per analyte is used per cycle, and/or wherein different sets of decoding oligonucleotides are used in different cycles in combination with the
25 corresponding set of signal oligonucleotides in the same cycle, in particular

wherein a set of decoding oligonucleotides and/or non-signal decoding oligonucleotides is reserved for optional detection of subgroups of analytes.

In some advantageous embodiments, the number of different sets of decoding oligonucleotides per
30 analyte comprising different translator elements (c) corresponds to the number of different sets of

signal oligonucleotides comprising different connector elements (C). All sets of decoding oligonucleotides for the different analytes may comprise the same type(s) of translator element(s) (c).

In some advantageous embodiments of the method according to the present disclosure, the sample is contacted with at least a set of non-signal decoding oligonucleotides for binding to a particular identifier element (T) of analyte-specific probes, wherein the decoding oligonucleotides in the same set of non-signal decoding oligonucleotides interacting with the same different identifier element (T), wherein each non-signal decoding oligonucleotide comprises an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of a unique identifier sequence, and does not comprise a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

As mentioned above, the sample may be contacted with at least two (2) different sets of non-signal decoding oligonucleotides for binding to at least two different identifier elements (T) of analyte-specific probes, each set of non-signal decoding oligonucleotides interacting with a different identifier element (T), wherein each non-signal decoding oligonucleotide comprises an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of a unique identifier sequence, and does not comprise a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

In some advantageous embodiments of the method according to the present disclosure, the different sets of non-signal decoding oligonucleotides may be comprised in a pre-mixture of different sets of non-signal decoding oligonucleotides or exist separately.

Furthermore, in some advantageous embodiments of the method according to the present disclosure, the sample is contacted with a set of non-signal oligonucleotides, each non-signal oligonucleotide comprising:

(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of the translator element (c), and
(bb) a quencher (Q), a signal element and a quencher (Q), or does not comprise a signal element.

In further embodiments, the sample may be contacted with:

at least two sets of non-signal oligonucleotides, each non-signal oligonucleotide comprising:

- (aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of the translator element (c), and
- (bb) a quencher (Q), a signal element and a quencher (Q), or does not comprise a signal element.

5

As mentioned above, the different sets of non-signal oligonucleotides may be comprised in a pre-mixture of different sets of non-signal oligonucleotides or exist separately.

10

In further embodiments, the decoding oligonucleotides in a particular set of decoding oligonucleotides interacts with identical identifier elements (T) which are unique to a particular analyte.

15

As mentioned above, the different sets of decoding oligonucleotides may be comprised in a pre-mixture of different sets of decoding oligonucleotides or exist separately as well as the different sets of analyte-specific probes may be comprised in a pre-mixture of different sets of analyte-specific probes or exist separately as well the different sets of signal oligonucleotides may be comprised in a pre-mixture of different sets of signal oligonucleotides or exist separately.

20

In some advantageous embodiments of the method according to the present disclosure, the binding element (S) comprise a nucleic acid comprising a nucleotide sequence allowing a specific binding to the analyte to be encoded, preferably a specific hybridization to the analyte to be encoded.

25

In some advantageous embodiments of the method according to the present disclosure, after step A) and before step B) the non-bound analyte-specific probes may be removed, in particular by washing, further after step B) and before step C) the non-bound decoding oligonucleotides may be removed, in particular by washing further, after step C) and before step D) the non-bound signal oligonucleotides may be removed, in particular by washing.

30

In some advantageous embodiments of the method according to the present disclosure, the analyte specific probes may be incubated with the sample, thereby allowing a specific binding of the analyte specific probes to the analytes to be encoded, further the decoding oligonucleotides may be incubated with the sample, thereby allowing a specific hybridization of the decoding oligonucleotides to identifier elements (T) of the respective analyte-specific probes, further the signal oligonucleotides may be incubated with the sample, thereby allowing a specific hybridization of the signal oligonucleotides to translator elements (T) of the respective decoding oligonucleotides.

As mentioned above, the analyte to be encoded may be a nucleic acid, preferably DNA, PNA, RNA, in particular mRNA, a peptide, polypeptide, a protein or combinations thereof. Therefore, the binding element (S) may comprise an amino acid sequence allowing a specific binding to the analyte to be encoded. Examples for a binding element (S) are moieties which are affinity moieties from affinity substances or affinity substances in their entirety selected from the group consisting of antibodies, antibody fragments, anticalin proteins, receptor ligands, enzyme substrates, lectins, cytokines, lymphokines, interleukins, angiogenic or virulence factors, allergens, peptidic allergens, recombinant allergens, allergen-idiotypical antibodies, autoimmune-provoking structures, tissue-rejection-inducing structures, immunoglobulin constant regions and combinations thereof. In particular, the binding element (S) is an antibody or an antibody fragment selected from the group consisting of Fab, scFv; single domain, or a fragment thereof, bis scFv, Fab 2, Fab 3, minibody, diabody, triabody, tetrabody and tandab.

By this measure the method is further developed to such an extent that the encoded analytes can be detected by any means which is adapted to visualize the signal element. Examples of detectable physical features include e.g. light, chemical reactions, molecular mass, radioactivity, etc.

In some advantageous embodiments, the signal caused by the signal element, therefore in particular the binding of the signal oligonucleotides to the decoding oligonucleotides, interacting with the corresponding analyte probes, bound to the respective analyte is determined by:

- (a) Imaging at least a portion of the sample; and/or
- (b) Using an optical imaging technique; and/or
- (c) Using a fluorescence imaging technique; and/or
- (d) Multi-color fluorescence imaging technique; and/or
- (e) Super-resolution fluorescence imaging technique.

The kits and method according to the present disclosure may be used ideally for *in vitro* methods for diagnosis of a disease selected from the group comprising cancer, neuronal diseases, cardiovascular diseases, inflammatory diseases, autoimmune diseases, diseases due to a viral or bacterial infection, skin diseases, skeletal muscle diseases, dental diseases and prenatal diseases.

Further, the kits and method according to the present disclosure may be used also ideally for *in vitro* methods for diagnosis of a disease in plants selected from the group comprising: diseases caused by biotic stress, preferably by infectious and/or parasitic origin, or diseases caused by abiotic stress, preferably caused by nutritional deficiencies and/or unfavorable environment.

5 Further, the kits and method according to the present disclosure may be used also ideally for *in vitro* methods for screening, identifying and/or testing a substance and/or drug comprising:

(a) contacting a test sample comprising a sample with a substance and/or drug

(b) detecting different analytes in a sample by sequential signal-encoding of said analytes with a method according to the present disclosure.

10 An optical multiplexing system suitable for the method according to the present disclosure, comprising at least:

- a reaction vessel for containing the kits or part of the kits according to the present disclosure;

- a detection unit comprising a microscope, in particular a fluorescence microscope;

15 - a camera;

- a liquid handling device.

In some embodiments, optical multiplexing system may comprises further a heat and cooling device and/or a robotic system.

20 Some examples of suitable construction techniques or materials that may be adapted for use in connection with the present disclosure may be described in, e.g., commonly-assigned U.S. Patent No. 6,734,401 titled "ENHANCED SAMPLE PROCESSING DEVICES SYSTEMS AND METHODS" (Bedingham et

al.) and U.S. Patent Application Publication No. US 2002/0064885 titled "SAMPLE PROCESSING DEVICES." Other useable device constructions may be found in, e.g., U.S. Provisional Patent Application Serial No. 60/214,508 filed on June 28, 2000 and entitled "THERMAL PROCESSING DEVICES AND METHODS"; U.S. Provisional Patent Application Serial No. 60/214,642 filed on June 28, 2000 and
5 entitled "SAMPLE PROCESSING DEVICES, SYSTEMS AND METHODS"; U.S. Provisional Patent Application Serial No. 60/237,072 filed on October 2, 2000 and entitled "SAMPLE PROCESSING DEVICES, SYSTEMS AND METHODS"; U.S. Provisional Patent Application Serial No. 60/260,063 filed on January 6, 2001 and titled "SAMPLE PROCESSING DEVICES, SYSTEMS AND METHODS"; U.S. Provisional Patent Application Serial No. 60/284,637 filed on April 18, 2001 and titled "ENHANCED SAMPLE PROCESSING
10 DEVICES, SYSTEMS AND METHODS"; and U.S. Patent Application Publication No. US 2002/0048533 titled "SAMPLE PROCESSING DEVICES AND CARRIERS." Other potential device constructions may be found in, e.g., U.S. Patent No. 6,627,159 titled "CENTRIFUGAL FILLING OF SAMPLE PROCESSING DEVICES" (Bedingham et al.).

The optical multiplexing system according to the present disclosure may comprise a plurality of process
15 chambers (e.g. reaction vessel) each for holding a respective sample and one or more sets of probes like sets of analyte specific probes, sets of decoding oligonucleotides/non-signal oligonucleotides and/or sets of signal oligonucleotides/non-signal-oligonucleotides. For example, the process chambers may comprised in a rotatable disk or in a movable well-plate like a 96-well plate; a motor to rotate said disk or to move the well-plate, wherein in particular the motor may be part of a robotic system.

20 The optical multiplexing system according to the present disclosure may comprise further at least one or a plurality of optical modules, in particular wherein the system comprises a housing having at least one or a plurality of locations adapted to receive the optical modules, wherein each of the plurality of optical module(s) are removable from the locations of the housing.

25 In some advantageous embodiments, the optical multiplexing system according to the present disclosure may comprise a detector, and in particular a fiber optic bundle coupled to the plurality of optical modules to convey the fluorescent light from the multiple optical modules to the detector.

In particular, the optical module(s) includes an optical channel each optical module having a light source selected for exciting a different one of the dyes and a lens to capture fluorescent light emitted,

said optical module(s) being optically configured to interrogate the fluorescent dyes at different wavelengths.

In a further embodiment, the system may include a microfluidic cartridge (also referred to herein as a microfluidic device) having at least one flow-through channel. The optical multiplexing system includes a fluorescence imaging system. Further features of the system may be a temperature measurement and/or a control system. In some embodiments, the system comprises a pressure measurement and control system for applying variable pneumatic pressures, e.g. to the microfluidic cartridge. The optical multiplexing system may comprise a storage device for holding multiple reagents, such as a well-plate. Further, the optical multiplexing system may comprise a liquid handling system, in particular comprising e.g. at least one robotic pipettor for aspirating, mixing, and dispensing reagent mixtures e.g. to the microfluidic cartridge and/or to the reaction vessel(s). Furthermore, the system may comprise means for data storage, processing, and output; and in particular a system controller to coordinate the various devices and functions.

In some embodiments, the method according to the present disclosure encodes a nucleic acid analyte, such as an mRNA, e.g. such an mRNA coding for a particular protein.

In some advantageous embodiments, the method described herein is used for specific detection of many different analytes in parallel. The technology allows to distinguish a higher number of analytes than different signals are available. The process includes at least four consecutive rounds of specific binding, signal detection and selective denaturation (if a next round is required), eventually producing a signal code. To decouple the dependency between the analyte specific binding and the oligonucleotides providing the detectable signal, a so called "decoding"-oligonucleotide is introduced. The decoding oligonucleotide transcribes the information of the analyte specific probe set to the signal oligonucleotides.

In a specific embodiment the method may comprise the steps of: 1. providing one or more analyte specific probe sets, the set of analyte specific probes consist of one or more different probes, each differing in the binding moiety that specifically interacts with the analyte, all probes of a single probe set are tethered to a sequence element (unique identifier), that is unique to a single probe set and allows the specific hybridization of a decoding oligonucleotide, 2. specific binding of the probe sets to

their target binding sites of the analyte, 3. eliminating non-bound probes (e.g. by a wash step), 4. providing a mixture of decoding oligonucleotides that specifically hybridize to the unique identifier sequences of the probe sets, the decoding oligonucleotides comprise of at least two sequence elements, a first element that is complementary to the unique identifier sequences of the
5 corresponding probe set and a second sequence element (translator element) that provides a sequence for the specific hybridization of a signal oligonucleotide, the translator element defines the type of signal that is recruited to the decoding oligonucleotide, 5. specific hybridization of the decoding oligonucleotides to the unique identifier sequences provided by the bound probe sets, 6. eliminating non-bound decoding oligonucleotides (e.g. by washing step), 7. providing a mixture of signal
10 oligonucleotides, comprising of a signal that can be detected and a nucleic acid sequence that specifically hybridizes to the translator element of one of the decoding oligonucleotides used in the former hybridization step, 8. specific hybridization of the signal oligonucleotides, 9. eliminating non-bound signal oligonucleotides, 10. detection of the signals, 11. selective release of decoding oligonucleotides and signal oligonucleotides while the binding of specific probe sets to the analyte is
15 almost or completely unaffected, 12. eliminating released decoding oligonucleotide and signal oligonucleotides (e.g. by a washing step) while the binding of specific probes sets to the analytes is almost or completely unaffected , repeating the steps 4 to 12 at least three times until the detection of a sufficient number of signals to generate an encoding scheme for each different analyte of interest.

It is to be understood that the before-mentioned features and those to be mentioned in the following
20 cannot only be used in the combination indicated in the respective case, but also in other combinations or in an isolated manner without departing from the scope of the disclosure.

The disclosure is now further explained by means of embodiments resulting in additional features, characteristics and advantages of the disclosure. The embodiments are of pure illustrative nature and do not limit the scope or range of the disclosure. The features mentioned in the specific embodiments
25 are general features of the disclosure which are not only applicable in the specific embodiment but also in an isolated manner in the context of any embodiment of the disclosure.

The method disclosed herein is used for specific detection of many different analytes in parallel. The technology allows distinguishing a higher number of analytes than different signals are available. The process preferably includes at least two consecutive rounds of specific binding, signal detection and

selective denaturation (if a next round is required), eventually producing a signal code. To decouple the dependency between the analyte specific binding and the oligonucleotides providing the detectable signal, a so called “decoding” oligonucleotide is introduced. The decoding oligonucleotide transcribes the information of the analyte specific probe set to the signal oligonucleotides.

5 Methods and Examples

In an application variant, the analyte or target is nucleic acid, e.g. DNA or RNA, and the probe set comprises oligonucleotides that are partially or completely complementary to the whole sequence or a subsequence of the nucleic acid sequence to be detected (Figure 1). The nucleic acid sequence specific oligonucleotide probe sets comprising analyte-specific probes (1) including a binding element (S) that specifically hybridizes to the target nucleic acid sequence to be detected, and an identifier element (T) comprising a nucleotide sequence which is unique to said set of analyte-specific probes (unique identifier sequence).

In an advantageous embodiment of the present disclosure, the analyte/target is a nucleic acid, e.g. RNA, and two probe sets comprising oligonucleotides that are partially or completely complementary to distinctive regions of a single nucleic acid sequence target (Figure 15). The nucleic acid sequence specific oligonucleotide probe sets comprising two sets of analyte-specific probes each (1 and 1', 2 and 2'), both including a binding element (S) that specifically hybridizes to the target nucleic acid sequence to be detected, and each with a different identifier element (T) comprising a nucleotide sequence which is unique to said set of analyte-specific probes (unique identifier sequence). The two sets are used for decoding (1, 2) of the analyte and detection of presence/absence of exclusive elements that differentiate subgroups of analytes (1' and 2').

In a further application variant, the analyte or target is a protein and the probe set comprises one or more proteins, e.g. antibodies (Figure 2). The protein specific probe set comprising analyte-specific probes (1) including a binding element (T) such as the (hyper-)variable region of an antibody, that specifically interacts with the target protein to be detected, and the identifier element (T).

In a further application variant, at least one analyte is a nucleic acid and at least a second analyte is a protein and at least the first probe set binds to the nucleic acid sequence and at least the second probe set binds specifically to the protein analyte. Other combinations are possible as well.

An Embodiments of the general method present may be:

5 Step 1: Applying the at least 20 analyte- or target-specific probe sets. The target nucleic acid sequence is incubated with a probe set consisting of oligonucleotides with sequences complementary to the target nucleic acid. In this example, a probe set of 5 different probes is shown, each comprising a sequence element complementary to an individual subsequence of the target nucleic acid sequence (S1 to S5). In this example, the regions do not overlap. Each of the oligonucleotides targeting the same nucleic acid sequence comprises the identifier element or unique identifier sequence (T), respectively.

10 Step 2: Hybridization of the probe set. The probe set is hybridized to the target nucleic acid sequence under conditions allowing a specific hybridization. After the incubation, the probes are hybridized to their corresponding target sequences and provide the identifier element (T) for the next steps.

Step 3: Eliminating non-bound probes. After hybridization, the unbound oligonucleotides are eliminated, e.g. by washing steps.

15 Step 4: Applying the decoding oligonucleotides. The decoding oligonucleotides consisting of at least two sequence elements (t) and (c) are applied. While sequence element (t) is complementary to the unique identifier sequence (T), the sequence element (c) provides a region for the subsequent hybridization of signal oligonucleotides (translator element).

20 Step 5: Hybridization of decoding oligonucleotides. The decoding oligonucleotides are hybridized with the unique identifier sequences of the probes (T) via their complementary first sequence elements (t). After incubation, the decoding oligonucleotides provide the translator sequence element (c) for a subsequent hybridization step.

Step 6: Eliminating the excess of decoding oligonucleotides. After hybridization, the unbound decoding oligonucleotides are eliminated, e.g. by washing steps.

Step 7: Applying the signal oligonucleotide. The signal oligonucleotides are applied. The signal oligonucleotides comprise at least one second connector element (C) that is essentially complementary to the translator sequence element (c) and at least one signal element that provides a detectable signal (F).

5 Step 8: Hybridization of the signal oligonucleotides. The signal oligonucleotides are hybridized via the complementary sequence connector element (C) to the translator element (c) of decoding oligonucleotide. After incubation, the signal oligonucleotides are hybridized to their corresponding decoding oligonucleotides and provide a signal (F) that can be detected.

10 Step 9: Eliminating the excess of signal oligonucleotides. After hybridization, the unbound signal oligonucleotides are eliminated, e.g. by washing steps.

Step 10: Signal detection. The signals provided by the signal oligonucleotides are detected.

The following steps (steps 11 and 12) are unnecessary for the last detection round.

15 Step 11: Selective denaturation. The hybridization between the unique identifier sequence (T) and the first sequence element (t) of the decoding oligonucleotides is dissolved. The destabilization can be achieved via different mechanisms well known to the trained person like for example: increased temperature, denaturing agents, etc. The target- or analyte-specific probes are not affected by this step.

20 Step 12: Eliminating the denatured decoding oligonucleotides. The denatured decoding oligonucleotides and signal oligonucleotides are eliminated (e.g. by washing steps) leaving the specific probe sets with free unique identifier sequences, reusable in a next round of hybridization and detection (steps 4 to 10). This detection cycle (steps 4 to 12) is repeated at least four times until the planned encoding scheme is completed.

In some advantageous embodiments, in a Step 13 an additional cycle of steps 4 to 10 is performed to read subgroup/variation specific signals.

Another Embodiment of the general method of the present disclosure using multi-decoders may be (Fig. 16):

Step 1: Target nucleic acids: In this example three different target nucleic acids (A), (B) and (C) have to be detected and differentiated by using only two different types of signal oligonucleotides. Before starting the experiment, a certain encoding scheme is set. In this example, the three different nucleic acid sequences are encoded by three rounds of detection with three different signal types (1), (2) and (1/2) and a resulting hamming distance of 3 to allow for error detection. The planned codewords are:

sequence A: (1) – (1) – (2)

sequence B: (2) – (2) – (1/2)

sequence C: (1/2) – (1/2) – (1)

Step 2: Hybridization of the probe sets: For each target nucleic acid, an own probe set is applied, specifically hybridizing to the corresponding nucleic acid sequence of interest. Each probe set provides a unique identifier sequence (T1), (T2) or (T3). This way each different target nucleic acid is uniquely labeled. In this example sequence (A) is labeled with (T1), sequence (B) with (T2) and sequence (C) with (T3). The illustration in Fig. 16 summarizes Steps 1 to 3 of Fig. 3.

Step 3: Hybridization of the decoding oligonucleotides and multi-decoders: For each unique identifier present, a certain decoding oligonucleotide or multi-decoder is applied specifically hybridizing to the corresponding unique identifier sequence by its first sequence element (here (t1) to (T1), (t2) to (T2) and (t3) to (T3)). Each of the decoding oligonucleotides or multi-decoders provides a translator or two translator elements that define the signals that will be generated after hybridization of signal oligonucleotides. Here nucleic acid sequence (A) is labeled with (c1), (B) is labeled with (c2) and (C) is labeled with both translator elements (c1) and (c2) resulting in the signal (1/2). The illustration in Fig. 16 summarizes steps 4 to 6 of Fig.3.

Step 4: Hybridization of signal oligonucleotides: For each type of translator element, a signal oligonucleotide with a certain signal, differentiable from signals of other signal oligonucleotides, is applied. This signal oligonucleotide can specifically hybridize to the corresponding translator element. The illustration in Fig. 16 summarizes steps 7 to 9 of Fig. 3

5 Step 5: Signal detection for the encoding scheme: The different signals are detected. Note that in this example the nucleic acids (A), (B) and (C) can already be distinguished after the first round of detection. This is in contrast to the step 5 of Fig. 5 explained by the additional signal type (1/2) that can be realized due to multi-decoders. Although nucleic acid sequences can already be distinguished, the additional rounds contribute to the planned hamming distance
10 of 3. The illustration in Fig. 16 corresponds to step 10 of Fig. 3.

Step 6: Selective denaturation: The decoding (and signal) oligonucleotides and/or multi-decoders of all nucleic acid sequences to be detected are selectively denatured and eliminated as described in steps 11 and 12 of Fig.3. Afterwards the unique identifier sequences of the different probe sets can be used for the next round of hybridization and detection.

15 Step 7: Second round of detection: A next round of hybridization and detection is done as described in steps 3 to 5. Note that in this new round the mix of different decoding oligonucleotides and multi-decoders is changed. For example, decoding oligonucleotide of nucleic acid sequence (A) used in the first round comprised of sequence elements (t1) and (c1) while the new multi decoder of round 2 comprises of the sequence elements (t1), (c1) and (c2).
20 Note that now a hamming distance of 2 is already given after 2 rounds, which is the final result of the example in Fig. 3 after 3 rounds.

Step 8: Third round of detection: Again, a new combination of decoding oligonucleotides and/or multi-decoders is used leading to new signal combinations. After signal detection, the resulting codewords for the three different nucleic acid sequences are not only unique and
25 therefore distinguishable but comprise a hamming distance of 3 to other codewords. Due to the hamming distance, an error in the detection of the signals (signal exchange) would not result in a valid codeword and therefore could be detected and because of hamming distance 3 also corrected, in contrast to the encoding scheme of Fig. 3. This way three different nucleic

acids can be distinguished in three detection rounds with two different signals, allowing an error detection and correction.

Note that in every round of detection, the type of signal provided by a certain unique identifier is controlled by the use of a certain decoding oligonucleotide. As a result, the sequence of decoding oligonucleotides applied in the detection cycles transcribes the binding specificity of the probe set into a unique signal sequence.

The steps of decoding oligonucleotide hybridization (steps 4 to 6) and signal oligonucleotide hybridization (steps 7 to 9) can also be combined in two alternative ways as shown in Figure 4.

Opt. 1: Simultaneous hybridization. Instead of the steps 4 to 9 of Figure 3, specific hybridization of decoding oligonucleotides and signal oligonucleotides can also be done simultaneously leading to the same result as shown in step 9 of Figure 3, after eliminating the excess decoding- and signal oligonucleotides.

Opt. 2: Preincubation. Additionally to option 1 of Figure 3, decoding- and signal oligonucleotides can be preincubated in a separate reaction before being applied to the target nucleic acid with the already bound specific probe set.

1. Example for signal encoding of three different nucleic acid sequences by two different signal types and three detection rounds

Figure 3 shows the general concept of generation and detection of specific signals mediated by decoding oligonucleotides. It does not show the general concept of encoding that can be achieved by this procedure. To illustrate the use of the process shown in Figure 3 for the generation of an encoding scheme, Figure 5 shows a general example for a multiple round encoding experiment with three different nucleic acid sequences. In this example, the encoding scheme includes error detection.

Step 1: Target nucleic acids. In this example three different target nucleic acids (A), (B) and (C) have to be detected and differentiated by using only two different types of signal. Before starting the experiment, a certain encoding scheme is set. In this example, the three different nucleic acid

sequences are encoded by three rounds of detection with two different signals (1) and (2) and a resulting hamming distance of 2 to allow for error detection. The planned codewords are:

sequence A: (1) – (2) – (2);

sequence B: (1) – (1) – (1);

5 sequence C: (2) – (1) – (2).

Step 2: Hybridization of the probe sets. For each target nucleic acid, an own probe set is applied, specifically hybridizing to the corresponding nucleic acid sequence of interest. Each probe set provides a unique identifier sequence (T1), (T2) or (T3). This way each different target nucleic acid is uniquely labeled. In this example sequence (T) is labeled with (T1), sequence (B) with (T2) and sequence (C) with (T3). The illustration summarizes steps 1 to 3 of Figure 3.

10

Step 3: Hybridization of the decoding oligonucleotides. For each unique identifier present, a certain decoding oligonucleotide is applied specifically hybridizing to the corresponding unique identifier sequence by its first sequence element (here (t1) to (T1), (t2) to (T2) and (t3) to (T3)). Each of the decoding oligonucleotides provides a translator element that defines the signal that will be generated after hybridization of signal oligonucleotides. Here nucleic acid sequences (A) and (B) are labeled with the translator element (c1) and sequence (C) is labeled with (c2). The illustration summarizes steps 4 to 6 of Figure 3.

15

Step 4: Hybridization of signal oligonucleotides. For each type of translator element, a signal oligonucleotide with a certain signal (2), differentiable from signals of other signal oligonucleotides, is applied. This signal oligonucleotide can specifically hybridize to the corresponding translator element. The illustration summarizes steps 7 to 9 of Figure 3.

20

Step 5: Signal detection for the encoding scheme. The different signals are detected. Note that in this example the nucleic acid sequence (C) can be distinguished from the other sequences by the unique signal (2) it provides, while sequences (A) and (B) provide the same kind of signal (1) and cannot be distinguished after the first cycle of detection. This is due to the fact, that the number of different

25

nucleic acid sequences to be detected exceeds the number of different signals available. The illustration corresponds to step 10 of Figure 3.

Step 6: Selective denaturation. The decoding (and signal) oligonucleotides of all nucleic acid sequences to be detected are selectively denatured and eliminated as described in steps 11 and 12 of Figure 3.

5 Afterwards the unique identifier sequences of the different probe sets can be used for the next round of hybridization and detection.

Step 7: Second round of detection. A next round of hybridization and detection is done as described in steps 3 to 5. Note that in this new round the mix of different decoding oligonucleotides is changed. For example, decoding oligonucleotide of nucleic acid sequence (A) used in the first round comprised of
10 sequence elements (t1) and (c1) while the new decoding oligonucleotide comprises of the sequence elements (t1) and (c2). Note that now all three sequences can clearly be distinguished due to the unique combination of first and second round signals.

Step 8: Third round of detection. Again, a new combination of decoding oligonucleotides is used leading to new signal combinations. After signal detection, the resulting codewords for the three
15 different nucleic acid sequences are not only unique and therefore distinguishable but comprise a hamming distance of 2 to other codewords. Due to the hamming distance, an error in the detection of the signals (signal exchange) would not result in a valid codeword and therefore could be detected. By this way three different nucleic acids can be distinguished in three detection rounds with two different signals, allowing error detection.

20 2. Advantages over prior art technologies

Coding strategy

Compared to state-of-the-art methods, one particular advantage of the method according to the disclosure is the use of decoding oligonucleotides breaking the dependencies between the target specific probes and the signal oligonucleotides.

Without decoupling target specific probes and signal generation, two different signals can only be generated for a certain target if using two different molecular tags. Each of these molecular tags can only be used once. Multiple readouts of the same molecular tag do not increase the information about the target. In order to create an encoding scheme, a change of the target specific probe set after each round is required (SeqFISH) or multiple molecular tags must be present on the same probe set (like merFISH, intronSeqFISH).

Following the method according to the disclosure, different signals are achieved by using different decoding oligonucleotides reusing the same unique identifier (molecular tag) and a small number of different, mostly cost-intensive signal oligonucleotides. This leads to several advantages in contrast to the other methods.

- (1) The encoding scheme is not defined by the target specific probe set as it is the case for all other methods of prior art. Here the encoding scheme is transcribed by the decoding oligonucleotides. This leads to a much higher flexibility concerning the number of rounds and the freedom in signal choice for the codewords. Looking on the methods of prior art (e.g. merFISH or intronSeqFISH), the encoding scheme (number, type and sequence of detectable signals) for all target sequences is predefined by the presence of the different tag sequences on the specific probe sets (4 of 16 different tags per probe set in the case of merFISH and 5 of 60 different tags in the case of intron FISH). In order to produce a sufficient number of different tags per probe set, the methods use rather complex oligonucleotide designs with several tags present on one target specific oligonucleotide. In order to change the encoding scheme for a certain target nucleic acid, the specific probe set has to be replaced. The method according to the disclosure describes the use of a single unique tag sequence (unique identifier) per analyte, because it can be reused in every detection round to produce a new information. The encoding scheme is defined by the order of decoding oligonucleotides that are used in the detection rounds. Therefore, the encoding scheme is not predefined by the specific probes (or the unique tag sequence) but can be adjusted to different needs, even during the experiment. This is achieved by simply changing the decoding oligonucleotides used in the detection rounds or adding additional detection rounds.

(2) The number of different signal oligonucleotides must match the number of different tag sequences with methods of prior art (16 in the case of merFISH and 60 in the case of intronSeqFISH). Using the method according to the disclosure, the number of different signal oligonucleotides matches the number of different signals used. Due to this, the number of signal oligonucleotides stays constant for the method described here and never exceeds the number of different signals but increases with the complexity of the encoding scheme in the methods of prior art (more detection rounds more different signal oligonucleotides needed). As a result, the method described here leads to a much lower complexity (unintended interactions of signal oligonucleotides with environment or with each other) and dramatically reduces the cost of the assay since the major cost factor are the signal oligonucleotides.

(3) In the methods of prior art, the number of different signals generated by a target specific probe set is restricted by the number of different tag sequences the probe set can provide. Since each additional tag sequence increases the total size of the target specific probe, there is a limitation to the number of different tags a single probe can provide. This limitation is given by the size dependent increase of several problems (unintended inter- and intramolecular interactions, costs, diffusion rate, stability, errors during synthesis etc.). Additionally, there is a limitation of the total number of target specific probes that can be applied to a certain analyte. In case of nucleic acids, this limitation is given by the length of the target sequence and the proportion of suitable binding sites. These factors lead to severe limitations in the number of different signals a probe set can provide (4 signals in the case of merFISH and 5 signals in the case of intronSeqFISH). This limitation substantially affects the number of different codewords that can be produced with a certain number of detection rounds. In the approach of the disclosure only one tag is needed and can be freely reused in every detection round. This leads to a low oligonucleotide complexity/length and at the same time to the maximum encoding efficiency possible (number of colors^{number of rounds}). The vast differences of coding capacity of our method compared to the other methods is shown in Figures 1 and 5. Due to this in approach of the disclosure a much lower number of detection rounds is needed to produce the same amount of information. A lower number of detection rounds is connected to lower cost, lower

experimental time, lower complexity, higher stability and success rate, lower amount of data to be collected and analyzed and a higher accuracy of the results.

Coding capacity

All three methods compared in the Table 1 below use specific probe sets that are not denatured between different rounds of detection. For intronSeqFISH there are four detection rounds needed to produce the pseudo colors of one coding round, therefore data is only given for rounds 4, 8, 12, 16 and 20. The merFISH-method uses a constant number of 4 signals, therefore the data starts with the smallest number of rounds possible. After 8 detection rounds our method exceeds the maximum coding capacity reached with 20 rounds of merFISH (depicted with one asterisk) and after 12 rounds of detection the maximum coding capacity of intron FISH is exceeded (depicted with two asterisks). For the method according to the disclosure usage of 3 different signals is assumed (as is with intronSeqFISH).

NUMBER OF ROUNDS:	CODING CAPACITY		
	Method of the present disclosure	intron FISH	merFISH
1	3	-	-
2	9	-	-
3	27	-	-
4	81	12	1
5	243	-	5
6	729	-	15
7	2187	-	35
8*	6561	144	70
9	19683	-	126
10	59049	-	210
11	177147	-	330
12**	531441	1728	495

13	1594323	-	715
14	4782969	-	1001
15	14348907	-	1365
16	43046721	20736	1820
17	129140163	-	2380
18	387420489	-	3060
19	1162261467	-	3876
20	3486784401	248832	4845

Table 1: Comparison of coding capacity

As shown in Figure 6 the number of codewords for merFISH does not exponentially increase with the number of detection cycles but gets less effective with each added round. In contrast, the number of codewords for intronSeqFISH in the method according to the disclosure increases exponentially. The slope of the curve for the proposed method is much higher than that of intron FISH, leading to more than 10,000 times more codewords usable after 20 rounds of detection.

Note that this maximum efficiency of coding capacity is also reached in case of seqFISH, where specific probes are denatured after every detection round and a new probe set is specifically hybridized to the target sequence for each detection round. However, this method has major downsides to technologies using only one specific hybridization for their encoding scheme (all other methods):

- (1) For the efficient denaturation of the specific probes, rather crude conditions must be used (high temperatures, high concentrations of denaturing agent, long incubation times) leading to much higher probability for the loss or the damage of the analyte.
- (2) For each round of detection an own probe set has to be used for every target nucleic acid sequence. Therefore, the number of specific probes needed for the experiment scales with the number of different signals needed for the encoding scheme. This dramatically increases the complexity and the cost of the assay.

(3) Because the hybridization efficiency of every target nucleic acid molecule is subject to some probabilistic effects, the fluctuations of signal intensity between the different detection rounds is much higher than in methods using only one specific hybridization event, reducing the proportion of complete codes.

5 (4) The time needed for the specific hybridization is much longer than for the hybridization of signal oligonucleotides or decoding oligonucleotides (as can be seen in the method parts of the intronSeqFISH, merFISH and seqFISH publications), which dramatically increases the time needed to complete an experiment.

10 Due to these reasons all other methods use a single specific hybridization event and accept the major downside of lower code complexity and therefore the need of more detection rounds and a higher oligonucleotide design complexity.

The method according to the disclosure combines the advantages of seqFISH (mainly complete freedom concerning the encoding scheme) with all advantages of methods using only one specific hybridization event while eliminating the major problems of such methods.

15 Note that the high numbers of codewords produced after 20 rounds can also be used to introduce higher hamming distances (differences) between different codewords, allowing error detection of 1, 2 or even more errors and even error corrections. Therefore, even very high coding capacities are still practically relevant.

20 For the detection of subgroups/variations within a group of analytes/targets that share certain parts (e.g. mRNA splice variants), two separate codewords might be used. However, signals will be generated at the very same physical location, so that a mixed readout will be the results for this naïve approach. Using an additional round to add information to an already established code circumvents this issue.

25 As mentioned above, the usage of multi-decoders further increases the coding capacity of the encoding scheme. Instead of being limited to the having exactly the same number of different signal types as different signal oligonucleotides and corresponding translator elements, the use of multi-decoders increases the signal types that can be used to: $(N \times (N+1))/2$ (with N being the number of

different signal oligonucleotides used). For the code used in table 1 with 3 different signal oligonucleotides this would mean the following 7 different signal types could be used: (S1),(S2),(S3),(S1/S2),(S1/S3),(S2/S3),(S1/S2/S3). The effect to the coding efficiency can be seen in Table 1b and Figure 18.

NUMBER OF ROUNDS:	CODING CAPACITY			
	Method of the present disclosure	Method of the present disclosure with multi-decoders	intron FISH	merFISH
1	3	7	-	-
2	9	49	-	-
3	27	343	-	-
4	81	2401	12	1
5*	243	16807	-	5
6	729	117649	-	15
7**	2187	823543	-	35
8	6561	5764801	144	70
9	19683	40353607	-	126
10	59049	282475249	-	210
11	177147	1977326743	-	330
12***	531441	$1,3841 \times 10^{10}$	1728	495
13	1594323	$9,6889 \times 10^{10}$	-	715
14	4782969	$6,7822 \times 10^{11}$	-	1001
15	14348907	$4,7476 \times 10^{12}$	-	1365
16	43046721	$3,3233 \times 10^{13}$	20736	1820
17	129140163	$2,3263 \times 10^{14}$	-	2380
18	387420489	$1,6284 \times 10^{15}$	-	3060
19	1162261467	$1,1399 \times 10^{16}$	-	3876
20	3486784401	$7,9792 \times 10^{16}$	248832	4845

5 Table 1b shows the coding capacity of the four methods.

All four methods compared in table 1b use specific probe sets that are not denatured between different rounds of detection. For intronSeqFISH there are four detection rounds needed to produce the pseudo colors of one coding round, therefore data is only given for rounds 4, 8,12,16 and 20. The merFISH-method uses a constant number of 4 signals, therefore the data starts with the smallest number of rounds possible. After 4 detection rounds the method with multi-decoders as described here exceeds the maximum coding capacity reached with 20 rounds of merFISH (depicted with one asterisk), after 7 rounds of detection the maximum coding capacity of intron FISH is exceeded

(depicted with two asterisks) and after 12 rounds of detection the maximum coding capacity of the method of the present disclosure is exceeded (depicted with three asterisks). The usage of 3 different signal oligonucleotides is assumed (as is with intronSeqFISH).

3. Selective denaturation, oligonucleotide assembly and reuse of unique identifiers are surprisingly efficient

A key factor of the method according to the disclosure is the consecutive process of decoding oligonucleotide binding, signal oligonucleotide binding, signal detection and selective denaturation. In order to generate an encoding scheme, this process has to be repeated several times (depending on the length of the codeword). Because the same unique identifier is reused in every detection cycle, all events from the first to the last detection cycle are depending on each other. Additionally, the selective denaturation depends on two different events: While the decoding oligonucleotide has to be dissolved from the unique identifier with highest efficiency, specific probes have to stay hybridized with highest efficiency.

Due to this the efficiency E of the whole encoding process can be described by the following equation:

$$E = B_{sp} \times (B_{de} \times B_{si} \times E_{de} \times S_{sp})^n$$

E = total efficiency

B_{sp} = binding of specific probes

B_{de} = binding of decoding oligonucleotides

B_{si} = binding of signal oligonucleotides

E_{de} = elimination of decoding oligonucleotides

S_{sp} = stability of specific probes during elimination process

n = number of detection cycles

Based on this equation the efficiency of each single step can be estimated for a given total efficiency of the method. The calculation is hereby based on the assumption, that each process has the same efficiency. The total efficiency describes the portion of successfully decodable signals of the total signals present.

The total efficiency of the method is dependent on the efficiency of each single step of the different factors described by the equation. Under the assumption of an equally distributed efficiency the total efficiency can be plotted against the single step efficiency as shown in Figure 7. As can be seen, a practically relevant total efficiency for an encoding scheme with 5 detection cycles can only be achieved with single step efficiencies clearly above 90%. For example, to achieve a total efficiency of 50% an average efficiency within each single step of 97.8% is needed. These calculations are even based on the assumption of a 100% signal detection and analysis efficiency. Due to broad DNA melting curves of oligonucleotides of a variety of sequences, the inventors assumed prior to experiments that the selective denaturation would work less efficient for denaturation of decoding oligonucleotides and that sequence specific binding probes are not stable enough. In contrast to this assumption, we found a surprising effectiveness of all steps and a high stability of sequence specific probes during selective denaturation.

Experimentally, the inventors achieved a total decoding efficiency of about 30% to 65% based on 5 detection cycles. A calculation of the efficiency of each single step (Bsp, Bde, Bsi, Ede, Ssp) by the formula given above revealed an average efficiency of about 94.4% to 98%. These high efficiencies are very surprising and cannot easily be anticipated by a well-trained person in this field.

4. Experimental data

Background

The experiment shows the specific detection of 10 to 50 different mRNAs species in parallel with single molecule resolution. It is based on 5 detection cycles, 3 different fluorescent signals and an encoding scheme without signal gaps and a hamming distance of 2 (error detection). The experiment proves the enablement and functionality of the method according to the disclosure.

Oligonucleotides and their sequences

All oligonucleotide sequences used in the experiment (target specific probes, decoding oligonucleotides, signal oligonucleotides) are listed in the sequence listing of the appendix. The signal oligonucleotide R:ST05*O_Atto594 was ordered from biomers.net GmbH. All other oligonucleotides

were ordered from Integrated DNA Technologies. Oligonucleotides were dissolved in water. The stock solutions (100 μ M) were stored at -20°C.

Experimental overview

The 50 different target specific probe sets are divided into 5 groups. The name of the transcript to be detected and the name of the target specific probe set are the same (transcript variant names of www.ensembl.org). The term "new" indicates a revised probe design. All oligonucleotide sequences of the probe sets can be found in the sequence listing. The table lists the unique identifier name of the probe set as well as the names of the decoding oligonucleotides used in the different detection cycles. The resulting code shows the sequence of fluorescent signals generated during the 5 detection cycles (G(reen)=Alexa Fluor 488, O(range)= Atto 594, Y(ellow)= Alexa Fluor 546).

		Decoding oligonucleotides in detection cycle:					
target transcript	unique identifier	1	2	3	4	5	resulting code
Group 1							
DDX5-201	ST21	ST21-ST07	ST21-ST05	ST21-ST07	ST21-ST05	ST21-ST06	GOGOY
RAD17-208	ST02	ST02-ST06	ST02-ST07	ST02-ST06	ST02-ST06	ST02-ST07	YGYYG
SPOCK1-202	ST03	ST03-ST06	ST03-ST06	ST03-ST07	ST03-ST05	ST03-ST05	YGOO
FBXO32-203	ST04	ST04-ST07	ST04-ST06	ST04-ST06	ST04-ST06	ST04-ST05	GYYO
THRAP3-203	ST14	ST14-ST07	ST14-ST05	ST14-ST05	ST14-ST07	ST14-ST05	GOOGO
GART-203	ST11	ST11-ST06	ST11-ST07	ST11-ST06	ST11-ST05	ST11-ST05	YGYO
KAT2A-201	ST13	ST13-ST06	ST13-ST06	ST13-ST07	ST13-ST06	ST13-ST07	YGYG
HPRT1-201	ST12	ST12-ST06	ST12-ST07	ST12-ST07	ST12-ST06	ST12-ST06	YGGY
CCNA2-201	ST22	ST22-ST05	ST22-ST07	ST22-ST06	ST22-ST06	ST22-ST05	OGYO
NKRF-201	ST23	ST23-ST05	ST23-ST06	ST23-ST07	ST23-ST06	ST23-ST05	OYGO
Group 2							
CCNE1-201-new	NT01	NT01-ST07	NT01-ST07	NT01-ST06	NT01-ST06	NT01-ST06	GGYY
COG5-201	NT03	NT03-ST06	NT03-ST06	NT03-ST05	NT03-ST05	NT03-ST06	YOOY

FBN1-201	NT04	NT04-ST05	NT04-ST07	NT04-ST06	NT04-ST07	NT04-ST07	OGYGG
DYNC1H1-201	NT05	NT05-ST07	NT05-ST06	NT05-ST07	NT05-ST06	NT05-ST06	GYGYY
CKAP5-202	NT06	NT06-ST05	NT06-ST06	NT06-ST07	NT06-ST05	NT06-ST06	OYGOY
KRAS-202	NT07	NT07-ST06	NT07-ST05	NT07-ST06	NT07-ST06	NT07-ST05	YOYYO
EGFR-207	NT08	NT08-ST07	NT08-ST06	NT08-ST05	NT08-ST05	NT08-ST05	GYOOO
TP53-205	NT09	NT09-ST06	NT09-ST05	NT09-ST06	NT09-ST07	NT09-ST07	YOYGG
NF1-204	XT01	XT01-ST06	XT01-ST06	XT01-ST07	XT01-ST07	XT01-ST06	YYGGY
NF2-204	XT02	XT02-ST07	XT02-ST06	XT02-ST05	XT02-ST06	XT02-ST07	GYOYG
Group 3							
ACO2-201	XT03	XT03-ST06	XT03-ST06	XT03-ST06	XT03-ST07	XT03-ST05	YYYGO
AKT1-211	XT04	XT04-ST07	XT04-ST06	XT04-ST07	XT04-ST07	XT04-ST05	GYGGO
LYPLAL1-202	XT05	XT05-ST07	XT05-ST05	XT05-ST06	XT05-ST05	XT05-ST05	GOYOO
PKD2-201	XT06	XT06-ST06	XT06-ST07	XT06-ST05	XT06-ST05	XT06-ST07	YGOOG
ENG-204	XT09	XT09-ST05	XT09-ST05	XT09-ST06	XT09-ST06	XT09-ST06	OYYYY
FANCE-201	XT10	XT10-ST05	XT10-ST07	XT10-ST06	XT10-ST05	XT10-ST06	OGYOY
MET-201	XT12	XT12-ST05	XT12-ST06	XT12-ST05	XT12-ST06	XT12-ST06	OYOYY
NOTCH2-201	XT13	XT13-ST05	XT13-ST05	XT13-ST06	XT13-ST07	XT13-ST05	OYGOO
SPOP-206	XT14	XT14-ST05	XT14-ST07	XT14-ST05	XT14-ST07	XT14-ST06	OGOGY
ABL1-202	XT16	XT16-ST05	XT16-ST06	XT16-ST06	XT16-ST05	XT16-ST05	OYYOO
Group 4							
ATP11C-202	XT17	XT17-ST07	XT17-ST06	XT17-ST06	XT17-ST05	XT17-ST06	GYYOY
BCR-202	XT18	XT18-ST05	XT18-ST06	XT18-ST06	XT18-ST07	XT18-ST06	OYYGY
CAV1-205	XT19	XT19-ST07	XT19-ST05	XT19-ST06	XT19-ST07	XT19-ST06	GOYGY
CDK2-201	XT20	XT20-ST05	XT20-ST05	XT20-ST07	XT20-ST07	XT20-ST06	OOGGY
DCAF1-202	XT201	XT201-ST06	XT201-ST06	XT201-ST05	XT201-ST07	XT201-ST07	YYOGG
FHOD1-201	XT202	XT202-ST05	XT202-ST07	XT202-ST07	XT202-ST05	XT202-ST07	OGGOG
GMDS-202	XT203	XT203-ST07	XT203-ST05	XT203-ST07	XT203-ST06	XT203-ST05	GOGYO
IFNAR1-201	XT204	XT204-ST06	XT204-ST07	XT204-ST05	XT204-ST07	XT204-ST05	YGOGO
NSMF-203	XT206	XT206-ST07	XT206-ST06	XT206-ST07	XT206-ST05	XT206-ST07	GYGOG
POLA2-201	XT208	XT208-ST06	XT208-ST06	XT208-ST06	XT208-ST05	XT208-ST07	YYYOG

Group 5							
BRCA1-210new	NT10	NT10-ST07	NT10-ST05	NT10-ST06	NT10-ST06	NT10-ST07	GOYYG
JAK1-201new	XT11	XT11-ST05	XT11-ST05	XT11-ST07	XT11-ST06	XT11-ST07	OOGYG
STRAP-202	XT207	XT207-ST07	XT207-ST07	XT207-ST06	XT207-ST05	XT207-ST07	GGYOG
SERPINB5-201	XT209	XT209-ST07	XT209-ST05	XT209-ST05	XT209-ST05	XT209-ST07	GOOOG
SETX-201	XT210	XT210-ST06	XT210-ST07	XT210-ST06	XT210-ST07	XT210-ST06	YGYGY
WDFY1-201	XT212	XT212-ST05	XT212-ST07	XT212-ST05	XT212-ST06	XT212-ST07	OGOYG
TACC1-201	XT213	XT213-ST05	XT213-ST07	XT213-ST07	XT213-ST07	XT213-ST05	OGGGO
KIF2A-203	XT214	XT214-ST07	XT214-ST07	XT214-ST06	XT214-ST07	XT214-ST05	GGYGO
CDT1-201	XT215	XT215-ST07	XT215-ST07	XT215-ST07	XT215-ST05	XT215-ST05	GGGOO
CENPE-202	XT216	XT216-ST07	XT216-ST06	XT216-ST05	XT216-ST07	XT216-ST06	GYOGY

Table 2: Experimental overview

Variations of the experiment

Some variations of the experiment have been performed. Experiments 1 to 4 mainly differ in the number of transcripts detected in parallel. The groups listed as target specific probe sets refer to table 6. Experiments 5 to 8 are single round, single target controls for comparison with the decoded signals.

Experiment	Target specific probe sets used	No. of detection cycles	Imaging with trolox
1. 50 transcripts_T+	Groups 1 to 5 of table 6	5	+
2. 50 transcripts_T-	Groups 1 to 5 of table 6	5	-
3. 30 transcripts_T+	Groups 2 to 4 of table 6	5	+
4. 10 transcripts_T+	Group 1 of table 6	5	+
5. DDX5	DDX5-ST21	1	-
6. RAD17	RAD17-ST02	1	-
7. SPOCK1	SPOCK1-ST03	1	-
8. THRAP3	THRAP3-ST14	1	-

Table 3: Variations of the experiment

Experimental details*A. Seeding and cultivation of cells*

HeLa cells were grown in HeLa cell culture medium to nearly 100% confluency. The HeLa cell culture medium comprises DMEM (Thermo Fisher, Cat.: 31885) with 10% FCS (Biochrom, Cat.: S0415), 1% Penicillin-Streptomycin (Sigma-Aldrich, Cat.: P0781) and 1% MEM Non-Essential Amino Acids Solution (Thermo Fisher, Cat.: 11140035). After aspiration of cell culture medium, cells were trypsinized by incubation with trypsin EDTA solution (Sigma-Aldrich, Cat.: T3924) for 5 min at 37°C after a washing step with PBS (1,424 g/l $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$, 0,276 g/l, $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$, 8,19 g/l NaCl in water, pH 7,4). Cells were then seeded on the wells of a μ -Slide 8 Well ibidiTreat (ibidi, Cat.: 80826). The number of cells per well was adjusted to reach about 50% confluency after adhesion of the cells. Cells were incubated over night with 200 μ l HeLa cell culture medium per well.

B. Fixation of cells

After aspiration of cell culture medium and two washing steps with 200 μ l 37°C warm PBS per well, cells were fixed with 200 μ l precooled methanol (-20°C, Roth, Cat.: 0082.1) for 10 min at -20°C.

C. Counterstaining with Sudan Black

Methanol was aspirated and 150 μ l of 0.2% Sudan Black-solution diluted in 70% ethanol were added to each well. Wells were incubated for 5 min in the dark at room temperature. After incubation cells were washed three times with 400 μ l 70% ethanol per well to eliminate the excess of Sudan Black-solution.

D. Hybridization of analyte/target-specific probes

Before hybridization, cells were equilibrated with 200 µl sm-wash-buffer. The sm-wash-buffer comprises 30 mM Na₃Citrate, 300 mM NaCl, pH7, 10% formamide (Roth, Cat.:P040.1) and 5mM Ribonucleoside Vanadyl Complex (NEB, Cat.: S1402S). For each target-specific probe set 1 µl of a 100 µM oligonucleotide stock solution was added to the mixture. The oligonucleotide stock solution comprises equimolar amounts of all target specific oligonucleotides of the corresponding target specific probe set. The total volume of the mixture was adjusted to 100 µl with water and mixed with 100 µl of a 2x concentrated hybridization buffer solution. The 2x concentrated hybridization buffer comprises 120 mM Na₃Citrate, 1200 mM NaCl, pH7, 20% formamide and 20 mM Ribonucleoside Vanadyl Complex. The resulting 200 µl hybridization mixture was added to the corresponding well and incubated at 37°C for 2 h. Afterwards cells were washed three times with 200 µl per well for 10 min with target probe wash buffer at 37°C. The target probe wash buffer comprises 30 mM Na₃Citrate, 300 mM NaCl, pH7, 20% formamide and 5 mM Ribonucleoside Vanadyl Complex.

E. Hybridization of decoding oligonucleotides

Before hybridization, cells were equilibrated with 200 µl sm-wash-buffer. For each decoding oligonucleotide 1,5 µl of a 5 µM stock solution were added to the mixture. The total volume of the mixture was adjusted to 75 µl with water and mixed with 75 µl of a 2x concentrated hybridization buffer solution. The resulting 150 µl decoding oligonucleotide hybridization mixture was added to the corresponding well and incubated at room temperature for 45 min. Afterwards cells were washed three times with 200 µl per well for 2 min with sm-wash-buffer at room temperature.

F. Hybridization of signal oligonucleotides

Before hybridization, cells were equilibrated with 200 µl sm-wash-buffer. The signal oligonucleotide hybridization mixture was the same for all rounds of experiments 1 to 4 and comprised 0,3 µM of each signal oligonucleotide (see table A3) in 1x concentrated hybridization buffer solution. In each round 150 µl of this solution were added per well and incubated at room temperature for 45 min. The procedure was the same for experiments 5 to 8 with the exception that the final concentration of each signal oligonucleotide was 0,15 µM.

Afterwards cells were washed three times with 200 µl per well for 2 min with sm-wash-buffer at room temperature.

G. Fluorescence and white light imaging

Cells were washed once with 200 µl of imaging buffer per well at room temperature. In experiments without Trolox (see table 7, last column) imaging buffer comprises 30 mM Na₃Citrate, 300 mM NaCl, pH7 and 5mM Ribonucleoside Vanadyl Complex. In experiments with Trolox, imaging buffer additionally contains 10 % VectaCell Trolox Antifade Reagent (Vector laboratories, Cat.: CB-1000), resulting in a final Trolox concentration of 10 mM.

A Zeiss Axiovert 200M microscope with a 63x immersion oil objective (Zeiss, apochromat) with numerical aperture of 1.4, a pco.edge 4.2 CMOS camera (PCO AG) and an LED-light source (Zeiss, colibri 7) was used for imaging of the regions. Filter sets and LED-wavelengths were adjusted to the different optima of the fluorophores used. Illumination times per image were 1000 ms for Alexa Fluor 546 and Atto 594 and 400 ms for Alexa Fluor 488.

In each experiment, three regions were randomly chosen for imaging. For each region, a z-stack of 32 images was detected with a z-step size of 350 nm. Additionally, one white light image was taken from the regions. In experiments with more than one detection cycle, the regions of the first detection round were found back and imaged in every subsequent round.

H. Selective denaturation

For selective denaturation, every well was incubated with 200 µl of sm-wash-buffer at 42°C for 6 min. This procedure was repeated six times.

Steps (E) to (H) were repeated 5 times in experiments 1 to 4. Step (H) was omitted for the 5th detection cycle.

I. Analysis

Based on custom ImageJ-plugins a semi-automated analysis of the raw data was performed to distinguish the specific fluorescent signals from the background. The resulting 3D-point clouds of all three fluorescent channels were combined in silico with a custom VBA script. The resulting combined 3D-point clouds of the 5 detection cycles were aligned to each other on the basis of a VBA script. The resulting alignments revealed the codewords for each unique signal detected. Successfully decoded signals were used for quantitative and spatial analysis of the experiments based on custom VBA-scripts and ImageJ-plugins.

Results

1. Absolute numbers of decoded signals

The absolute numbers of successfully decoded signals for all transcripts are listed for each region of each experiment in the following Table 4. In summary, the sum of correct codes depicts the total number of decoded signals that were assigned to transcripts detectable in the corresponding experiment, while the sum of incorrect codes is the total number of decoded signals not detectable in the corresponding experiment. The total number of signals comprises successfully decoded as well as unsuccessfully decoded signals.

	Experiment 1: region:			Experiment 2: region:			Experiment 3: region:			Experiment 4: region:		
transcript name:	1	2	3	1	2	3	1	2	3	1	2	3
Group 1												
DDX5-201	1214	1136	927	1144	1509	1176	2964	2034	2141	8	2	2
RAD17-208	40	126	50	26	55	62	22	30	33	7	9	10
SPOCK1-202	581	655	301	483	875	149	1349	621	539	2	10	8
FBXO32-203	153	175	68	113	106	78	301	160	269	5	13	9
THRAP3-203	1079	2180	1035	810	1179	1047	2318	1609	1609	6	8	16
GART-203	422	397	346	350	333	202	766	658	569	5	3	2
KAT2A-201	141	310	166	174	307	186	382	315	340	5	1	3

HPRT1-201	63	79	34	44	116	71	85	88	112	1	0	6
CCNA2-201	91	248	205	95	134	138	241	151	238	10	20	9
NKRF-201	162	318	153	101	99	135	313	254	209	7	5	12
Group 2												
CCNE1-201- new	75	180	38	57	110	97	0	0	1	122	104	120
COG5-201	57	21	38	26	45	23	0	0	1	56	86	60
FBN1-201	202	1338	499	456	513	571	0	1	3	450	778	895
DYNC1H1-201	554	892	398	664	1026	666	4	3	7	823	1148	1248
CKAP5-202	43	23	77	51	98	74	1	2	1	94	190	212
KRAS-202	331	417	355	302	333	230	0	0	1	279	637	371
EGFR-207	527	252	372	293	519	322	0	1	0	411	719	818
TP53-205	116	324	194	138	198	169	0	1	4	182	280	181
NF1-204	381	676	320	347	522	416	3	2	0	507	642	659
NF2-204	434	638	361	336	468	401	0	0	2	508	523	636
Group 3												
ACO2-201	456	759	444	333	367	345	0	0	0	556	681	681
AKT1-211	351	710	301	230	437	297	0	0	3	558	614	690
LYPLAL1-202	65	62	51	33	58	51	7	6	8	28	34	42
PKD2-201	72	194	124	95	129	69	1	0	0	122	164	169
ENG-204	472	890	458	446	494	558	0	2	0	1145	799	1119
FANCE-201	24	82	61	56	67	56	0	0	2	119	131	153
MET-201	268	744	333	426	275	462	0	0	0	790	662	782
NOTCH2-201	344	823	404	172	256	208	4	0	3	402	779	772
SPOP-206	43	377	139	68	117	100	0	0	0	215	289	300
ABL1-202	224	72	218	107	122	153	4	1	1	302	393	480
Group 4												
ATP11C-202	170	116	121	86	165	128	2	1	1	130	206	234
BCR-202	180	401	185	177	149	169	1	0	0	321	372	485
CAV1-205	728	777	644	328	653	567	2	0	5	613	997	852
CDK2-201	306	937	367	297	385	358	4	1	3	568	742	888

DCAF1-202	119	292	187	59	67	65	0	1	0	108	171	131
FHOD1-201	60	233	143	132	185	157	1	0	1	194	294	300
GMDS-202	67	124	49	56	80	63	7	2	3	59	73	114
IFNAR1-201	81	221	135	99	104	55	1	0	1	159	266	238
NSMF-203	448	583	386	293	453	331	8	4	11	525	608	616
POLA2-201	74	111	62	45	72	67	2	4	2	41	75	57
Group 5												
BRCA1-210new	230	704	248	324	439	374	2	1	0	2	3	3
JAK1-201new	157	554	223	185	259	263	0	1	0	5	4	2
STRAP-202	42	75	31	18	52	40	3	1	0	6	4	4
SERPINB5-201	324	598	343	286	344	364	6	13	9	0	1	2
SETX-201	212	540	254	291	439	336	2	2	2	12	9	5
WDFY1-201	43	516	218	176	206	147	0	0	0	4	2	8
TACC1-201	69	373	131	80	156	118	1	0	0	21	29	32
KIF2A-203	442	879	445	298	519	430	5	1	2	6	11	9
CDT1-201	31	27	33	19	61	28	15	8	9	0	8	1
CENPE-202	192	246	215	94	262	225	0	1	0	8	9	9
Summary												
sum of correct codes:	1296 0	2340 5	1289 0	1131 9	1591 7	1279 7	8741	5920	6059	1038 7	1345 7	1430 3
sum of incorrect codes:	0	0	0	0	0	0	86	60	86	120	151	152
total number of signals:	4295 9	7215 7	3218 5	3203 7	5879 3	3547 0	1354 9	9182	1010 9	2670 1	3296 6	3545 1
% successfully decoded:	30,2	32,4	40,0	35,3	27,1	36,1	64,5	64,5	59,9	38,9	40,8	40,3

Table 4: Absolute numbers of decoded signals

Table 4 shows a very low number of incorrectly decoded signals compared to the number of correctly decoded signals. The absolute values for decoded signals of a certain transcript are very similar

between different regions of one experiment. The fraction of the total number of signals that can be successfully decoded is between 27.1 % and 64.5 %. This fraction depends on the number of transcripts and/or the total number of signals present in the respective region/experiment.

Conclusion

- 5 The method according to the disclosure produces a low amount of incorrectly assigned codewords and can therefore be considered specific. The fraction of successfully decodable signals is very high, even with very high numbers of signals per region and very high numbers of transcripts detected in parallel. The high fraction of assignable signals and the high specificity make the method practically useful.

Comparison of relative transcript abundancies between different experiments

- 10 As shown in Figure 8 for both comparisons (A and B) the overlap of detected transcripts between the experiments is used for the analysis. Each bar represents the mean abundance of all three regions of an experiment. The standard deviation between these regions is also indicated.

Correlation of relative transcript abundancies between different experiments

- 15 As can be seen in Figure 9 the mean relative abundances of transcripts from experiment 1 are correlated to the abundances of the overlapping transcripts of experiment 3, 4 and 2. The correlation coefficient as well as the formula for the linear regression are indicated for each correlation.

- 20 Figure 8 shows low standard deviations, indicating low variations of relative abundances between different regions of one experiment. The differences of relative abundances between transcripts from different experiments are also very low. This is the case for the comparison of transcripts from group 1 (Fig. 8A), that were detected in experiments 1, 2 and 3. It is also the case for the comparison of the transcripts from groups 2, 3 and 4 that were overlapping between experiments 1, 2 and 4. The very high correlation of these abundances can also be seen in Figure 9. The abundances of transcripts from experiment 1 correlate very well with the abundances of the other multi round experiments. The

correlation factors are between 0.88 and 0.91, while the slope of the linear regressions is between 0.97 and 1.05.

Conclusion

5 The relative abundancies of transcripts correlate very well between different regions of one experiment but also between different experiments. This can be clearly seen by the comparisons of Figures 3 and 4. The main difference between the experiments is the number of different targets and hence the total number of signals detected. Therefore, the number of transcripts detected as well as the number and density of signals does not interfere with the ability of the method to accurately quantify the number of transcripts. The very good correlations further support the specificity and
10 stability of the method, even with very high numbers of signals.

Comparison of intercellular distribution of signals

In Figure 10 the maximum projections of image stacks are shown. A: region 1 of experiment 7 (single round, single transcript experiment detecting SPOCK1), B: 2D-projection of all selected signals from experiment 1, region 1 assigned to SPOCK1, C: region 1 of experiment 8 (single round, single transcript
15 experiment detecting THRAP3), D: 2D-projection of all selected signals from experiment 1, region 1 assigned to THRAP3.

Comparison of intracellular distribution of signals

In Figure 11 the maximum projections of image stacks are shown. Magnified sub regions of the corresponding regions are shown. A: region 1 of experiment 8 (single round, single transcript
20 experiment detecting THRAP3), B: 2D-projection of selected signals from experiment 1, region 1 assigned to THRAP3, C: region 1 of experiment 5 (single round, single transcript experiment detecting DDX5), D: 2D-projection of all selected signals from experiment 1, region 1 assigned to DDX5.

Figure 10 shows huge differences of intercellular distributions between different transcripts. SPOCK1 seems to be highly abundant in some cells but nearly absent in other cells (Figure 10 A). THRAP3 shows

a more uniform distribution over all cells of a region (Figure 10 C). These spatial distribution patterns can also clearly be observed with the point clouds assigned to the corresponding transcripts from experiment 1 (Figure 10 B and D).

Figure 11 shows huge differences of intracellular distributions between different transcripts. THRAP3 can be mainly observed in the periphery (cytoplasm) of the cells (Figure 11 A), while DDX5 shows a higher abundance in the center (nucleus) of the cells (Figure 11 C). These intracellular distributions can also be observed with the point clouds of experiment 1 assigned to THRAP3 and DDX5 (Figure 11 B and D).

Conclusion

Next to the reliability of quantification, the point clouds of multi round experiments also show the same intracellular and intercellular distribution patterns of transcripts. This is clearly proven by the direct comparison of the assigned point clouds with signals from single round experiments detecting only one characteristic mRNA-species.

Distribution pattern of different cell cycle dependent transcripts

All images of Figure 12 show region 1 of experiment 1. In each image, a point cloud is shown, that is assigned to a certain transcript, A: CCNA2, B: CENPE, C: CCNE1, D: all transcripts. Figure 12 shows the transcripts of three different cell cycle dependent proteins. CENPE (Figure 12 B) is also known as Centromere protein E and accumulates during G2 phase. It is proposed to be responsible for spindle elongation and for chromosome movement. It is not present during interphase. CCNA2 (Figure 12 A) is also known as Cyclin A2. It regulates the cell cycle progression by interacting with CDK1 during transition from G2 to M-phase. Interestingly there is an obvious colocalization of both mRNA-species. They are mainly present in the three central cells of region 1. CCNE1 (Figure 12 C) is also known as Cyclin E1. This cyclin interacts with CDK2 and is responsible for the transition from G1 to S-phase. Figure 12 shows clearly, that the transcripts of this gene are not present in the three central cells, but quite equally distributed over the other cells. It therefore shows an anti-localization to the other two transcripts. The data for the corresponding point-clouds are derived from a point cloud with a very high number of points and a very high point density (Figure 12 D gives an impression).

Conclusion

The three decoded point clouds of cell cycle dependent proteins shown in Figure 12, show distribution patterns that can be explained by their corresponding function. These data strongly suggest, that the method of the present disclosure reliably produces biological relevant data, even with a low number
5 of signals per cell (Figure 12 C) and with very high signal densities (Figure 12 D).

Sequence listing

In the accompanying sequence listing SEQ ID Nos. 1-1247 refer to nucleotide sequences of exemplary target-specific oligonucleotides. The oligonucleotides listed consist of a target specific binding site (5'-end) a spacer/linker sequence (gtaac or tagac) and the unique identifier sequence, which is the same
5 for all oligonucleotides of one probe set.

In the accompanying sequence listing SEQ ID Nos. 1248-1397 refer to nucleotide sequences of exemplary decoding oligonucleotides.

In the accompanying sequence listing SEQ ID Nos. 1398-1400 refer to the nucleotide sequences of exemplary signal oligonucleotides. For each signal oligonucleotide the corresponding fluorophore is
10 present twice. One fluorophore is covalently linked to the 5'-end and one fluorophore is covalently linked to the 3'-end. SEQ ID No. 1398 comprises at its 5' terminus "5Alex488N", and at its 3' terminus "3AlexF488N". SEQ ID No. 1399 comprises at its 5' terminus "5Alex546", and at its 3' terminus 3Alex546N. SEQ ID No. 1400 comprises at its 5' terminus and at its 3' terminus "Atto594".

Claims

1. A multiplex method for detecting different analytes and different subgroups/variations of an analyte in a sample comprising:

(A) contacting the sample with at least twenty (20) different sets of analyte-specific probes for encoding of at least 20 different analytes, each set of analyte-specific probes interacting with a different analyte, wherein if the analyte is a nucleic acid each set of analyte-specific probes comprises at least five (5) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each analyte-specific probe comprising

 - (aa) a binding element (S) that specifically interacts with one of the different analytes to be encoded, and
 - (bb) an identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

wherein the analyte-specific probes of a particular set of analyte-specific probes differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T),

wherein the analyte-specific probes in each set of analyte-specific probes binds to the same analyte and comprises the same nucleotide sequence of the identifier element (T) which is unique to said analyte; and

contacting the sample with at least two different sets of analyte-specific probes for at least one analyte and a variation thereof,

wherein the analyte-specific probes comprised in these different sets interacting with the same analyte, but specifically interact with different sub-structures of the same analyte,

wherein the analyte-specific probes of the first set of analyte-specific probes interacts with a sub-structure which is comprised in all variations of an analyte,

wherein the analyte-specific probes of the second set of analyte-specific probes (subgroup-specific probes) interacts with a sub-structure which is comprised only in a specific variation of the analyte,

wherein the analyte-specific probes of the first set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence), and

wherein the analyte-specific probes of the second set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

wherein the identifier elements (T) of the analyte-specific probes of the first set of analyte-specific probes and the identifier elements (T) of the analyte-specific probes of the second set of analyte-specific probes are different for binding different decoding oligonucleotides and/or non-signal decoding oligonucleotides.

(B) contacting the sample with at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding oligonucleotides for an individual analyte each decoding oligonucleotide comprises:

(aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

(bb) a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

wherein the decoding oligonucleotides of a set for an individual analyte differ from the decoding oligonucleotides of another set for a different analyte in the first connect element (t); and

(C) contacting the sample with at least a set of signal oligonucleotides, each signal oligonucleotide comprising:

(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide, and

(bb) a signal element.

(D) Detecting the signal caused by the signal element;

(E) selectively removing the decoding oligonucleotides and signal oligonucleotides from the sample, thereby essentially maintaining the specific binding of the analyte-specific probes to the analytes to be encoded;

- (F) Performing at least three (3) further cycles comprising steps B) to E) to generate an encoding scheme with a code word per analyte,
- (G) Performing at least one (1) further cycle comprising steps B) to E) to identify the subgroup-specific probes, wherein in particular the cycle may stop with step (D).
2. The method according to claim 1, wherein the set of analyte-specific probes comprises at least five (5) subgroup-specific probes which specifically interact with different sub-structures of the same variation of an analyte.
 3. The method according to any of claims 1 to 2, wherein if the analyte is a nucleic acid, each set of analyte-specific probes comprises at least ten (10) analyte-specific probes, in particular at least fifteen (15) analyte-specific probes, in particular at least twenty (20) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each analyte-specific probe.
 4. The method according to any one of claims 1 to 3, wherein contacting a subgroup of at least one analyte with a set of at least five (5) subgroup-specific probes which differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T).
 5. The method according to any one of claims 1 to 4, wherein the sample is contacted with the subgroup-specific probe set according to claim 30, wherein the method comprises an additional further cycle comprising steps B) to E) to identify the variation interacting with the subgroup-specific probe, wherein in particular the cycle may stop with step (D).
 6. The method according to any one of claims 1 to 5, wherein all steps are automated, in particular wherein steps B) to G) are automated, in particular by using a robotic system.
 7. The method according to any one of claims 1 to 6, wherein all steps are performed in a fluidic system.
 8. The method according to any one of claims 1 to 7, wherein each analyte is associated with a specific code word, wherein said code word comprise a number of positions, and wherein each

position corresponds to one cycle resulting in a plurality of distinguishable encoding schemes with the plurality of code words.

9. The method according to any one of claims 1 to 8, wherein said encoding scheme is predetermined and allocated to the analyte to be encoded.
10. The method according to any one of claims 1 to 9 wherein the code words obtained for the individual analytes in the performed cycles comprise the detected signals and additionally at least one element corresponding to no detected signal.
11. The method according to any one of claims 1 to 10, wherein no signal is detected for at least one analyte within at least one cycle.
12. The method according to of any one of claims 1 to 11, wherein for at least for one individual analyte a position of the code word is zero (0).
13. The method according to of any one of claims 1 to 12, wherein the code word zero (0) is generated by using no decoding oligonucleotides having an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of a corresponding analyte-specific probe for an individual analyte.
14. The method according to of any one of claims 1 to 13, wherein if at least for one individual analyte a position of the code word is zero (0) in this cycle no corresponding decoding oligonucleotides having an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of a corresponding analyte-specific probe for an individual analyte are used.
15. The method according to of any one of claims 1 to 14, wherein the sample is contacted with at least two different sets of signal oligonucleotides, wherein the signal oligonucleotides in each set comprise a different signal element and comprise a different connector element (C).
16. The method according to any one of claims 1 to 15, wherein the sample is contacted with at least two different sets of decoding oligonucleotides per analyte,

wherein the decoding oligonucleotides comprised in these different sets comprise the same identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

wherein the decoding oligonucleotides of the different sets per analyte differ in the translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

17. The method according to any one of claims 1 to 16, wherein the sample is contacted with at least two different sets of decoding oligonucleotides per analyte,

wherein the decoding oligonucleotides comprised in these different sets comprise the same identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

wherein the decoding oligonucleotides of the different sets per analyte differ in the translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

wherein only one set of decoding oligonucleotides per analyte is used per cycle, and/or wherein different sets of decoding oligonucleotides are used in different cycles in combination with the corresponding set of signal oligonucleotides in the same cycle.

18. The method according to any one of claims 1 to 17, wherein the number of different sets of decoding oligonucleotides per analyte comprising different translator elements (c) corresponds to the number of different sets of signal oligonucleotides comprising different connector elements (C).

19. The method according to any one of claims 1 to 18, wherein all sets of decoding oligonucleotides for the different analytes comprise the same type(s) of translator element(s) (c).

20. The method according to any one of claims 1 to 19, wherein the sample is contacted with at least a set of non-signal decoding oligonucleotides for binding to a particular identifier element (T) of analyte-specific probes, wherein the decoding oligonucleotides in the same set of non-signal decoding oligonucleotides interacting with the same different identifier element (T),

wherein each non-signal decoding oligonucleotide comprises an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of a unique identifier sequence, and does not comprise a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

21. The method according to any one of claims 1 to 20, wherein the sample is contacted with: at least two (2) different sets of non-signal decoding oligonucleotides for binding to at least two different identifier elements (T) of analyte-specific probes, each set of non-signal decoding oligonucleotides interacting with a different identifier element (T), wherein each non-signal decoding oligonucleotide comprises an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of a unique identifier sequence, and does not comprise a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.
22. The method according to any one of claims 20 to 21, wherein the different sets of non-signal decoding oligonucleotides may be comprised in a pre-mixture of different sets of non-signal decoding oligonucleotides or exist separately.
23. The method according to any one of claims 1 to 22, wherein the sample is contacted with a set of non-signal oligonucleotides, each non-signal oligonucleotide comprising:
- (aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of the translator element (c), and
 - (bb) a quencher (Q), a signal element and a quencher (Q), or does not comprise a signal element.
24. The method according to any one of claims 1 to 23, wherein the sample is contacted with: at least two sets of non-signal oligonucleotides, each non-signal oligonucleotide comprising:
- (aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of the translator element (c), and
 - (bb) a quencher (Q), a signal element and a quencher (Q), or does not comprise a signal element.

25. The method according to any one of claims 23 to 24, wherein the different sets of non-signal oligonucleotides may be comprised in a pre-mixture of different sets of non-signal oligonucleotides or exist separately.
26. The method according to any one of claims 1 to 25, wherein the decoding oligonucleotides in a particular set of decoding oligonucleotides interacts with identical identifier elements (T) which are unique to a particular analyte.
27. The method according to any one of claims 1 to 26, wherein the different sets of decoding oligonucleotides may be comprised in a pre-mixture of different sets of decoding oligonucleotides or exist separately.
28. The method according to any one of claims 1 to 27, wherein the different sets of analyte-specific probes may be comprised in a pre-mixture of different sets of analyte-specific probes or exist separately.
29. The method according to any one of claims 1 to 28, wherein the different sets of signal oligonucleotides may be comprised in a pre-mixture of different sets of signal oligonucleotides or exist separately.
30. The method according to any one of claims 1 to 29, wherein the sample is a biological sample, preferably comprising biological tissue, further preferably comprising biological cells and/or extracts and/or part of cells.
31. The method according to claim 30, wherein the cell is a prokaryotic cells or a eukaryotic cell, in particular a mammalian cell, in particular a human cell.
32. The method according to claim 30, wherein the biological tissue, biological cells, extracts and/or part of cells are fixed.
33. The method according to any one of claims 1 to 32, wherein the analytes are fixed in a permeabilized sample, such as a cell-containing sample.

34. The method according to any one of claims 1 to 33, wherein the binding element (S) comprise a nucleic acid comprising a nucleotide sequence allowing a specific binding to the analyte to be encoded, preferably a specific hybridization to the analyte to be encoded.
35. The method according to any one of claims 1 to 34, wherein after step A) and before step B) the non-bound analyte-specific probes are removed, in particular by washing.
36. The method according to any one of claims 1 to 35, wherein after step B) and before step C) the non-bound decoding oligonucleotides are removed, in particular by washing.
37. The method according to any one of claims 1 to 36, wherein after step C) and before step D) the non-bound signal oligonucleotides are removed, in particular by washing.
38. The method according to any one of claims 1 to 37, wherein the analyte specific probes are incubated with the sample, thereby allowing a specific binding of the analyte specific probes to the analytes to be encoded.
39. The method according to any one of claims 1 to 38, wherein the decoding oligonucleotides are incubated with the sample, thereby allowing a specific hybridization of the decoding oligonucleotides to identifier elements (T) of the respective analyte-specific probes.
40. The method according to any one of claims 1 to 39, wherein the signal oligonucleotides are incubated with the sample, thereby allowing a specific hybridization of the signal oligonucleotides to translator elements (T) of the respective decoding oligonucleotides.
41. The method according to any of claims 1 to 40, wherein the analyte to be encoded is a nucleic acid, preferably DNA, PNA or RNA, in particular mRNA.
42. The method according to any of claims 1 to 41, wherein the analyte to be encoded is a peptide, polypeptide or a protein.
43. The method according to any of claims 1 to 42, wherein the binding element (S) comprise an amino acid sequence allowing a specific binding to the analyte to be encoded.

44. The method according to any of claims 1 to 43, wherein the binding element (S) comprises moieties which are affinity moieties from affinity substances or affinity substances in their entirety selected from the group consisting of antibodies, antibody fragments, anticalin proteins, receptor ligands, enzyme substrates, lectins, cytokines, lymphokines, interleukins, angiogenic or virulence factors, allergens, peptidic allergens, recombinant allergens, allergen-idiotypal antibodies, autoimmune-provoking structures, tissue-rejection-inducing structures, immunoglobulin constant regions and combinations thereof.
45. The method according to any of claims 1 to 44, wherein the binding element (S) is an antibody or an antibody fragment selected from the group consisting of Fab, scFv; single domain, or a fragment thereof, bis scFv, Fab 2, Fab 3, minibody, diabody, triabody, tetrabody and tandab.
46. The method according to any of claims 1 to 45, wherein the signal caused by the signal element, therefore in particular the binding of the signal oligonucleotides to the decoding oligonucleotides, interacting with the corresponding analyte probes, bound to the respective analyte is determined by:
- (a) Imaging at least a portion of the sample; and/or
 - (b) Using an optical imaging technique; and/or
 - (c) Using a fluorescence imaging technique; and/or
 - (d) Multi-color fluorescence imaging technique; and/or
 - (e) Super-resolution fluorescence imaging technique.
47. The method according to any one of claims 1 to 46, wherein the decoding oligonucleotides in at least one set of decoding oligonucleotides are multi-decoders comprising
- (aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and
 - (bb) at least two translator elements (c), wherein the translator elements comprising different nucleotide sequences allowing a specific hybridization of a different signal oligonucleotide.
48. The method according to claim 47, wherein the different signal oligonucleotides comprise a different signal element and comprise a different connector element (C).

49. A kit for multiplex analyte encoding, comprising

(A) at least twenty (20) different sets of analyte-specific probes for encoding of at least 20 different analytes, each set of analyte-specific probes interacting with a different analyte, wherein if the analyte is a nucleic acid each set of analyte-specific probes comprises at least five (5) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each analyte-specific probe comprising

(aa) a binding element (S) that specifically interacts with one of the different analytes to be encoded, and

(bb) an identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

wherein the analyte-specific probes of a particular set of analyte-specific probes differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T),

wherein the analyte-specific probes in each set of analyte-specific probes binds to the same analyte and comprises the same nucleotide sequence of the identifier element (T) which is unique to said analyte; and

(B) at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding oligonucleotides for an individual analyte each decoding oligonucleotide comprises:

(aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

(bb) a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

wherein the decoding oligonucleotides of a set for an individual analyte differ from the decoding oligonucleotides of another set for a different analyte in the identifier connect element (t); and

(C) a set of signal oligonucleotides, each signal oligonucleotide comprising:

(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide, and

(bb) a signal element.

50. The kit according to claim 49, wherein the kit comprises at least two different sets of analyte-specific probes for an analyte,
wherein the analyte-specific probes comprised in these different sets interacting with the same analyte, but specifically interact with different sub-structures of the same analyte,
wherein the analyte-specific probes of the first set of analyte-specific probes interacts with a sub-structure which is comprised in all variations of an analyte,
wherein the analyte-specific probes of the second set of analyte-specific probes (subgroup-specific probes) interacts with a sub-structure which is comprised only in a specific variation of the analyte,
wherein the analyte-specific probes of the first set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence), and
wherein the analyte-specific probes of the second set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),
wherein the identifier elements (T) of the analyte-specific probes of the first set of analyte-specific probes and the identifier elements (T) of the analyte-specific probes of the second set of analyte-specific probes are different.
51. The kit according to any one of claims 49 to 50, wherein the kit comprises at least five (5) sets of subgroup-specific probes that differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T).
52. The kit according to any one of claims 49 to 51, wherein the kit does not comprise sets of analyte-specific probes and/or subgroup-specific probes as defined in claim 47.
53. The kit according to any one of claims 49 to 52, wherein if the analyte is a nucleic acid, each set of analyte-specific probes comprises at least ten (10) analyte-specific probes, in particular at least fifteen (15) analyte-specific probes, in particular at least twenty (20) analyte-specific probes which specifically interact with different sub-structures of the same analyte.
54. The kit according to any one of claims 49 to 53, wherein if the analyte is a peptide, a polypeptide or a protein, each set of analyte-specific probes comprises at least two (2) analyte-specific probes, in particular at least three (3) analyte-specific probes, in particular at least four

- (4) analyte-specific probes which specifically interact with different sub-structures of the same analyte.
55. The kit according to any one of claims 49 to 54, wherein the kit comprises at least two different sets of signal oligonucleotides, wherein the signal oligonucleotides in each set comprise a different signal element and comprise a different connector element (C).
56. The kit according to any one of claims 49 to 55, wherein the kit comprises at least two different sets of decoding oligonucleotides per analyte,
wherein the decoding oligonucleotides comprised in these different sets comprise the same identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and
wherein the decoding oligonucleotides of the different sets per analyte differ in the translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.
57. The kit according to any one of claims 49 to 56, wherein the kit comprises at least two different sets of decoding oligonucleotides per analyte,
wherein the decoding oligonucleotides comprised in these different sets comprise the same identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and
wherein the decoding oligonucleotides of the different sets for at least one analyte differ in the translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.
58. The kit according to of any one of claims 49 to 57, wherein the number of different sets of decoding oligonucleotides per analyte comprising different translator elements (c) corresponds to the number of different sets of signal oligonucleotides comprising different connector elements (C).
59. The kit according to any one of claims 49 to 58, wherein the decoding oligonucleotides in a particular set of decoding oligonucleotides interacts with identical identifier elements (T) which are unique to a particular analyte.

60. The kit according to any one of claims 49 to 59, wherein all sets of decoding oligonucleotides for the different analytes comprise the same type(s) of translator element(s) (c).

61. The kit according to any one of claims 49 to 60, wherein the kit comprises:

(D) at least a set of non-signal decoding oligonucleotides for binding to a particular identifier element (T) of analyte-specific probes, wherein the decoding oligonucleotides in the same set of non-signal decoding oligonucleotides interacting with the same different identifier element (T), wherein each non-signal decoding oligonucleotide comprises an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of a unique identifier sequence, and does not comprise a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

62. The kit according to any one of claims 49 to 61, wherein the kit comprises:

(D) at least two (2) different sets of non-signal decoding oligonucleotides for binding to at least two different identifier elements (T) of analyte-specific probes, each set of non-signal decoding oligonucleotides interacting with a different identifier element (T), wherein each non-signal decoding oligonucleotide comprises an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of a unique identifier sequence, and does not comprise a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

63. The kit according to any one of claims 49 to 62, wherein the different sets of non-signal decoding oligonucleotides may be comprised in a pre-mixture of different sets of non-signal decoding oligonucleotides or exist separately.

64. The kit according to any one of claims 49 to 63, wherein the kit comprises:

(E) a set of non-signal oligonucleotides, each non-signal oligonucleotide comprising:

- (aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of the translator element (c), and
- (bb) a quencher (Q), a signal element and a quencher (Q), or does not comprise a signal element.

65. The kit according to any one of claims 49 to 64, wherein the kit comprises:

(E) at least two sets of non-signal oligonucleotides, each non-signal oligonucleotide comprising:

- (aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of the translator element (c), and
- (bb) a quencher (Q), a signal element and a quencher (Q), or does not comprise a signal element.

66. The kit according to any one of claims 49 to 65, wherein the different sets of non-signal oligonucleotides may be comprised in a pre-mixture of different sets of non-signal oligonucleotides or exist separately.

67. The kit according to any one of claims 49 to 66, wherein the decoding oligonucleotides in a particular set of decoding oligonucleotides interacts with identical identifier elements (T) which are unique to a particular analyte.

68. The kit according to any one of claims 49 to 67, wherein the different sets of decoding oligonucleotides may be comprised in a pre-mixture of different sets of decoding oligonucleotides or exist separately.

69. The kit according to any one of claims 49 to 68, wherein the different sets of analyte-specific probes may be comprised in a pre-mixture of different sets of analyte-specific probes or exist separately.

70. The kit according to any one of claims 49 to 69, wherein the different sets of signal oligonucleotides may be comprised in a pre-mixture of different sets of signal oligonucleotides or exist separately.
71. The kit according to any of claims 49 to 70, wherein the analyte to be encoded is a nucleic acid, preferably DNA, PNA or RNA, in particular mRNA.
72. The kit according to any of claims 49 to 71, wherein the analyte to be encoded is a peptide, polypeptide or a protein.
73. The kit according to any of claims 49 to 72, wherein the binding element (S) comprises an amino acid sequence allowing a specific binding to the analyte to be encoded.
74. The kit according to any of claims 49 to 73, wherein the binding element (S) comprises moieties which are affinity moieties from affinity substances or affinity substances in their entirety selected from the group consisting of antibodies, antibody fragments, anticalin proteins, receptor ligands, enzyme substrates, lectins, cytokines, lymphokines, interleukins, angiogenic or virulence factors, allergens, peptidic allergens, recombinant allergens, allergen-idiotypal antibodies, autoimmune-provoking structures, tissue-rejection-inducing structures, immunoglobulin constant regions and combinations thereof.
75. The kit according to any of claims 49 to 74, wherein the binding element (S) is an antibody or an antibody fragment selected from the group consisting of Fab, scFv; single domain, or a fragment thereof, bis scFv, F(ab)2, F(ab)3, minibody, diabody, triabody, tetrabody and tandab.
76. The kit according to any one of claims 49 to 75, wherein the decoding oligonucleotides in at least one set of decoding oligonucleotides are multi-decoders comprising
- (aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and
 - (bb) at least two translator elements (c), wherein the translator elements comprising different nucleotide sequences allowing a specific hybridization of a different signal oligonucleotide.

77. The kit according to claim 76, wherein the different signal oligonucleotides comprise a different signal element and comprise a different connector element (C).
78. A multiplex method for detecting different analytes in a sample by sequential signal-encoding of said analytes, comprising:

(A) contacting the sample with at least twenty (20) different sets of analyte-specific probes for encoding of at least 20 different analytes, each set of analyte-specific probes interacting with a different analyte, wherein if the analyte is a nucleic acid each set of analyte-specific probes comprises at least five (5) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each analyte-specific probe comprising

(aa) a binding element (S) that specifically interacts with one of the different analytes to be encoded, and

(bb) an identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

wherein the analyte-specific probes of a particular set of analyte-specific probes differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T),

wherein the analyte-specific probes in each set of analyte-specific probes binds to the same analyte and comprises the same nucleotide sequence of the identifier element (T) which is unique to said analyte; and

(B) contacting the sample with at least one set of decoding oligonucleotides per analyte, wherein in each set of decoding oligonucleotides for an individual analyte each decoding oligonucleotide comprises:

(aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

(bb) a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

wherein the decoding oligonucleotides of a set for an individual analyte differ from the decoding oligonucleotides of another set for a different analyte in the first connect element (t); and

(C) contacting the sample with at least a set of signal oligonucleotides, each signal oligonucleotide comprising:

- (aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of a translator element (c) comprised in a decoding oligonucleotide, and
- (bb) a signal element.

(D) Detecting the signal caused by the signal element;

(E) selectively removing the decoding oligonucleotides and signal oligonucleotides from the sample, thereby essentially maintaining the specific binding of the analyte-specific probes to the analytes to be encoded;

(F) Performing at least three (3) further cycles comprising steps B) to E) to generate an encoding scheme with a code word per analyte, wherein in particular the last cycle may stop with step (D).

79. The method according to claim 78, wherein if the analyte is a nucleic acid, each set of analyte-specific probes comprises at least ten (10) analyte-specific probes, in particular at least fifteen (15) analyte-specific probes, in particular at least twenty (20) analyte-specific probes which specifically interact with different sub-structures of the same analyte, each analyte-specific probe.

80. The method according to of any one of claims 78 to 79, wherein the sample is contacted with at least two different sets of analyte-specific probes for an analyte, wherein the analyte-specific probes comprised in these different sets interacting with the same analyte, but specifically interact with different sub-structures of the same analyte, wherein the analyte-specific probes of the first set of analyte-specific probes interacts with a sub-structure which is comprised in all variations of an analyte, wherein the analyte-specific probes of the second set of analyte-specific probes (subgroup-specific probe set) interacts with a sub-structure which is comprised only in a specific variation of the analyte, wherein the analyte-specific probes of the first set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence), and

wherein the analyte-specific probes of the second set of analyte-specific probes comprise the same identifier element (T) comprising a nucleotide sequence which is unique to the analyte to be encoded (unique identifier sequence),

wherein the identifier elements (T) of the analyte-specific probes of the first set of analyte-specific probes and the identifier elements (T) of the analyte-specific probes of the second set of analyte-specific probes are different.

81. The method according to any one of claims 78 to 80, wherein contacting a subgroup of at least one analyte with a set of at least five (5) subgroup-specific probes which differ from the analyte-specific probes of another set of analyte-specific probes in the nucleotide sequence of the identifier element (T).
82. The method according to any one of claims 78 to 81, wherein the sample is contacted with the subgroup-specific probe set according to claim 30, wherein the method comprises an additional further cycle comprising steps B) to E) to identify the variation interacting with the subgroup-specific probe, wherein in particular the cycle may stop with step (D).
83. The method according to any one of claims 78 to 82, wherein all steps are automated, in particular wherein steps B) to F) are automated, in particular by using a robotic system.
84. The method according to any one of claims 78 to 83, wherein all steps are performed in a fluidic system.
85. The method according to any one of claims 78 to 84, wherein each analyte is associated with a specific code word, wherein said code word comprise a number of positions, and wherein each position corresponds to one cycle resulting in a plurality of distinguishable encoding schemes with the plurality of code words.
86. The method according to any one of claims 78 to 85, wherein said encoding scheme is predetermined and allocated to the analyte to be encoded.
87. The method according to any one of claims 78 to 86, wherein the code words obtained for the individual analytes in the performed cycles comprise the detected signals and additionally at least one element corresponding to no detected signal.

88. The method according to any one of claims 78 to 87, wherein no signal is detected for at least one analyte within at least one cycle.
89. The method according to of any one of claims 78 to 88, wherein for at least for one individual analyte a position of the code word is zero (0).
90. The method according to of any one of claims 78 to 89, wherein the code word zero (0) is generated by using no decoding oligonucleotides having an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of a corresponding analyte-specific probe for an individual analyte.
91. The method according to of any one of claims 78 to 90, wherein if at least for one individual analyte a position of the code word is zero (0) in this cycle no corresponding decoding oligonucleotides having an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of a corresponding analyte-specific probe for an individual analyte are used.
92. The method according to of any one of claims 78 to 91, wherein the sample is contacted with at least two different sets of signal oligonucleotides, wherein the signal oligonucleotides in each set comprise a different signal element and comprise a different connector element (C).
93. The method according to any one of claims 78 to 92, wherein the sample is contacted with at least two different sets of decoding oligonucleotides per analyte, wherein the decoding oligonucleotides comprised in these different sets comprise the same identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and wherein the decoding oligonucleotides of the different sets per analyte differ in the translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.
94. The method according to any one of claims 78 to 93, wherein the sample is contacted with at least two different sets of decoding oligonucleotides per analyte,

wherein the decoding oligonucleotides comprised in these different sets comprise the same identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and

wherein the decoding oligonucleotides of the different sets per analyte differ in the translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide;

wherein only one set of decoding oligonucleotides per analyte is used per cycle, and/or wherein different sets of decoding oligonucleotides are used in different cycles in combination with the corresponding set of signal oligonucleotides in the same cycle.

95. The method according to any one of claims 78 to 94, wherein the number of different sets of decoding oligonucleotides per analyte comprising different translator elements (c) corresponds to the number of different sets of signal oligonucleotides comprising different connector elements (C).
96. The method according to any one of claims 78 to 95, wherein all sets of decoding oligonucleotides for the different analytes comprise the same type(s) of translator element(s) (c).
97. The method according to any one of claims 78 to 96, wherein the sample is contacted with at least a set of non-signal decoding oligonucleotides for binding to a particular identifier element (T) of analyte-specific probes, wherein the decoding oligonucleotides in the same set of non-signal decoding oligonucleotides interacting with the same different identifier element (T),
wherein each non-signal decoding oligonucleotide comprises an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of a unique identifier sequence, and does not comprise a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.
98. The method according to any one of claims 78 to 97, wherein the sample is contacted with: at least two (2) different sets of non-signal decoding oligonucleotides for binding to at least two different identifier elements (T) of analyte-specific probes, each set of non-signal decoding oligonucleotides interacting with a different identifier element (T),

wherein each non-signal decoding oligonucleotide comprises an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of a unique identifier sequence, and does not comprise a translator element (c) comprising a nucleotide sequence allowing a specific hybridization of a signal oligonucleotide.

99. The method according to any one of claims 78 to 98, wherein the different sets of non-signal decoding oligonucleotides may be comprised in a pre-mixture of different sets of non-signal decoding oligonucleotides or exist separately.
100. The method according to any one of claims 78 to 99, wherein the sample is contacted with a set of non-signal oligonucleotides, each non-signal oligonucleotide comprising:
(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of the translator element (c), and
(bb) a quencher (Q), a signal element and a quencher (Q), or does not comprise a signal element.
101. The method according to any one of claims 78 to 100, wherein the sample is contacted with:
at least two sets of non-signal oligonucleotides, each non-signal oligonucleotide comprising:
(aa) a translator connector element (C) comprising a nucleotide sequence which is essentially complementary to at least a section of the nucleotide sequence of the translator element (c), and
(bb) a quencher (Q), a signal element and a quencher (Q), or does not comprise a signal element.
102. The method according to any one of claims 100 to 101, wherein the different sets of non-signal oligonucleotides may be comprised in a pre-mixture of different sets of non-signal oligonucleotides or exist separately.
103. The method according to any one of claims 78 to 102, wherein the decoding oligonucleotides in a particular set of decoding oligonucleotides interacts with identical identifier elements (T) which are unique to a particular analyte.

104. The method according to any one of claims 78 to 103, wherein the different sets of decoding oligonucleotides may be comprised in a pre-mixture of different sets of decoding oligonucleotides or exist separately.
105. The method according to any one of claims 78 to 104, wherein the different sets of analyte-specific probes may be comprised in a pre-mixture of different sets of analyte-specific probes or exist separately.
106. The method according to any one of claims 78 to 105, wherein the different sets of signal oligonucleotides may be comprised in a pre-mixture of different sets of signal oligonucleotides or exist separately.
107. The method according to any one of claims 78 to 106, wherein the sample is a biological sample, preferably comprising biological tissue, further preferably comprising biological cells and/or extracts and/or part of cells.
108. The method according to claim 107, wherein the cell is a prokaryotic cells or a eukaryotic cell, in particular a mammalian cell, in particular a human cell.
109. The method according to claim 107, wherein the biological tissue, biological cells, extracts and/or part of cells are fixed.
110. The method according to any one of claims 78 to 109, wherein the analytes are fixed in a permeabilized sample, such as a cell-containing sample.
111. The method according to any one of claims 78 to 110, wherein the binding element (S) comprise a nucleic acid comprising a nucleotide sequence allowing a specific binding to the analyte to be encoded, preferably a specific hybridization to the analyte to be encoded.
112. The method according to any one of claims 78 to 111, wherein after step A) and before step B) the non-bound analyte-specific probes are removed, in particular by washing.
113. The method according to any one of claims 78 to 112, wherein after step B) and before step C) the non-bound decoding oligonucleotides are removed, in particular by washing.

114. The method according to any one of claims 78 to 113, wherein after step C) and before step D) the non-bound signal oligonucleotides are removed, in particular by washing.
115. The method according to any one of claims 78 to 114, wherein the analyte specific probes are incubated with the sample, thereby allowing a specific binding of the analyte specific probes to the analytes to be encoded.
116. The method according to any one of claims 78 to 115, wherein the decoding oligonucleotides are incubated with the sample, thereby allowing a specific hybridization of the decoding oligonucleotides to identifier elements (T) of the respective analyte-specific probes.
117. The method according to any one of claims 78 to 116, wherein the signal oligonucleotides are incubated with the sample, thereby allowing a specific hybridization of the signal oligonucleotides to translator elements (T) of the respective decoding oligonucleotides.
118. The method according to any of claims 78 to 117 wherein the analyte to be encoded is a nucleic acid, preferably DNA, PNA or RNA, in particular mRNA.
119. The method according to any of claims 78 to 118, wherein the analyte to be encoded is a peptide, polypeptide or a protein.
120. The method according to any of claims 78 to 119, wherein the binding element (S) comprise an amino acid sequence allowing a specific binding to the analyte to be encoded.
121. The method according to any of claims 78 to 120, wherein the binding element (S) comprises moieties which are affinity moieties from affinity substances or affinity substances in their entirety selected from the group consisting of antibodies, antibody fragments, anticalin proteins, receptor ligands, enzyme substrates, lectins, cytokines, lymphokines, interleukins, angiogenic or virulence factors, allergens, peptidic allergens, recombinant allergens, allergen-idiotypical antibodies, autoimmune-provoking structures, tissue-rejection-inducing structures, immunoglobulin constant regions and combinations thereof.
122. The method according to any of claims 78 to 121, wherein the binding element (S) is an antibody or an antibody fragment selected from the group consisting of Fab, scFv; single

domain, or a fragment thereof, bis scFv, Fab 2, Fab 3, minibody, diabody, triabody, tetrabody and tandab.

123. The method according to any of claims 78 to 122, wherein the signal caused by the signal element, therefore in particular the binding of the signal oligonucleotides to the decoding oligonucleotides, interacting with the corresponding analyte probes, bound to the respective analyte is determined by:
- (f) Imaging at least a portion of the sample; and/or
 - (g) Using an optical imaging technique; and/or
 - (h) Using a fluorescence imaging technique; and/or
 - (i) Multi-color fluorescence imaging technique; and/or
 - (j) Super-resolution fluorescence imaging technique.
124. The method according to any one of claims 78 to 123, wherein the decoding oligonucleotides in at least one set of decoding oligonucleotides are multi-decoders comprising
- (aa) an identifier connector element (t) comprising a nucleotide sequence which is essentially complementary to at least a section of the unique identifier sequence of the identifier element (T) of the corresponding analyte-specific probe set, and
 - (bb) at least two translator elements (c), wherein the translator elements comprising different nucleotide sequences allowing a specific hybridization of a different signal oligonucleotide.
125. The method according to claim 124, wherein the different signal oligonucleotides comprise a different signal element and comprise a different connector element (C).
126. An *in vitro* method for diagnosis of a disease selected from the group comprising cancer, neuronal diseases, cardiovascular diseases, inflammatory diseases, autoimmune diseases, diseases due to a viral or bacterial infection, skin diseases, skeletal muscle diseases, dental diseases and prenatal diseases comprising the use of the multiplex method according to any one of claims 1 to 48 and/or of claims 78 to 125.
127. An *in vitro* method for diagnosis of a disease in plants selected from the group comprising: diseases caused by biotic stress, preferably by infectious and/or parasitic origin, or diseases caused by abiotic stress, preferably caused by nutritional deficiencies and/or unfavorable

environment, said method comprising the use of the multiplex method according to any one of claims 1 to 48 and/or of claims 78 to 125.

128. An optical multiplexing system suitable for the method according to any one of claims 1 to 48 and/or of claims 78 to 125, comprising at least:
- one reaction vessel for containing the kits or part of the kits according to any one of claims 49 to 77;
 - a detection unit comprising a microscope, in particular a fluorescence microscope
 - a camera
 - a liquid handling device.
129. The optical multiplexing system according to claim 128, wherein the system comprises further a heat and cooling device.
130. The optical multiplexing system according to any one of claim 128 to 129, wherein the system comprises further a robotic system.
131. An *in vitro* method for screening, identifying and/or testing a substance and/or drug comprising:
- (a) contacting a test sample comprising a sample with a substance and/or drug
 - (b) detecting different analytes in a sample by sequential signal-encoding of said analytes with a method according to any one of claims 1 to 48 and/or of claims 78 to 125.
132. The *in vitro* method according to claim 131, wherein the sample is a biological sample, preferably comprising biological tissue, further preferably comprising biological cells, in particular wherein the cell is a prokaryotic cells or a eukaryotic cell, in particular a mammalian cell, in particular a human cell.




Fig. 1




Fig. 2




Fig. 3




Fig. 3 continued








Fig. 3 continued

10



11




12



Fig. 3 continued

Opt. 1



Opt. 2




Fig. 4




Fig. 5

3




Fig. 5 continued

4




Fig. 5 continued

10/32

5




Fig. 5 continued

6




Fig. 5 continued

7




Fig. 5 continued

8




Fig. 5 continued




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11







Fig. 12

Round 1



⋮



⋮



R 1	R 2	R 3	R 4	R 5	R 6	R 7	R 8
A							
B							
A							
A							
B							
A							
A							

Fig. 13

Round 2




FIG. 13 continued

Round 3




Fig. 13 continued

Round 8




Fig. 13 continued





Fig. 14


26/32

Round 0


Target 1




Target 1'



Target 2



Target 2'



R1	R2	R3	R4	R5

--	--	--	--	--

--	--	--	--	--


--	--	--	--	--

Round 1

Target 1




Target 1'



Target 2



Target 2'



[...]

R1	R2	R3	R4	R5
A				

A				
---	--	--	--	--

B				
---	--	--	--	--


B				
---	--	--	--	--

Round 4

Target 1




Target 1'



Target 2



Target 2'



R1	R2	R3	R4	R5
A	B	-	A	


A	B	-	A	
---	---	---	---	--

B	-	B	A	
---	---	---	---	--


B	-	B	A	
---	---	---	---	--

Round 5


Target 1



Target 1'



Target 2



Target 2'



R1	R2	R3	R4	R5
A	B	-	A	-

A	B	-	A	B
---	---	---	---	---

B	-	B	A	-
---	---	---	---	---

B	-	B	A	B
---	---	---	---	---

Fig.15





Fig. 16

Step 1:



Step 2:





Fig. 17

Step 3:



Step 4:





Fig. 17 (continued)

Step 5:



Step 6:





Fig. 17 (continued)

Step 7:



Step 8:




Fig. 17 (continued)




Fig. 18

SEQUENCE LISTING

<110> Resolve BioSciences GmbH

<120> MULTIPLEX METHOD FOR DETECTING DIFFERENT ANALYTES IN A SAMPLE

<130> RES-PA01-USprov

<160> 1400

<170> BiSSAP 1.3.6

<210> 1

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1

actactagag accggtagaa atgagtaacg attaccgact tatcc

45

<210> 2

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 2

tggcggggaa cgaagtatat agtaacgatt accgacttat cc

42

<210> 3

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 3

tggcgtcaat gggtgcggtg taacgattac cgacttatcc

40

<210> 4

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 4

tcggtcactc gaataacccg gtaacgatta ccgacttatc c

41

<210> 5

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 5

ctccaaatcg aggtgcacca gtaacgatta ccgacttatc c

41

<210> 6

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 6

ggccagttcc cgagttggtg taacgattac cgacttatcc

40

<210> 7

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 7

agacttcaag cgacatgctc tgtaacgatt accgacttat cc

42

<210> 8

<211> 42

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 8
 ggagcaccac cgtagataca agtaacgatt accgacttat cc 42

 <210> 9
 <211> 44
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 9
 ctctccaaat cacgtatttg tgggtaacga ttaccgactt atcc 44

 <210> 10
 <211> 45
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 10
 agagtttgcc tatcaggtct tattgtaacg attaccgact tatcc 45

 <210> 11
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 11
 ggccaagtcg cactccacag taacgattac cgacttatcc 40

 <210> 12
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Target Specific Oligonucleotide

<400> 12

tccttttcta cgatcatgaca cagtaacgat taccgactta tcc

43

<210> 13

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 13

ttccattaga cgaataagtt tttcagtaac gattaccgac ttatcc

46

<210> 14

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 14

tttctggtaa gctcatcaca tctgtaacga ttaccgactt atcc

44

<210> 15

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 15

gagtaggggt agtcataatt gatgagtaac gattaccgac ttatcc

46

<210> 16

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 16
ttcttccaat tcgatgaata taatccgtaa cgattaccga cttatcc 47

<210> 17
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 17
tgttattagg tgtaaagaaa gtgtatggta acgattaccg acttatcc 48

<210> 18
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 18
gagataaggt cgctcacttg cgtaacgatt accgacttat cc 42

<210> 19
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 19
acctctgtct tcgaccaact ggtaacgatt accgacttat cc 42

<210> 20
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 20
acccctggaa cgacctgaac gtaacgatta ccgacttatc c 41

<210> 21
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 21
agtatctgtc cgcacggtca gtaacgatta ccgacttatc c 41

<210> 22
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 22
accccttttg cccgcagagg taacgattac cgacttatcc 40

<210> 23
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 23
ttaaagcagg ctagagtaac ctcgtaacga ttaccgactt atcc 44

<210> 24
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 24
gcattggata accaatcata ggtggtaacg attaccgact tatcc 45

<210> 25
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 25
tcccctagtc cgagttgctc gtaaccctaa ttatgggaat c 41

<210> 26
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 26
ccaatttgca cttgatgtg tagtaaccct aattatggga atc 43

<210> 27
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 27
ttttgccagt agaacaagca tggttaaccct aattatggga atc 43

<210> 28
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 28
ggaggcaagg ttccgcaacg taaccctaatt tatgggaatc 40

<210> 29
<211> 44

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 29
agaattccac gtaaatacaca tgcgtaaccc taattatggg aatc 44

<210> 30
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 30
tatgcatgta cagggaagta tccgtaaccc taattatggg aatc 44

<210> 31
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 31
gtgtgcatgc ctagaaaaa gcgtaaccct aattatggga atc 43

<210> 32
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 32
agcttttgtg cccttatcat gagtaaccct aattatggga atc 43

<210> 33
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 33
 cttcattagt atcttgtcac ttggggtaac cctaattatg ggaatc 46

 <210> 34
 <211> 45
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 34
 agatgatgac cctaccaaatt ttgggtaacc ctaattatgg gaatc 45

 <210> 35
 <211> 44
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 35
 aggcaagaga tagatatgtg ggcgtaaccc taattatggg aatc 44

 <210> 36
 <211> 44
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 36
 cagctgccac tataatcatg ttgtgaaccc taattatggg aatc 44

 <210> 37
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 37
 ggaacatgct aatttaaggt gagtgtaacc ctaattatgg gaatc 45

<210> 38
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 38
 aggactttgc tatatcaagt agttcgtaac cctaattatg ggaatc 46

<210> 39
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 39
 aaaggagata gtaacaatgg ttttcgtaac cctaattatg ggaatc 46

<210> 40
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 40
 aaatcagtgg ttcaccctgt tcgtaaccct aattatggga atc 43

<210> 41
 <211> 48
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 41
cttgtcataa gataattagg caaattagta accctaatta tgggaatc 48

<210> 42
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 42
tcattaagtt aatgctaagg atctttgtaa ccctaattat gggaatc 47

<210> 43
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 43
tgtcactggt acaagtggac ttgtaaccct aattatggga atc 43

<210> 44
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 44
ttggtcacta tacaagtgac ttctgtaacc ctaattatgg gaatc 45

<210> 45
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 45

aggaaaatgg gcgtaaagga gggtaacctt aattatggga atc 43

<210> 46
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 46
ttcatctaca atagggacaa caaacgtaac cctaattatg ggaatc 46

<210> 47
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 47
gataagtcta cgtggaaaag catgtaacct taattatggg aatc 44

<210> 48
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 48
caggactaca gttaagcatt tactgtaacc ctaattatgg gaatc 45

<210> 49
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 49
gtctaggaaa ttgccgtggt tggtaacctt aattatggga atc 43

<210> 50
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 50
aatcatcgtc tcgaaagcgg tgtaacccta attatgggaa tc 42

<210> 51
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 51
cttgacaaa ttcgaaggtc cagtaaccct aattatggga atc 43

<210> 52
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 52
gatgactctg ttcgcatcct cggtaacctt aattatggga atc 43

<210> 53
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 53
gatgctagtg tcaaacctgc cgtaacccta attatgggaa tc 42

<210> 54

<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 54
tgatacaggg ctcgtactta tccgtaaccc taattatggg aatc 44

<210> 55
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 55
aggagtcaca cgagttgaaa aggtaaccct aattatggga atc 43

<210> 56
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 56
ctcattacac cgaggtatga agggtaaccc taattatggg aatc 44

<210> 57
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 57
ctctgtcacg gctcgggtgg taaccctaatt tatgggaatc 40

<210> 58
<211> 43
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 58

ctaccatattg tacccgacct cagtaaccct aattatggga atc

43

<210> 59

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 59

aaccttaggt cgggtataga gaggtaaccc taattatggg aatc

44

<210> 60

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 60

gaagcactta gacactgtaa ggcgtaaccc taattatggg aatc

44

<210> 61

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 61

aataatcacc ggcagtaacg ggtaacccta attatgggaa tc

42

<210> 62

<211> 43

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 62
 aggaagaaac ctatggcaga cagtaaccct aattatggga atc 43

 <210> 63
 <211> 46
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 63
 catgtgttat tacgatgttc tttgtgtaac cctaattatg ggaatc 46

 <210> 64
 <211> 45
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 64
 actactgttt ggtacttgta tctggtaacc ctaattatgg gaatc 45

 <210> 65
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 65
 aaatcagtgg cggacagtag cgtaacccta attatgggaa tc 42

 <210> 66
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Target Specific Oligonucleotide

<400> 66

caggcaatgc cgactggatt gtaaccctaa ttatgggaat c

41

<210> 67

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 67

tcctatctaa gaccaactat aggtatggta accctaatta tgggaatc

48

<210> 68

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 68

gggaactgtc tattgagcac tcgtaaccct aattatggga atc

43

<210> 69

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 69

attacaatct ttagtactca tggaaagtaa ccctaattat gggaatc

47

<210> 70

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 70
aaggtattct catgcctaga atattgtaac cctaattatg ggaatc 46

<210> 71
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 71
tggacagaca cgttgtcatt tggtaacctt aattatggga atc 43

<210> 72
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 72
ctctcattac aatgctatac atttaacgta accctaatta tgggaatc 48

<210> 73
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 73
tgcagctcgc aacggaacaa gtaacggatt ttacaacttt a 41

<210> 74
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 74
gagtccatcc ggacattgac ctgtaacgga ttttacaact tta 43

<210> 75
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 75
cttgaacggc ctcgacgagg gtaacggatt ttacaacttt a 41

<210> 76
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 76
cctcctcggt tatattggcc ccgtaacgga ttttacaact tta 43

<210> 77
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 77
accgagactt cgaaaatgaa cgagtaacgg attttacaac tta 44

<210> 78
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 78
cctctggctc gaaactgaaa gggtaacgga ttttacaact tta 43

<210> 79
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 79
tgctatggac tagatctcgg caagtaacgg attttacaac tta 44

<210> 80
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 80
gccttgaccg gtcagaagac ggtaacggat tttacaactt ta 42

<210> 81
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 81
taccacagag atcgagctg cgtaacggat tttacaactt ta 42

<210> 82
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 82
accagcccga acctcgcccg taacggattt tacaacttta 40

<210> 83
<211> 44

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 83
actgtatgct tgccggtaat tctgtaacgg attttacaac ttta 44

<210> 84
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 84
gaacatgaac cggcccccgcac gtaacggatt ttacaacttt a 41

<210> 85
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 85
caggaatccc gtcaagggtg ggtaacggat tttaactt ta 42

<210> 86
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 86
tctcgattta cctcgtttaa gatctcgtaa cggattttac aacttta 47

<210> 87
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 87
 agaaccatgg tcgaactgac ctgtaacgga ttttacaact tta 43

<210> 88
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 88
 tctgaggggc tacgctgaga gtaacggatt ttacaacttt a 41

<210> 89
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 89
 aagcctctgt tacgcccacg gtaacggatt ttacaacttt a 41

<210> 90
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 90
 aatgattcaa ctcgtactgg atcccgtaac ggattttaca acttta 46

<210> 91
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 91
 cctcggaaat cccgattctg atagtaacgg attttacaac tttta 44

<210> 92
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 92
 ggcccctact cggttgtggg gtaacggatt ttacaacttt a 41

<210> 93
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 93
 ggaaaatgga acgaaactcc tggtgtaacg gattttacaa ctta 45

<210> 94
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 94
 ctgggtcgtg cgaggtcctg taacggattt tacaacttta 40

<210> 95
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 95
cacggggcta ggacggggtg taacggattt tacaacttta 40

<210> 96
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 96
ccgatggcgt actcgtcggg taacccttat tcggtacta 39

<210> 97
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 97
gatcagatca gaatccgagg tggtaacctt tattcggtac ta 42

<210> 98
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 98
ggttgacttc gcgacagttg gtaaccctta ttcggtacta 40

<210> 99
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 99

gacctgctca ttcgaggtga gtaaccctta ttcggtacta 40

<210> 100
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 100
tcacgtagta gcggcttcgg taacccttat tcggtacta 39

<210> 101
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 101
ccaaagatgg gcctacttgt cagtaaccct tattcggtac ta 42

<210> 102
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 102
gacagagctg cacgcttggg taacccttat tcggtacta 39

<210> 103
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 103
ctgggcctgt ttgcgctcag taacccttat tcggtacta 39

<210> 104
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 104
tccttaggca tgcgcggcgt aacccttatt cggtacta 38

<210> 105
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 105
cagcggcagt actcgctgtg taacccttat tcggtacta 39

<210> 106
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 106
atgccaccga tgacccgcgt aacccttatt cggtacta 38

<210> 107
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 107
atcagcgtcg ctccctcggt aacccttatt cggtacta 38

<210> 108

<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 108
ctttgagagc tcgaacatcg tgtaaccctt attcggtact a 41

<210> 109
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 109
ttccagtagt taaggcagag cagtaaccct tattcggtac ta 42

<210> 110
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 110
gagctgcagg atcgggtccg taacccttat tcggtacta 39

<210> 111
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 111
acatgagtgg tttcgtagcg ggtaaccctt attcggtact a 41

<210> 112
<211> 40
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 112

tgccgatgac atggaactcg gtaaccctta ttcggtacta

40

<210> 113

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 113

tggtgtaatt gaccttgtag gtagtaaccc ttattcggta cta

43

<210> 114

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 114

cattggccga aagcaggctg taacccttat tcggtacta

39

<210> 115

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 115

gagacctctg ccgaaactgg gtaaccctta ttcggtacta

40

<210> 116

<211> 41

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 116
 agtcttgtgc ttcgggtcaa agtaaccctt attcggtact a 41

 <210> 117
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 117
 cctcttctcg cctggcatag ggtaaccctt attcggtact a 41

 <210> 118
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 118
 gtaacggtga aaatggaccg ggtaaccctt attcggtact a 41

 <210> 119
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 119
 tccctctaag ggattaatgc cagtaaccct tattcggtac ta 42

 <210> 120
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Target Specific Oligonucleotide

<400> 120

agttcaagta tcccgcgact agtaacaatt agagtgaaat acc

43

<210> 121

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 121

gaacgcaggc tgtttactgt tgtaacaatt agagtgaaat acc

43

<210> 122

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 122

ggtccaggta aactaatggc tggtacaatt tagagtgaat tacc

44

<210> 123

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 123

ctctgttgag ttacctcgc aagtaacaat tagagtgaat tacc

44

<210> 124

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 124
tacttcaact aaccagtcca cggtacaat tagagtgaat tacc 44

<210> 125
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 125
ccatgagaca aggcttaaga ctgtaacaat tagagtgaat tacc 44

<210> 126
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 126
cggccaaaga atagtcgtag cgtaacaatt agagtgaat acc 43

<210> 127
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 127
ccatttcct aaggatgtg tgagtaaca ttagagtga atacc 45

<210> 128
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 128
ctctcact gtagtgatg tctgtaaca attagagtga aatacc 46

<210> 129
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 129
cagctttgtc ccgtgactgt gtaacaatta gagtgaaata cc 42

<210> 130
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 130
tgctgcaatg ctagcagcgg taacaattag agtgaaatac c 41

<210> 131
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 131
aagacaggaa cctatcaatg tagtgtaaca attagagtga aatacc 46

<210> 132
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 132
tagattagat tatgccaag tcaggtaaca attagagtga aatacc 46

<210> 133
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 133
catgtaaccc actttagggtt tacagtaaca attagagtg aatacc 46

<210> 134
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 134
ccagtctttc gtattaatga ttcaggtaac aattagagtg aaatacc 47

<210> 135
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 135
tgcaaccctg ctcgtcttcg gtaacaatta gagtgaaata cc 42

<210> 136
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 136
gtgtaggtat catctgtaat gtacagtaac aattagagtg aaatacc 47

<210> 137
<211> 41

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 137
tcccggactt cagtaccgcg taacaattag agtgaaatac c 41

<210> 138
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 138
cgaggagggtt gcgaaaggcg taacaattag agtgaaatac c 41

<210> 139
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 139
tatacatata ctcaacactt atagagggtg acaattagag tgaaatacc 49

<210> 140
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 140
gtaatagata ccataatttg tacttgggta acaattagag tgaaatacc 49

<210> 141
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 141
 tgctgctgctg ctagaccgt aacaattaga gtgaaatacc 40

 <210> 142
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 142
 gcgtggcgag ccaaagacgt aacaattaga gtgaaatacc 40

 <210> 143
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 143
 tccgcggttg ttggacgggt aacaattaga gtgaaatacc 40

 <210> 144
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 144
 ctgtcacata cgcaaactgg tgtaacatcg ttatagctag a 41

 <210> 145
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 145
tcgccatata ccggtcaaag agtaacatcg ttatagctag a 41

<210> 146
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 146
tggatgggtgc aataatccga gggtaacatc gttatagcta ga 42

<210> 147
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 147
agtgctgatc ccttaagtat gtcgtaacat cgttatagct aga 43

<210> 148
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 148
acctccatta accaatccag aaggtaacat cgttatagct aga 43

<210> 149
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 149
tgggtgtactt gaccactta ttgtgaacat cgttatagct aga 43

<210> 150
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 150
cagaagagaa cgtggagcag ggtaacatcg ttatagctag a 41

<210> 151
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 151
tccctgtgaa gtttatagac ttcagtaaca tcgttatagc taga 44

<210> 152
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 152
tgtaaaagca aacgcacgcc gtaacatcgt tatagctaga 40

<210> 153
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 153

attcagatga cgagaaatga tacagtaaca tcgttatagc taga	44
<210> 154	
<211> 39	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 154	
tggtcacgcc atttcggcg taacatcggt atagctaga	39
<210> 155	
<211> 45	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 155	
agcaagtata ccataaggaa attcagtaac atcggtatag ctaga	45
<210> 156	
<211> 40	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 156	
ctcgccgtcc tgtcgatttt gtaacatcgt tatagctaga	40
<210> 157	
<211> 38	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 157	
agcgagccga gaactccggt aacatcggt tagctaga	38

<210> 158
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 158
tattttgttc agacaacatg gctgtaacat cgttatagct aga 43

<210> 159
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 159
ccacttggtgta caacggagcc gtaacatcgt tatagctaga 40

<210> 160
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 160
cagaacacct gcgaggagag gtaacatcgt tatagctaga 40

<210> 161
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 161
ttcatcagcg acgcccctgg taacatcggt atagctaga 39

<210> 162

<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 162
cctgcaaaaa aacggtcacg tgtaacatcg ttatagctag a 41

<210> 163
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 163
tgtgggagtc ccttaggtca agtaacatcg ttatagctag a 41

<210> 164
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 164
gcatcgggag cacgcactgt aacatcgta tagctaga 38

<210> 165
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 165
ggctctgcac aacgcttgcg taacatcgta atagctaga 39

<210> 166
<211> 41
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 166

agccaggaca caatagtcag ggtaacatcg ttatagctag a

41

<210> 167

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 167

agccaggaca caatagtcag ggtaacatcg ttatagctag a

41

<210> 168

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 168

ttgcacatcc tacggtcttc tgtaacttac tacggagtta ac

42

<210> 169

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 169

gtagctcatt cgcaaacttt gggtaactta ctacggagtt aac

43

<210> 170

<211> 41

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 170
 cctttaagcg cgtcgtgtcc gtaacttact acggagttaa c 41

 <210> 171
 <211> 39
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 171
 cctcgacgca tgatgccggt aacttactac ggagttaac 39

 <210> 172
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 172
 gccccatggc tcgtgtaggg taacttacta cggagttaac 40

 <210> 173
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 173
 ccaattgtgt tccggcaagt tgtaacttac tacggagtta ac 42

 <210> 174
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Target Specific Oligonucleotide

<400> 174

gataggattt ggtcggaaac ctgtaactta ctacggagtt aac

43

<210> 175

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 175

tagttgccaa cggtgttgta gtaacttact acggagttaa c

41

<210> 176

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 176

cttggcctat gcggaagtaa cgtaacttac tacggagtta ac

42

<210> 177

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 177

ctcgagcga taggaaccat gtaacttact acggagttaa c

41

<210> 178

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 178
tttgcattcg tccatatcaa ctggttaactt actacggagt taac 44

<210> 179
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 179
tcaatatcaa cgggtaaacc gggtaactta ctacggagtt aac 43

<210> 180
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 180
ttgttactga cgtgggaaat attggttaact tactacggag ttaac 45

<210> 181
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 181
tctccgctga taccgggtg taacttacta cggagttaac 40

<210> 182
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 182
ggccagtcac cgaaatttca tgtaacttac tacggagtta ac 42

<210> 183
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 183
agttcgtagc ctatctcaca ctgtaactta ctacggagtt aac 43

<210> 184
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 184
cacattcccg tacgtttgct ggtaacttac tacggagtta ac 42

<210> 185
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 185
agtgagtccc tatgtatcct ttctgtaact tactacggag ttaac 45

<210> 186
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 186
aagcattata acgtgatcca caggtaactt actacggagt taac 44

<210> 187
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 187
tgcgccctga agcgcacgta acttactacg gagttaac 38

<210> 188
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 188
taaaaaatag cacgattaca gtatacgtaa cttactacgg agttaac 47

<210> 189
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 189
catatcgacg gattgagcct aacgtaactt actacggagt taac 44

<210> 190
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 190
cggtttctcg cgagagaaat agtaacttac tacggagtta ac 42

<210> 191
<211> 43

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 191
cttcccatct cgtgtaacat gagtaactta ctacggagtt aac 43

<210> 192
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 192
gcatttcaca tcggactgta ccgtaacttc gaaacggaaa c 41

<210> 193
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 193
tggaattctc ggcggaccag taacttcgaa acggaaac 38

<210> 194
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 194
gaagtggaaa tacgaccttt gcgtaacttc gaaacggaaa c 41

<210> 195
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 195
 gctggtcctt tgcgtaacat gtaacttcga aacggaaac 39

<210> 196
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 196
 ttttcatcta ttcgagatgc tcccgtactt tcgaaacgga aac 43

<210> 197
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 197
 tattcatccc gtgggtagt agtaacttcg aaacggaaac 40

<210> 198
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 198
 taaaaatagg cccgatttg tctgtaactt cgaaacggaa ac 42

<210> 199
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 199
 tccaaccttg acgacaagat agggttaactt cgaaacggaa ac 42

<210> 200
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 200
 aggcaacagt cgaaccattc tgtaacttcg aaacggaaac 40

<210> 201
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 201
 gcttcatttg cgactgctct tgtaacttcg aaacggaaac 40

<210> 202
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 202
 catcaggacg cttgtattgg tggttaacttc gaaacggaaa c 41

<210> 203
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 203
atcttcaatc cgagaatcca gcgtaacttc gaaacggaaa c 41

<210> 204
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 204
ctgtagtgtg gtagtaagga agagtaactt cgaaacggaa ac 42

<210> 205
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 205
gaacacctta cttacaacac ctggttaactt cgaaacggaa ac 42

<210> 206
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 206
gtacattgta caccgttaca atgggtaact tcgaaacggaa aac 43

<210> 207
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 207

tttcaagtcg tctatgttag ctggttaactt cgaaacggaa ac 42

<210> 208
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 208
caaagcaact atatgaagct tcattgtaac ttcgaaacgg aaac 44

<210> 209
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 209
catacttcta tcgagagctc agggtaactt cgaaacggaa ac 42

<210> 210
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 210
acgaagaaat cgagtaggtc tagggtaact tcgaaacgga aac 43

<210> 211
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 211
gaatcattga gtcgaccctt cagtaacttc gaaacggaaa c 41

<210> 212
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 212
 tgatgtgctt aagtagtgca gcgtaacttc gaaacggaaa c 41

<210> 213
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 213
 tccacggcat gatacatata acgtaacttc gaaacggaaa c 41

<210> 214
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 214
 tctcagagca tcccgaatcc agtaacttcg aaacggaaac 40

<210> 215
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 215
 gtggaacgaa gagtaggtag tttgtaactt cgaaacggaa ac 42

<210> 216

<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 216
gatcaatact ggacggagtc aggtaacctc gtcggatca 39

<210> 217
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 217
gagcttggtta ctcgtgcctt ggtaacctcg tcggatca 38

<210> 218
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 218
cttcttacac ttgcggacgc gtaacctcgt cggatca 37

<210> 219
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 219
caatacctat tccgttacac acttgtaacc tcgtcggatc a 41

<210> 220
<211> 39
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 220

gctccttcag tccggtttta ttgtaacctc gtcggatca

39

<210> 221

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 221

gacgcacgag ccgtgatctg taacctcgtc ggatca

36

<210> 222

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 222

gactgctaag gcataggaat tttcgtaacc tcgtcggatc a

41

<210> 223

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 223

caccacataa ttacggggac acgtaacctc gtcggatca

39

<210> 224

<211> 34

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 224
 cggcaaggcc cttcgagta acctcgtcgg atca 34

 <210> 225
 <211> 37
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 225
 tccatctggt acgtggtggg gtaacctcgt cggatca 37

 <210> 226
 <211> 38
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 226
 gtcctgccgc gtatgatttc tgtaacctcg tcggatca 38

 <210> 227
 <211> 37
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 227
 tggtcaggct gacgactgca gtaacctcgt cggatca 37

 <210> 228
 <211> 36
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Target Specific Oligonucleotide

<400> 228

gcatggaggt ccgtcctgtg taacctcgtc ggatca

36

<210> 229

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 229

ttgagggagc gtaatcccaa ggtaacctcg tcggatca

38

<210> 230

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 230

ccggcgtctg cgtacttccg taacctcgtc ggatca

36

<210> 231

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 231

cgactatctg cgtctatcat ccgtaacctc gtcggatca

39

<210> 232

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 232
gagaattcga tgatcaactc acggtaacct cgtcggatca 40

<210> 233
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 233
tggcctgtcg tccggtctgt aacctcgtcg gatca 35

<210> 234
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 234
cagggattcc gtcatatggc tgtaacctcg tcggatca 38

<210> 235
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 235
agacatcgat ggtacatatg ggtgtaacct cgtcggatca 40

<210> 236
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 236
tctgagctgt atcgctgcaa gtaacctcgt cggatca 37

<210> 237
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 237
tcttaggccc attcggttga gtaacctcgt cggatca 37

<210> 238
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 238
ttatacaccg tgccgaacgc gtaacctcgt cggatca 37

<210> 239
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 239
atgccctttg cgatctgcac gtaacctcgt cggatca 37

<210> 240
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 240
ggcagaattc cgaagttcag cgtaacataa tcgtagtttc gg 42

<210> 241
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 241
gtttccttca cgacaggtgt ggtaacataa tcgtagtttc gg 42

<210> 242
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 242
ctggtagaaa tgcgactaaa gacgtaacat aatcgtagtt tcgg 44

<210> 243
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 243
tgaccagcat cgtttcatct aatgtaacat aatcgtagtt tcgg 44

<210> 244
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 244
ttcgaagttc aaccgagtga cgtaacataa tcgtagtttc gg 42

<210> 245
<211> 42

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 245
ccaccaatcc aatgcggaat tgtaacataa tcgtagtttc gg 42

<210> 246
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 246
agactcgggtg ccattcgtat tgtaacataa tcgtagtttc gg 42

<210> 247
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 247
ataactgcta actgcgcaac cgtaacataa tcgtagtttc gg 42

<210> 248
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 248
gtagtgaggc cgcttataac cagtaacata atcgtagttt cgg 43

<210> 249
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 249
 ggtgatgatt cgatggagtg aagtaacata atcgtagttt cgg 43

 <210> 250
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 250
 ctgctgcttt acgtttggtg cgtaacataa tcgtagtttc gg 42

 <210> 251
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 251
 tcatcaacca cgtctttgga tagtaacata atcgtagttt cgg 43

 <210> 252
 <211> 44
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 252
 aggcagatct taaagtgttg gttgtaacat aatcgtagtt tcgg 44

 <210> 253
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 253
tgagggctta tacgaaagca aggtaacata atcgtagttt cgg 43

<210> 254
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 254
gctcagtact gactttggta tgtgtaacat aatcgtagtt tcgg 44

<210> 255
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 255
cagtcaatca ttagatccac atctgtaaca taatcgtagt ttcgg 45

<210> 256
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 256
ggaagctgct cgtcgaagcg taacataatc gtagtttcgg 40

<210> 257
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 257
gagaagatac ttatagcttc ttgtctgtaa cataatcgta gtttcgg 47

<210> 258
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 258
tcaatgctat ctaactgatg aagagtaaca taatcgtagt ttcgg 45

<210> 259
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 259
atcttcccaa ttgatgtaag tacttgtaac ataatcgtag tttcgg 46

<210> 260
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 260
catcacagtc cgagacgccg taacataatc gtagtttcgg 40

<210> 261
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 261

cattccaccg gcctgtgcgg taacataatc gtagtttcgg 40

<210> 262
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 262
ggacagcact actctagagt aaggtaacat aatcgtagtt tcgg 44

<210> 263
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 263
tgccaagtaa cctagcacac ccgtaacata atcgtagttt cgg 43

<210> 264
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 264
gtgccacctt tcaccgtgag taaccggtag aattacgg 38

<210> 265
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 265
ccgcaggtac gacttgcctg taaccggtag aattacgg 38

<210> 266
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 266
tgggcttcaa tcagatgggc agtaaccggt agaattacgg 40

<210> 267
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 267
agaacaccag ggtacgcata gtgtaaccgg tagaattacg g 41

<210> 268
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 268
tctccgagag tgtcagcggg taaccggtag aattacgg 38

<210> 269
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 269
gtcttcccgg ccggtcttgg taaccggtag aattacgg 38

<210> 270

<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 270
catgttcag attgtcgcca gtaaccggta gaattacgg 39

<210> 271
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 271
ggttcagtcg ttgctgaaca gtaaccggta gaattacgg 39

<210> 272
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 272
agctaccaat tagaccact cggttaaccgg tagaattacg g 41

<210> 273
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 273
cgtagttctc gtctccgatc agtaaccggt agaattacgg 40

<210> 274
<211> 39
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 274

ggagctgaac ttgacgccag gtaaccggtga gaattacgg

39

<210> 275

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 275

taatggatgt actcgttggg cgtaaccggt agaattacgg

40

<210> 276

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 276

tctgtgcata gccgtcccgg taaccggtag aattacgg

38

<210> 277

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 277

tggctggacg gatcggatcg taaccggtag aattacgg

38

<210> 278

<211> 37

<212> DNA

<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 278
ggtttgcgtc gttgcggcgt aaccggtaga attacgg 37

<210> 279
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 279
tctctgggga cgtgacaaag gtaaccggta gaattacgg 39

<210> 280
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 280
gaattcatca gctagattgg caagtaaccg gtagaattac gg 42

<210> 281
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 281
tcactccgtg ggctaagcgg taaccggtag aattacgg 38

<210> 282
<211> 40
<212> DNA
<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 282

tgtaagggaa cacggaagtg ggtaaccggt agaattacgg

40

<210> 283

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 283

ctcaatggtg gcgcggatcg taaccggtag aattacgg

38

<210> 284

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 284

aaccactcaa tctgcgtctc ggtaaccggt agaattacgg

40

<210> 285

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 285

gctgtagggc gccattttgt gtaaccggta gaattacgg

39

<210> 286

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 286
tgagtgcagg cattgcgcag taaccggtag aattacgg 38

<210> 287
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 287
caaagtggct catgccacc gtaaccggtga gaattacgg 39

<210> 288
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 288
tctatatgct aaatgtattg ccatggtaac gcttctcata acact 45

<210> 289
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 289
ctatgaaact tcgtgggtcac tccgtaacgc ttctcataac act 43

<210> 290
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 290
aactaactca tctgcagtac catgtaacgc ttctcataac act 43

<210> 291
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 291
aaaacctgct tgatccacat tctgtaacgc ttctcataac act 43

<210> 292
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 292
acattaacaa atcactcttg attcagtaac gcttctcata acact 45

<210> 293
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 293
ttttgcttag ctcattgtaa acagtaacgc ttctcataac act 43

<210> 294
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 294
gaggagctgt tggataaata attttgtaac gcttctcata acact 45

<210> 295
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 295
aagcaggcag gtattgtatg attgtaacgc ttctcataac act 43

<210> 296
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 296
gcaacttata tatcagtggg gaatggtaac gcttctcata acact 45

<210> 297
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 297
agattatgta tgcattgaga ccaacgtaac gcttctcata acact 45

<210> 298
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 298
gatcatgact ctccttatgg ttaatgtaac gcttctcata acact 45

<210> 299
<211> 43

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 299
tgtgaaaccg gtttataaac ctagtaacgc ttctcataac act 43

<210> 300
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 300
aataagatta gctactgtct acagtggtaa cgcttctcat aacact 46

<210> 301
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 301
taaacaaata gtgatacatc cacacgtaac gcttctcata acact 45

<210> 302
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 302
ttcagtcac taacaatgta ttcttgtaac gcttctcata acact 45

<210> 303
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 303
 agctgtggga aagtctttaa ctcgtaacgc ttctcataac act 43

<210> 304
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 304
 atagatgaac tattgatgta cacaacgtaa cgcttctcat aacact 46

<210> 305
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 305
 tacagatgaa attgagacct aaaacgtaac gcttctcata acact 45

<210> 306
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 306
 agcaatttgg gttaacagaa atagagtaac gcttctcata acact 45

<210> 307
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 307
 aatccaatgg gataagtact attagtgtaa cgcttctcat aacact 46

<210> 308
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 308
 aatgttattc cgtggaaaat tacatgtaac gcttctcata acact 45

<210> 309
 <211> 47
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 309
 ttacagaatt gtgtctgaaa aattatggta acgcttctca taacact 47

<210> 310
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 310
 atcagagagg cgctatgcct gtaacgcttc tcataacact 40

<210> 311
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 311
cggcgacacg atacagcggg aacgcttctc ataacact 38

<210> 312
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 312
cacttcaaat gcgcaacaag cgtaacgtcg ctgaaaaatc 40

<210> 313
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 313
gtaagcactg cgcaagacaa gtaacgtcgc tgaaaaatc 39

<210> 314
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 314
gtgatgagct cgacaggata ttgtaacgtc gctgaaaaat c 41

<210> 315
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 315

atggcgtcgt cggcacacgt aacgtcgctg aaaaatc 37

<210> 316
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 316
tttacaacag cgtggcaagt ggtaacgtcg ctgaaaaatc 40

<210> 317
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 317
aggcatgaag tgagacaatg cgtaacgtcg ctgaaaaatc 40

<210> 318
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 318
cctggctagt ggtatatgtc acgtaacgtc gctgaaaaat c 41

<210> 319
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 319
gctgatgatg ttcaagcgca gtaacgtcgc tgaaaaatc 39

<210> 320
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 320
 ctgccagtta gttaggcaag ttgtaacgct gctgaaaaat c 41

<210> 321
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 321
 gcagctccgg gctacaagtg taacgtcgct gaaaaatc 38

<210> 322
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 322
 tggcagctgt ctaactggag cgtaacgtcg ctgaaaaatc 40

<210> 323
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 323
 acgcgtgtgc gagtagatgg taacgtcgct gaaaaatc 38

<210> 324

<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 324
agctccacga aggatgccag taacgtcgct gaaaaatc 38

<210> 325
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 325
tgaggacggc atcgagatcc gtaacgtcgct tgaaaaatc 39

<210> 326
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 326
gtcttgagac ccggtcttgg gtaacgtcgct tgaaaaatc 39

<210> 327
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 327
agtggctctgg atcggtgcgg taacgtcgct gaaaaatc 38

<210> 328
<211> 39
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 328

tccattctgg gtcgagtgga gtaacgtcgc tgaaaaatc

39

<210> 329

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 329

ggacccaag gtgttccaag gtaacgtcgc tgaaaaatc

39

<210> 330

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 330

agcagcttgg ctactccccg taacgtcgct gaaaaatc

38

<210> 331

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 331

tttgggtatg ggtactgtgt agagtaacgt cgctgaaaaa tc

42

<210> 332

<211> 39

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 332
 gccgcaggga tagatccagg gtaacgtcgc tgaaaaatc 39

 <210> 333
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 333
 tgaagacagt cctatggact tccgtaacgt cgctgaaaaa tc 42

 <210> 334
 <211> 37
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 334
 aagctgaagc gcgggtcagt aacgtcgctg aaaaatc 37

 <210> 335
 <211> 37
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 335
 ccacgcagcc cttcgagagt aacgtcgctg aaaaatc 37

 <210> 336
 <211> 45
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Target Specific Oligonucleotide

<400> 336

tagtaggtgt cgacaactag agcgtaactc ttcaagatta atacc

45

<210> 337

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 337

gatggtcctg atcgagaaac cagtaactct tcaagattaa tacc

44

<210> 338

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 338

aagaggactt cgctgaattg acgtaactct tcaagattaa tacc

44

<210> 339

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 339

gaacctccga ctgtatgtca gcgtaactct tcaagattaa tacc

44

<210> 340

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 340
tctgaattag agcgatgttg acagtaactc ttcaagatta atacc 45

<210> 341
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 341
gcattcctcc gatcgcacag taactcttca agattaatac c 41

<210> 342
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 342
ctctatatatt agctcgctgt tcaagtaact cttcaagatt aatacc 46

<210> 343
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 343
tattcatcac ggcgcgcttg taactcttca agattaatac c 41

<210> 344
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 344
cattggggac cgtgcataaa agtaactctt caagattaat acc 43

<210> 345
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 345
caaggggtgc actatttggg agtaactctt caagattaat acc 43

<210> 346
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 346
ggaccgtatt tcggcgaaat agtaactctt caagattaat acc 43

<210> 347
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 347
atactgcact tgtcggcatg agtaactctt caagattaat acc 43

<210> 348
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 348
atggcagatc gatccattgg tgtaactctt caagattaat acc 43

<210> 349
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 349
tccctttgga cgtcaagaa ggtaactctt caagattaat acc 43

<210> 350
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 350
aggcttgctg acatacgcag gtaactcttc aagattaata cc 42

<210> 351
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 351
cttgctttgt gcgaacaccc gtaactcttc aagattaata cc 42

<210> 352
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 352
ctgatatcga atgcaatgga tgagtaactc ttcaagatta atacc 45

<210> 353
<211> 43

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 353
taggactggg ccgtaaaaa cgtaactctt caagattaat acc 43

<210> 354
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 354
tgaccattct cgggacacta acgtaactct tcaagattaa tacc 44

<210> 355
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 355
atgattgggt ccgtaaaaat gcgtaactct tcaagattaa tacc 44

<210> 356
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 356
gtttcatgta tggtaggacc accgtaactc ttcaagatta atacc 45

<210> 357
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 357
 ctcttgcatc gtagcgaact agtaactctt caagattaat acc 43

<210> 358
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 358
 atgatgattc cctcggtcag agtaactctt caagattaat acc 43

<210> 359
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 359
 agtagagaag atcgctgata tccggtaact cttcaagatt aatacc 46

<210> 360
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 360
 aacccttgac atcgccagtt tgtaacgtac cgtttgtata tg 42

<210> 361
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 361
 gaaggttaaa cgagatttcc aaaggtaacg taccgtttgt atatg 45

<210> 362
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 362
 gccactcgac atttctgccg gtaacgtacc gtttgtatat g 41

<210> 363
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 363
 tcatactgtc cgcaacatcc ggtaacgtac cgtttgtata tg 42

<210> 364
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 364
 gccactcgac atttctgccg gtaacgtacc gtttgtatat g 41

<210> 365
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 365
tcatactgtc cgcaacatcc ggtaacgtac cgtttgtata tg 42

<210> 366
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 366
tgaattttgc ccgaacttca ctgtaacgta ccgtttgtat atg 43

<210> 367
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 367
acacactcgg agcgcgcgta acgtaccgtt tgtatatg 38

<210> 368
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 368
caaacctata tgcccgttga ctgtaacgta ccgtttgtat atg 43

<210> 369
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 369

caggaacctt taccatgttc atggtaacgt accgtttgta tatg 44

<210> 370
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 370
gaaaatctct acggatgaat ttcttgtaac gtaccgtttg tatatg 46

<210> 371
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 371
gctgctaaga tagccttggtg aggtaacgta ccgtttgtat atg 43

<210> 372
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 372
tggcactaaa aaccggagaa cgtaacgtac cgtttgtata tg 42

<210> 373
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 373
tgcgggaccg ccgatacagt aacgtaccgt ttgtatatg 39

<210> 374
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 374
ggaaattaaa cggagtctta caacgtaacg taccgtttgt atatg 45

<210> 375
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 375
agccagagag cggtatgccg taacgtaccg tttgtatatg 40

<210> 376
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 376
ccaccaagtg gggatgtgac gtaacgtacc gtttgtatat g 41

<210> 377
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 377
cacacatgac cttaagcgc tgtaacgtac cgtttgtata tg 42

<210> 378

<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 378
tccacagatt gcgctgtcta gtaacgtacc gtttgtatat g 41

<210> 379
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 379
ctccacggac aggttactgc gtaacgtacc gtttgtatat g 41

<210> 380
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 380
gcgtcatggc gtcagcacgt aacgtaccgt ttgtatatg 39

<210> 381
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 381
tcctggccgg caacacacgt aacgtaccgt ttgtatatg 39

<210> 382
<211> 42
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 382

agccattttg tcgaggtttg ggtaacgtac cgtttgata tg

42

<210> 383

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 383

catccgaagc atgatatgtg atggtaacgt accgtttgta tatg

44

<210> 384

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 384

tagtgtgttg cgtatcaagt atctagacga tgcgaattaa cac

43

<210> 385

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 385

ttattgtgaa ctctagacat gagagtagac gatgcgaatt aacac

45

<210> 386

<211> 46

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 386
 acagtgaata ctaagactgt aaaaactaga cgatgcgaat taacac 46

 <210> 387
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 387
 acacaaggca cgtagaaaca gtagacgatg cgaattaaca c 41

 <210> 388
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 388
 caatggacag cggttgtgaa atagacgatg cgaattaaca c 41

 <210> 389
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 389
 caccatcacc tatcgacaga gttagacgat gcgaattaac ac 42

 <210> 390
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Target Specific Oligonucleotide

<400> 390

cattgcatta cgttccacat ggtagacgat gcgaattaac ac

42

<210> 391

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 391

acacagagtg tccgataccc atagacgatg cgaattaaca c

41

<210> 392

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 392

ggtgattaca ttgagtgcta ggatagacga tgcgaattaa cac

43

<210> 393

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 393

tccacataag cggtcaaggt atagacgatg cgaattaaca c

41

<210> 394

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 394
cagaataatc gctattccta gctgtagacg atgcgaatta acac 44

<210> 395
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 395
ttacactcat acgtcgccgg tagacgatgc gaattaacac 40

<210> 396
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 396
tggccataaa ggctacttac aattagacga tgcgaattaa cac 43

<210> 397
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 397
tttcaagtta ttcgatctgc taacctagac gatgcgaatt aacac 45

<210> 398
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 398
agttagtcaa ggactttact aaggttagac gatgcgaatt aacac 45

<210> 399
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 399
ttacctcaaa tacgggctac catagacgat gcgaattaac ac 42

<210> 400
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 400
gagttatatt actctaacta aagccagtag acgatgcgaa ttaacac 47

<210> 401
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 401
ttgtcaacac gcataaaatc tgctagacga tgcgaattaa cac 43

<210> 402
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 402
tcatatacaa tcggggatct gagtagacga tgcgaattaa cac 43

<210> 403
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 403
cccacaaaaa tacccgtaag ttatagacga tgcgaattaa cac 43

<210> 404
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 404
cactaaatta ttacgaattt tgcaaagtag acgatgcgaa ttaacac 47

<210> 405
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 405
tcaaataaaa accgtcaaaa gtttatagac gatgccaatt aacac 45

<210> 406
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 406
agtgcaatgg taccacgtac tgtagacgat gcgaattaac ac 42

<210> 407
<211> 43

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 407
atgtgtcttg caattggatt ccctagacga tgcgaattaa cac 43

<210> 408
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 408
ggtgtgcgcg tcgtacacta gacccgttat aagtgttg 38

<210> 409
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 409
gtgtttaggg tcgcggttga tagaccggtt ataagtgttg 40

<210> 410
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 410
gagaatggcg aagtaaatgc cctagaccg ttataagtgt tg 42

<210> 411
<211> 42
<212> DNA
<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 411

gtagatggaa tagacacggc ttagacccg ttataagtgt tg

42

<210> 412

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 412

gctcttaatg catggtacaa ctgtagaccg gttataagtgt ttg

43

<210> 413

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 413

aaaccagtat ttcgtcacag tgatagaccg gttataagtgt ttg

43

<210> 414

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 414

gatgggaacg gtgtagagat gttagaccg ttataagtgt tg

42

<210> 415

<211> 42

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 415
 ttccaaatgc cgtcaaaact gttagaccgc ttataagtgt tg 42

<210> 416
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 416
 tgggtcacag acggtgtggt agaccgtta taagtgttg 39

<210> 417
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 417
 aatcaggtat acttctatcc ttgaaataga cccgttataa gtgttg 46

<210> 418
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 418
 tgctgtatta gcaacttgga acttagaccg gttataagtg ttg 43

<210> 419
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 419
gccaataaag cgatggttga tctagaccg ttataagtg tg 42

<210> 420
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 420
gtaaggatca ctggatccta ctgtagacc gttataagtg ttg 43

<210> 421
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 421
gacctattc agttgatgag aggtagacc gttataagtg ttg 43

<210> 422
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 422
gcataacaga cggttgcaag ttagaccgt tataagtggt g 41

<210> 423
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 423

acctaaagcg agttgctgag ttagaccggt tataagtgtt g 41

<210> 424
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 424
gagtcagaaa cacgcatgga atagaccggt tataagtgtt g 41

<210> 425
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 425
agcaactctg ataggctcac actagaccggt ttataagtgt tg 42

<210> 426
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 426
ccataccac tacggataaa gatgtagacc cggtataagt gttg 44

<210> 427
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 427
gctttctgta cgactcaggt tttagaccggt ttataagtgt tg 42

<210> 428
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 428
caatgttgag ccactaaacc actagaccg ttataagtgt tg 42

<210> 429
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 429
atgcttgat taggtccaaa gctagaccg ttataagtgt tg 42

<210> 430
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 430
cccggtgat gattagtttg gtagaccgt tataagtgtt g 41

<210> 431
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 431
ccatggcat accctggaat ttagaccgt tataagtgtt g 41

<210> 432

<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 432
attatactgt ccagcgtagg tggtagacaa ccgtcgtaa g 41

<210> 433
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 433
tcctggtaag gataggtacc atgtagacaa ccgtcgtaa g 41

<210> 434
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 434
cactgaaata ggacggaatc tgctagacaa ccgtcgtaa g 41

<210> 435
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 435
aaagtttatt ggcgcttgcc gtagacaacc gtcgttaag 39

<210> 436
<211> 39
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 436

gcaatgccat tagcgatacg atagacaacc gtcgttaag

39

<210> 437

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 437

tgattgaaca ccacgcgaca tagacaaccg tcgttaag

38

<210> 438

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 438

agtcttcgaa gcactattgc catagacaac cgtcgttaag

40

<210> 439

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 439

tcaatggttg atcggcctct ctagacaacc gtcgttaag

39

<210> 440

<211> 41

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 440
 tggcatgatg tctaatagga gtctagacaa ccgtcgtaa g 41

 <210> 441
 <211> 38
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 441
 ctgcggttta gccttgacgt tagacaaccg tcgttaag 38

 <210> 442
 <211> 38
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 442
 cccagaggac gccatcattt tagacaaccg tcgttaag 38

 <210> 443
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 443
 tttcttgaaa gacgacagca gttagacaac cgtcgttaag 40

 <210> 444
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Target Specific Oligonucleotide

<400> 444

attaaatggtt cggaaggatg acctagacaa ccgtcggttaa g

41

<210> 445

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 445

tcttttgtca gcacggttgc tagacaaccg tcgttaag

38

<210> 446

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 446

ctggatcagc tcgaccagga tagacaaccg tcgttaag

38

<210> 447

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 447

accatggtcc gacttctgcc tagacaaccg tcgttaag

38

<210> 448

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 448
ctggatattc ggttatctgg gctagacaac cgtcgttaag 40

<210> 449
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 449
atcccccttta cgatactctt cagtagacaa ccgtcgttaa g 41

<210> 450
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 450
tccagagcgg gaacagtatg tagacaaccg tcgtttaag 38

<210> 451
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 451
gttgcctgca taagatgggc tagacaaccg tcgtttaag 38

<210> 452
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 452
ccttttgtgc cgatgaccgc tagacaaccg tcgtttaag 38

<210> 453
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 453
gcttccgtgg actgggacgt agacaaccgt cgttaag 37

<210> 454
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 454
ccatagaagg acgaggtatt tcctagacaa ccgtcgtaa g 41

<210> 455
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 455
agaatgagtc gctgctcgat atagacaacc gtcgtaa g 39

<210> 456
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 456
gcttcgacaa acgcaaagcg tagactcaat gatgataaag a 41

<210> 457
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 457
gctagttcac agaaagacca ttttagactc aatgatgata aaga 44

<210> 458
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 458
cagctcatcg aaagcgaccc tagactcaat gatgataaag a 41

<210> 459
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 459
cggctgctac aaacctcggt agactcaatg atgataaaga 40

<210> 460
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 460
aacaatttga aggccccaca atagactcaa tgatgataaa ga 42

<210> 461
<211> 39

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 461
gcgtctgcac cggagactta gactcaatga tgataaaga 39

<210> 462
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 462
gcgctgctca ggcattggta gactcaatga tgataaaga 39

<210> 463
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 463
ttgttgtagta acaacataat ttcaagtaga ctcaatgatg ataaaga 47

<210> 464
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 464
ctccacgtcg gcgtgcatag actcaatgat gataaaga 38

<210> 465
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 465
ctgcggggat ttagccggt agactcaatg atgataaaga 40

<210> 466
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 466
atcttagcta ctgaccggct atagactcaa tgatgataaa ga 42

<210> 467
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 467
aagagattat acgcctcacg gatagactca atgatgataa aga 43

<210> 468
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 468
tttcgagtaa cgaaattagc tcctagactc aatgatgata aaga 44

<210> 469
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 469
 gacccgcaga ttggcacgta gactcaatga tgataaaga 39

<210> 470
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 470
 atggcccaa tctcgtttgg tagactcaat gatgataaag a 41

<210> 471
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 471
 ccagtagcta taacgaagtc ctctagactc aatgatgata aaga 44

<210> 472
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 472
 acaaattccc ggacactatg gatagactca atgatgataa aga 43

<210> 473
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 473
ttcacagagt tgataaggcc actagactca atgatgataa aga 43

<210> 474
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 474
aactttgccg gtctctttac attagactca atgatgataa aga 43

<210> 475
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 475
ttccaatgtg caagaatgat ttcttagact caatgatgat aaaga 45

<210> 476
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 476
ctccttctgg ggtatttcct gctagactca atgatgataa aga 43

<210> 477
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 477

ccacttcagt tggccggtat agactcaatg atgataaaga 40

<210> 478
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 478
tccgtcaacg tccgcagtta gactcaatga tgataaaga 39

<210> 479
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 479
agtgagatcg ccatagtgca atagactcaa tgatgataaa ga 42

<210> 480
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 480
gaaggtgacc ctataaggag tcatagacta caacaaaaga tcg 43

<210> 481
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 481
aacaccgctt gcatagttgt gtagactaca aaaaagatc g 41

<210> 482
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 482
tacagacgcg gaatcattct ctagactaca acaaaagatc g 41

<210> 483
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 483
tggaggaaat gagcatgacc ttagactaca acaaaagatc g 41

<210> 484
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 484
atggtgtaca ctcgaggctg atagactaca acaaaagatc g 41

<210> 485
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 485
ccttgtggta gacgttcagc ttagactaca acaaaagatc g 41

<210> 486

<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 486
ggatcagggtt taatgggtcac tatgtagact acaacaaaag atcg 44

<210> 487
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 487
cacacggtca acgctgtaca tagactacaa caaaagatcg 40

<210> 488
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 488
caggtgtttg cggaagttcc tagactacaa caaaagatcg 40

<210> 489
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 489
gtgctcatgg tcgtagagga tagactacaa caaaagatcg 40

<210> 490
<211> 43
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 490

aagtcaaagt acgtctcgat cattagacta caacaaaaga tcg

43

<210> 491

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 491

tcgtagcagc cgttggagat agactacaac aaaagatcg

39

<210> 492

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 492

tcgtggccag agtaggcatt agactacaac aaaagatcg

39

<210> 493

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 493

ggtactctcc aaacgctcgg tagactacaa caaaagatcg

40

<210> 494

<211> 42

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 494
 aggtacgaat agggatgtcg tctagactac aacaaaagat cg 42

<210> 495
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 495
 agggatcgtg acatcggtcc aatagactac aacaaaagat cg 42

<210> 496
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 496
 caggtgatct gcgccgttgt agactacaac aaaagatcg 39

<210> 497
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 497
 ccacaggcga tacaaccggt agactacaac aaaagatcg 39

<210> 498
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 498

cagcagcttc gaggctggg agactacaac aaaagatcg

39

<210> 499

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 499

ccctcacagg acgtcgatc agactacaac aaaagatcg

39

<210> 500

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 500

gcacgaagcc ttggtgtct agactacaac aaaagatcg

39

<210> 501

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 501

tgggaagtgt cggctttcat gtagactaca aaaaagatc g

41

<210> 502

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 502
tgggaagtgt cggctttcat gtagactaca acaaaagatc g 41

<210> 503
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 503
tgctgcact ttggccgcta gactacaaca aaagatcg 38

<210> 504
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 504
gtcttttggc acggtttctg ttagactgta ttcaacgtcc 40

<210> 505
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 505
tacttcttca acgcgaagag ctagactgta ttcaacgtcc 40

<210> 506
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 506
tttgaggttg tatccgctgc ttagactgta ttcaacgtcc 40

<210> 507
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 507
caagttgact aaatctcgta ctttctagac tgtattcaac gtcc 44

<210> 508
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 508
gccttattaa cggtatcttc agaatagact gtattcaacg tcc 43

<210> 509
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 509
tgttctggat ttcgcaggct ctagactgta ttcaacgtcc 40

<210> 510
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 510
gctttatcag gttatgttgc atgtagactg tattcaacgt cc 42

<210> 511
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 511
gattctggct tatagggtat tcactagact gtattcaacg tcc 43

<210> 512
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 512
ttttcctccc gcaattccta gatagactgt attcaacgtc c 41

<210> 513
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 513
tgtttccgtc aaatcgtgtg gtagactgta ttcaacgtcc 40

<210> 514
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 514
ggttccctct agatcttgcc tttagactgt attcaacgtc c 41

<210> 515
<211> 43

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 515
gcatgtacca cctatcatct aatgtagact gtattcaacg tcc 43

<210> 516
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 516
gttgccaaca cgagctgact tagactgtat tcaacgtcc 39

<210> 517
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 517
actgactact agttcaagcg catagactgt attcaacgtc c 41

<210> 518
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 518
tctcttgctc gctttggacc tagactgtat tcaacgtcc 39

<210> 519
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 519
 cactgctaga acaactatca atttgtagac tgtattcaac gtcc 44

 <210> 520
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 520
 ttacatggct taagttgggg agtagactgt attcaacgtc c 41

 <210> 521
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 521
 gtgaggggac gctcttgtat ttagactgta ttcaacgtcc 40

 <210> 522
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 522
 aacggtgcta tgcctagtag atagactgta ttcaacgtcc 40

 <210> 523
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 523
 ttgacctcc ctagagtgt atagactgta ttcaacgtcc 40

<210> 524
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 524
 atgtcccaat ggatacttaa agcctagact gtattcaacg tcc 43

<210> 525
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 525
 cttccagtaa cgagatactt tccttagact gtattcaacg tcc 43

<210> 526
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 526
 caaccatgaa ttagtcctt gggtagactg tattcaacgt cc 42

<210> 527
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 527
cagcattatt agacacttta actgttagac tgtattcaac gtcc 44

<210> 528
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 528
tgcacatatg attgacgctc agtagactct tatattgagt ggt 43

<210> 529
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 529
ttcaccgcct gcaacaagat agactcttat attgagtggt 40

<210> 530
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 530
ttcacttaca ggtaacacca agttagactc ttatattgag tggt 44

<210> 531
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 531

aagcaataga tcgtccataa gttatagact cttatattga gtggt 45

<210> 532
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 532
tacaagaacc ctaattgtaa taatagatag actcttatat tgagtgggt 48

<210> 533
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 533
gaataggacc aaagtgtccc ttgtagactc ttatattgag ttggt 44

<210> 534
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 534
tccatcagga ctaaattctca cactagactc ttatattgag ttggt 44

<210> 535
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 535
aaaggccata cgtttttcct acctagactc ttatattgag ttggt 44

<210> 536
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 536
gcagtgtaca atgaacgaga aattagactc ttatattgag tggt 44

<210> 537
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 537
ggcattctgc tttaagatca gaatagactc ttatattgag tggt 44

<210> 538
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 538
ggccagccac gattcacagt agactcttat attgagtgggt 40

<210> 539
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 539
gaagccagcg accggactta gactcttata ttgagtgggt 39

<210> 540

<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 540
ctgaggggtcg tcgttgtctt tagactctta tattgagtgg t 41

<210> 541
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 541
ctgaaccact ggcataagagt tctagactct tatattgagt ggt 43

<210> 542
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 542
aaatcaacca cgggtcgcgt agactcttat attgagtggg 40

<210> 543
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 543
agcaacagtc gacgagggat agactcttat attgagtggg 40

<210> 544
<211> 48
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 544

atatattcca tactactaac agacatatag actctttatat tgagtgggt

48

<210> 545

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 545

tccacaccgg catcggctag actctttatat tgagtgggt

38

<210> 546

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 546

agaagggcaa tccggtggct agactcttat attgagtgggt

40

<210> 547

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 547

tcagggagtc tgcgaccagt agactcttat attgagtgggt

40

<210> 548

<211> 40

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 548
 gctttgccag ctcaccactt agactcttat attgagtggg 40

<210> 549
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 549
 aaatacccat aaggcgtgat gctagactct tatattgagt ggt 43

<210> 550
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 550
 attactatcc tgcgtgaaat ccatagactc ttatattgag tggg 44

<210> 551
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 551
 cccaaagtcg aacagttttg tctagactct tatattgagt ggt 43

<210> 552
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 552

tcctcaaatg tccgaggatg atagacctat tctatgcttc g

41

<210> 553

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 553

gtgaacacaa cgtaagaaca ggtagacctt ttctatgctt cg

42

<210> 554

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 554

actcctctgg ttacgcttca ttttagacctt ttctatgctt cg

42

<210> 555

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 555

acctaacata accgtgctgc ctagacctat tctatgcttc g

41

<210> 556

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 556
ttcagttgac cgtctggaca ctagacctat tctatgcttc g 41

<210> 557
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 557
ctctgacaca cgtaacaata acatagacct attctatgct tcg 43

<210> 558
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 558
agtaatgtga ggtacaactg cattagacct attctatgct tcg 43

<210> 559
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 559
gcttctttcc cgcccaaat atagacctat tctatgcttc g 41

<210> 560
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 560
aaagaaaagc ggtctactag attatagacc tattctatgc ttcg 44

<210> 561
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 561
tgacgtgagg cgaaatttat gtagacctat tctatgcttc g 41

<210> 562
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 562
gcttattgca gcatggatg atagacctat tctatgcttc g 41

<210> 563
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 563
tgtcagtaga ctagagga gtagacctat ttctatgctt cg 42

<210> 564
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 564
ttggtccga ctaccaaca gtagacctat tctatgcttc g 41

<210> 565
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 565
ctcttaagta cgcaataatt ctctctagac ctattctatg cttcg 45

<210> 566
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 566
gttccgtata tgtcggatct ctctagacct attctatgct tcg 43

<210> 567
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 567
aaattcaccg gacggagtgt ttagacctat tctatgcttc g 41

<210> 568
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 568
tttgtgaaac cgtagtggct cttagacctt ttctatgctt cg 42

<210> 569
<211> 42

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 569
acctctttaa cgaaggtgtc agtagaccta ttctatgctt cg 42

<210> 570
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 570
ggactccggt tctaacttgg ttagacctat tctatgcttc g 41

<210> 571
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 571
atctctatat gacgtgctgt tggtagacct attctatgct tcg 43

<210> 572
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 572
gttgggaatta ttcggagact gagtagacct attctatgct tcg 43

<210> 573
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 573
 gcacatttga cgacggcttc tagacctatt ctatgcttcg 40

 <210> 574
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 574
 actccgtgta aacgcagtgg tagacctatt ctatgcttcg 40

 <210> 575
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 575
 acacataact cgттаacacg ttctagacct attctatgct tcg 43

 <210> 576
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 576
 cagatctgtt gagctaacag ggtagacatg ttataccatg cg 42

 <210> 577
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 577
ttctagacta tgcaaccctc taggtagaca tggtatacca tgcg 44

<210> 578
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 578
cacccatgtg agtaatacac tgctagacat gttataccat gcg 43

<210> 579
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 579
agtcccatat tgccgttcat gctagacatg ttataccatg cg 42

<210> 580
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 580
atttcctcat aacggtcacg gctagacatg ttataccatg cg 42

<210> 581
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 581
ttactgccta gctagcaggt tatagacatg ttataccatg cg 42

<210> 582
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 582
acgtgccctt ggtactatga ctagacatgt tataccatgc g 41

<210> 583
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 583
cttgccaaac cctagcttgg atagacatgt tataccatgc g 41

<210> 584
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 584
attatcactt aacgaaggctc ctttgtagac atgttatacc atgcg 45

<210> 585
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 585

atatacagcc taagcaccaa ttatgtagac atgttatacc atgcg 45

<210> 586
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 586
ggcaacaaaa cgtcattggca tagacatggt ataccatgcg 40

<210> 587
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 587
gtctgaggac taaccctaaa gggtagacat gttataccat gcg 43

<210> 588
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 588
cttaaaatag atcgaaactc tgtctctaga catgttatac catgcg 46

<210> 589
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 589
tgatctgtac aagctacgat tttatagaca tggtatacca tgcg 44

<210> 590
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 590
aaatcagtta taccaagggg agatagacat gttataccat gcg 43

<210> 591
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 591
taggaaaaca tacgtatact gaatatagac atgttatacc atgcg 45

<210> 592
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 592
agttggcctc acgttgcatt tagacatggt ataccatgcg 40

<210> 593
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 593
tttggctctg gcttgcaat tagacatggt ataccatgcg 40

<210> 594

<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 594
cagtagtcaa cgcagcactc atagacatgt tataccatgc g 41

<210> 595
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 595
caacaggatc acctaattt cccatagaca tggtatacca tgcg 44

<210> 596
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 596
tttggacaga tatctcctcg aaatagacat gttataccat gcg 43

<210> 597
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 597
aaaggctatc tacactttgg caatagacat gttataccat gcg 43

<210> 598
<211> 40
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 598

tgcttgatc ctatcccgac tagacatggt ataccatgcg

40

<210> 599

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 599

tgtggcacc tacacgtgc tagacatggt ataccatgcg

40

<210> 600

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 600

ggtgagctgg taatctgacc ttagacaatc tatttaccct acg

43

<210> 601

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 601

gttgaggca tgacgcaagt agacaatcta tttaccctac g

41

<210> 602

<211> 43

<212> DNA

<213> Artificial Sequence

<220>	
<223> Target Specific Oligonucleotide	
<400> 602	
aaaacgccta cgcacatgt ctagacaatc tatttacccct acg	43
<210> 603	
<211> 40	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 603	
tggtcctgcg cggatgtcta gacaatctat ttaccctacg	40
<210> 604	
<211> 41	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 604	
ggtgagcttc tccgtggcgt agacaatcta ttaccctac g	41
<210> 605	
<211> 41	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 605	
agcgcagggc caattgactt agacaatcta ttaccctac g	41
<210> 606	
<211> 43	
<212> DNA	
<213> Artificial Sequence	
<220>	

<223> Target Specific Oligonucleotide

<400> 606

ccgggtacac ggttttgatc ttagacaatc tattttaccct acg

43

<210> 607

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 607

ccggctcgat gtcgggtata gacaatctat ttaccctacg

40

<210> 608

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 608

ggcgccttct cgccacatta gacaatctat ttaccctacg

40

<210> 609

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 609

cacgttgaag cgcgggtgta gacaatctat ttaccctacg

40

<210> 610

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 610
gcccacagaa accggtttaa thtagacaat ctatttacct tacg 44

<210> 611
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 611
tcagaatgag cgcaatccag gtagacaatc tattttacct acg 43

<210> 612
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 612
ttcggacaca aagacgctcc tagacaatct attttacct cg 42

<210> 613
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 613
agcttgacgt aggtgtcggg tagacaatct attttacct cg 42

<210> 614
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 614
ggttcccgcc aaatttcccg tagacaatct attttacct cg 42

<210> 615
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 615
cagggctcat gatagtacaa cagtagacaa tctatttacc ctacg 45

<210> 616
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 616
ggactttagc gcggtctcct agacaatcta tttaccctac g 41

<210> 617
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 617
gcagccgttc taagcgctgt agacaatcta tttaccctac g 41

<210> 618
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 618
gctggtaaaag gcgcttcct agacaatcta tttaccctac g 41

<210> 619
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 619
gaagaagtcg gtgacgcggt agacaatcta tttaccctac g 41

<210> 620
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 620
ggctggaaac ctcgtccact agacaatcta tttaccctac g 41

<210> 621
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 621
tttattagag tttaggaggt cagaaataga caatctatTT accctacg 48

<210> 622
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 622
tgggaggtcc catattcaga ggtagacaat ctattttaccc tacg 44

<210> 623
<211> 44

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 623
tccagggatg tcctacttgt cctagacaat ctatttacct tacg 44

<210> 624
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 624
ccaggtttcc ggcacagtgg gtaactgaat tgctcacttta 40

<210> 625
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 625
tgttatactt tgctgctctt agtagagtaa ctgaattgtc acttta 46

<210> 626
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 626
agcttttaac caggtttcga cttcgtaact gaattgtcac tttta 44

<210> 627
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 627
 gtatgagaat cccgataaaa ctggtgtaac tgaattgtca cttta 45

 <210> 628
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 628
 aagaggacat cgaccaatcc tcagtaactg aattgtcact tta 43

 <210> 629
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 629
 ggtttgtgca agggtcgaaa acgtaactga attgtcactt ta 42

 <210> 630
 <211> 44
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 630
 acacctctcg tagctataga tgtggttaact gaattgtcac tttta 44

 <210> 631
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 631
 atgagagggc aaccgaggtg agtaactgaa ttgtcacttt a 41

<210> 632
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 632
 ccgctgtcag ggtctatcat tccgtaactg aattgtcact tta 43

<210> 633
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 633
 gcaatgagca tatcctcggg cgtaactgaa ttgtcacttt a 41

<210> 634
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 634
 ggcttgagtg gggtcaccca ggtaactgaa ttgtcacttt a 41

<210> 635
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 635
gcaaggatatg gcaatagctg agtgtaactg aattgtcact tta 43

<210> 636
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 636
cagtaatagt agagacgcca ctacagtaac tgaattgtca cttta 45

<210> 637
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 637
cttccaaagt gtcgcttcag agggtaactg aattgtcact tta 43

<210> 638
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 638
aggcaatfff cccgatactt tttattgtaa ctgaattgtc acttta 46

<210> 639
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 639

tgtagcttc tatagtcact attcgagtaa ctgaattgtc acttta 46

<210> 640
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 640
tcaacaagta atgtatcccg ttcattgtaac tgaattgtca cttta 45

<210> 641
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 641
tttccttggc cgtaagttgt tttcgtaact gaattgtcac tttta 44

<210> 642
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 642
gggtcaacc agtctgttac ctgtaactga attgtcactt ta 42

<210> 643
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 643
tctgagactg atagggaac atatgggtaa ctgaattgtc acttta 46

<210> 644
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 644
tctttgccac caatagcttg gagtaactga attgtcactt ta 42

<210> 645
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 645
ctcattggaa tggtagtag agcaagtaac tgaattgtca ctta 45

<210> 646
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 646
ctgagtaaag agcgtgtatt ccaggaact gaattgtcac tta 44

<210> 647
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 647
tggaggcata aagctggtag gcgtaactga attgtcactt ta 42

<210> 648

<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 648
ggatctcaag cgttgcaggc gtaacgatag atttatacga cg 42

<210> 649
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 649
gcaccgcgag cggactagta acgatagatt tatacgacg 39

<210> 650
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 650
tgctgaggtc gctcacgaag taacgataga tttatacgac g 41

<210> 651
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 651
ccggaccacg tagttaaatc ttgtaacgat agatttatac gacg 44

<210> 652
<211> 43
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 652

aagttctttt gggcgatgcc agtaacgata gattttatacg acg

43

<210> 653

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 653

gttcccttat tagtctaata ttttgcgtaa cgatagattt atacgacg

48

<210> 654

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 654

ttggaccagt gtacataagg atggtaacga tagatttata cgacg

45

<210> 655

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 655

tggcagtgcg cggatgggtcg taacgataga ttatacgac g

41

<210> 656

<211> 47

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 656
 ataccaattc tagtgagaag ttcacgtaac gatagattta tacgacg 47

<210> 657
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 657
 tctctgtagg gtaaggctct gtgtaacgat agatttatac gacg 44

<210> 658
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 658
 tttagaggta gaccattgtg tgggtaacga tagatttata cgacg 45

<210> 659
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 659
 agagagggca ctctacgctt gtaacgatag atttatacga cg 42

<210> 660
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 660

caaaaagccc tagctcagat gggtaacgat agatttatac gacg

44

<210> 661

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 661

cctctcctcc ctatttggct ggtaacgata gatttatacg acg

43

<210> 662

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 662

ttttacaacg aactcattag gtccgtaacg atagatttat acgacg

46

<210> 663

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 663

ggagtagatc ccccatctat tccgtaacga tagatttata cgacg

45

<210> 664

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 664
gtctcttgcc tcgtttctct ccgtaacgat agatttatac gacg 44

<210> 665
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 665
aattctggcg tagcacaac agtaacgata gatttatacg acg 43

<210> 666
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 666
ggccatgaac ccctaaatct aaagtaacga tagatttata cgacg 45

<210> 667
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 667
gcccactggg accatcttgg gtaacgatag atttatacga cg 42

<210> 668
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 668
taccacgtgg cactaacaca gtaacgatag atttatacga cg 42

<210> 669
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 669
ttctagcttt tagaccagca gttgtaacga tagatttata cgacg 45

<210> 670
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 670
cccaagtgct agtagaacct gcgtaacgat agatttatac gacg 44

<210> 671
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 671
aaacacatct atactcaaag acagagtaac gatagattta tacgacg 47

<210> 672
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 672
cacagacttg ccgactcttt ggtaacgata gatttatacg acg 43

<210> 673
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 673
cacatgttaa tgttcccgac cagtaacgat agatttatac gacg 44

<210> 674
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 674
attaatcggt tgcggatctg ccgtaacgat agatttatac gacg 44

<210> 675
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 675
tgggtaacat cggacaagtt tggtaacgat agatttatac gacg 44

<210> 676
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 676
tctgaagttt cgagccaatg ttgtaacgat agatttatac gacg 44

<210> 677
<211> 44

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 677
ccattttcac cgctgaaata gagtaacgat agattttatac gacg 44

<210> 678
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 678
ctggatcaca tgcgttgtca ggtaacgata gattttatac acg 43

<210> 679
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 679
atatttgcct cgtaagatcc cctgtaacga tagattttata cgacg 45

<210> 680
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 680
ctgaagcggg gttgtatcat agcgtaacga tagattttata cgacg 45

<210> 681
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 681
 tagaataatg gttcgtgacc ttcgtaacga tagatttata cgacg 45

 <210> 682
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 682
 acctgaaggc gacgaggagg taacgataga tttatacgac g 41

 <210> 683
 <211> 44
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 683
 gcctggagtc tatcgtacaa tcgtaacgat agatttatac gacg 44

 <210> 684
 <211> 47
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 684
 acatttaatt agaccgtaac ccttcgtaac gatagattta tacgacg 47

 <210> 685
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 685
gctctggcca tacttaacag atagtaacga tagatttata cgacg 45

<210> 686
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 686
cagcattgag tgataatgca atctgtaacg atagatttat acgacg 46

<210> 687
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 687
atacacaccc gctaccttac tggtaacgat agattttatac gacg 44

<210> 688
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 688
acaaagacga gaactatggc aagtaacgat agattttatac gacg 44

<210> 689
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 689
aggcagacgc tctaagtcta aagtaacgat agatttatac gacg 44

<210> 690
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 690
tctcttactc atcgtgaaag gcgtaacgat agatttatac gacg 44

<210> 691
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 691
gcctcaagtt cgcattcagc gtaacgatag atttatacga cg 42

<210> 692
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 692
gaaatggaaa cgттаacagc cagtaacgat agatttatac gacg 44

<210> 693
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 693

cacctgcttc ggaatctcag tgtaacgata gatttatacg acg 43

<210> 694
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 694
gacttgtgct tcgttaatta aacagtaacg atagatttat acgacg 46

<210> 695
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 695
gctgtaatat acgcccactt tagcgtaacg atagatttat acgacg 46

<210> 696
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 696
ttccattgtg cggttgggat tgtaacttat aaaggataga catc 44

<210> 697
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 697
ctccagtaat cgcttatggc ccgtaactta taaaggatag acatc 45

<210> 698
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 698
cctcttctcc gtcaagaagt tcgtaactta taaaggatag acatc 45

<210> 699
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 699
tgattgagat ggcggtatct gagtaactta taaaggatag acatc 45

<210> 700
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 700
gccaattata agtactcggg ctgtaactta taaaggatag acatc 45

<210> 701
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 701
ccaggccagc gtatgttccg taacttataa aggatagaca tc 42

<210> 702

<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 702
ctggggcaac caacacttgt gtaacttata aaggatagac atc 43

<210> 703
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 703
ggctggacaa taggctccca gtaacttata aaggatagac atc 43

<210> 704
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 704
aaagctatgg cacgaaagcc ggtaacttat aaaggataga catc 44

<210> 705
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 705
gcagtccatc taaggtggac tgtaacttat aaaggataga catc 44

<210> 706
<211> 46
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 706

tgtatatgga gtaccctctt gctgtaactt ataaaggata gacatc

46

<210> 707

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 707

ctggatcacc aaaacggcaa tgtaacttat aaaggataga catc

44

<210> 708

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 708

ccaggataac ctttacttgc cagtaactta taaaggatag acatc

45

<210> 709

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 709

atttccagct gcgatatcta ctcgtaactt ataaaggata gacatc

46

<210> 710

<211> 47

<212> DNA

<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 710
tttatagcag ctagtccttt cttggtaact tataaaggat agacatc 47

<210> 711
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 711
tgatatgaga ttttcccgga tgggtaactt ataaaggata gacatc 46

<210> 712
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 712
tgacaacagt tagggcggtg gtaacttata aaggatagac atc 43

<210> 713
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 713
ttggttcccg agtactgtct agtaacttat aaaggataga catc 44

<210> 714
<211> 45
<212> DNA
<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 714

gtttagttcc aacgccatct gtgtaactta taaaggatag acatc

45

<210> 715

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 715

aagagttgcg acagtatcac ccgtaactta taaaggatag acatc

45

<210> 716

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 716

gctgctggat atccctcaga agtaacttat aaaggataga catc

44

<210> 717

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 717

tgcaagacag actatgtcta tgggtaactt ataaaggata gacatc

46

<210> 718

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 718
cttcaaggac taggtcaatt gcagtaactt ataaaggata gacatc 46

<210> 719
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 719
gatatgctgc actaactagt cttggtaact tataaaggat agacatc 47

<210> 720
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 720
atctcgagca agacgttcag tgtaacggtt atcgtggaaa 40

<210> 721
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 721
ctgtccataa ttagtccatg aggagtaacg gttatcgtgg aaa 43

<210> 722
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 722
atctttggat tatactgcct gaccgtaacg gttatcgtgg aaa 43

<210> 723
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 723
cagcaagctt gcgaccttga gtaacggtta tcgtggaaa 39

<210> 724
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 724
agttaaagtt gagagatcat ctccagtaac ggttatcgtg gaaa 44

<210> 725
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 725
aggaatggat ctatcactat ttctagtaac ggttatcgtg gaaa 44

<210> 726
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 726
cagcataatg attaggtatg caaaagtaac ggttatcgtg gaaa 44

<210> 727
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 727
ttcagtctga taaaatctac agtcagtaac ggttatcgtg gaaa 44

<210> 728
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 728
tccaacactt cgtggggtcc gtaacggtta tcgtggaaa 39

<210> 729
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 729
agggtacaa tgtgatggcc gtaacggtta tcgtggaaa 39

<210> 730
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 730
tcaaggcat aacctggttc atcgtaacgg ttatcgtgga aa 42

<210> 731
<211> 42

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 731
cctacaacaa acttgtctgg aatgtaacgg ttatcgtgga aa 42

<210> 732
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 732
aaacaacaat ccgccc aaag ggtaacggtt atcgtggaaa 40

<210> 733
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 733
aaagctctac taagcagatg gcgtaacggt tatcgtggaa a 41

<210> 734
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 734
actgctgaca aagattcact gggtaacggt tatcgtggaa a 41

<210> 735
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 735
 ctgatagtct ataggctcat agtgcgtaac ggttatcgtg gaaa 44

 <210> 736
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 736
 atcactaatc acgacgccag ggtaacggtt atcgtggaaa 40

 <210> 737
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 737
 tggcgatgtc aataggactc cgtaacggtt atcgtggaaa 40

 <210> 738
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 738
 gaactctcat cttaggcttt gtagtaacgg ttatcgtgga aa 42

 <210> 739
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 739
 tcaacattac tgaacacta ctaaagtaac ggttatcgtg gaaa 44

<210> 740
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 740
 ggtcgccata acggagccgg taacggttat cgtggaaa 38

<210> 741
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 741
 ttcttacaga tatgagttca atgtttgtaa cggttatcgt ggaaa 45

<210> 742
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 742
 aggacagaac aaaacttctt agatggtaac ggttatcgtg gaaa 44

<210> 743
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 743
tcgcagccgc ctgaagcgta acggttatcg tggaaa 36

<210> 744
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 744
ggaatttgga accggcttgc gtaacggtac tttatctagc t 41

<210> 745
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 745
agagtcttga gtataatctt ggtaggtaac ggtactttat ctagct 46

<210> 746
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 746
attcaggaag catacactaa ttcttgtaac ggtactttat ctagct 46

<210> 747
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 747

tccagaaata agcgaaaata gcagtaacgg tactttatct agct 44

<210> 748
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 748
atcttttgaa ctactagcta caaaatgtaa cggtagcttta tctagct 47

<210> 749
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 749
taacaagctc gtaatggccc agtaacgcta ctttatctag ct 42

<210> 750
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 750
catccaaacc gtgtgaaagc tgtaacgcta ctttatctag ct 42

<210> 751
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 751
acaacgccat gtgcgatttg gtaacggtac tttatctagc t 41

<210> 752
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 752
ctacctacca ctaggtacct atcagtaacg gtactttatc tagct 45

<210> 753
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 753
aggacattta cgtgtacagc acgtaacggt actttatcta gct 43

<210> 754
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 754
cgctgaata caacgagtta acgtaacggt actttatcta gct 43

<210> 755
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 755
cttcagatt gtcgccgtta attgtaacgg tactttatct agct 44

<210> 756

<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 756
cagatttacc taaaccacca ccagtaacgg tactttatct agct 44

<210> 757
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 757
tttgagctga tctagtaggt cttcgtaacg gtactttatc tagct 45

<210> 758
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 758
tctgtagctc gatccctgga gtaacggtac tttatctagc t 41

<210> 759
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 759
caactgtcat tcggttaaac tgagtaacgg tactttatct agct 44

<210> 760
<211> 44
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 760

tttgcttccg ttcatacatta gtcgtaacgg tactttatct agct 44

<210> 761

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 761

acttccaata gtctggaaat cacagtaacg gtactttatc tagct 45

<210> 762

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 762

tcattctgctg gattaagcta atacgtaacg gtactttatc tagct 45

<210> 763

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 763

agataggctc ccgtatgccc gtaacggtac tttatctagc t 41

<210> 764

<211> 41

<212> DNA

<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 764
gcttctcggc taccacagac gtaacggtac tttatctagc t 41

<210> 765
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 765
agacttactc ttaagaccat acttcgtaac ggtactttat ctagct 46

<210> 766
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 766
gttgagaggt ggcgtttttg agtaacggta ctttatctag ct 42

<210> 767
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 767
tcaatacgtt tctgcaagag tttgtaacgg tactttatct agct 44

<210> 768
<211> 41
<212> DNA
<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 768

ttatggcctc tatagcatct cccgtaactc catctagacc g

41

<210> 769

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 769

cagtccgggc aactatctta ttgtaactcc atctagaccg

40

<210> 770

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 770

ttcaagatac gaataatcct ccgagtaact ccatctagac cg

42

<210> 771

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 771

gtaggcgctt agcttgattt tcgtaactcc atctagaccg

40

<210> 772

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 772
cttcaagtcg ggctcttgca gtaactccat ctagaccg 38

<210> 773
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 773
agaatgaggc acgcaaagct gtaactccat ctagaccg 38

<210> 774
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 774
ctcagcatcc gataggactt tcgtaactcc atctagaccg 40

<210> 775
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 775
aagtcactat aacacccgtc ctgtaactcc atctagaccg 40

<210> 776
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 776
ttggcatggt agatcgtcca ggtaactcca tctagaccg 39

<210> 777
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 777
caccttccaa cgactcaatc cgtaactcca tctagaccg 39

<210> 778
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 778
acaacctgta agtgtagttc tctggtaact ccatctagac cg 42

<210> 779
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 779
aatcagata ctcgtctaca gaatggtaac tccatctaga ccg 43

<210> 780
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 780
agcagcaagt cgcattttcc gtaactccat ctagaccg 38

<210> 781
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 781
actggcatgg cggataaaaa ggtaactcca tctagaccg 39

<210> 782
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 782
cgggtgctct cgtgaacaaa gtaactccat ctagaccg 38

<210> 783
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 783
gatcgaagag tcgagataag gatgtaactc catctagacc g 41

<210> 784
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 784
ttgttgaaga cgcttcata agtgtaactc catctagacc g 41

<210> 785
<211> 37

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 785
gtggtgacgc agaatcccgg taactccatc tagaccg 37

<210> 786
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 786
cattataaag acgtaataat ttaggggtgta actccatcta gaccg 45

<210> 787
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 787
gttcccactc ctagacatgt tgtaactcca tctagaccg 39

<210> 788
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 788
tttgttacac ggttaaacag ccgtaactcc atctagaccg 40

<210> 789
<211> 42
<212> DNA
<213> Artificial Sequence

<220>	
<223> Target Specific Oligonucleotide	
<400> 789	
gaggtaaata aacgtcgata ggaagtaact ccatctagac cg	42
<210> 790	
<211> 40	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 790	
ttaatgtgga gtgcaagttg gggtaactcc atctagaccg	40
<210> 791	
<211> 41	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 791	
ccttgatatct tagcttggga tgtgtaactc catctagacc g	41
<210> 792	
<211> 43	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 792	
tcaatgatca gcggatacct attgtaactc agtagatata gcg	43
<210> 793	
<211> 43	
<212> DNA	
<213> Artificial Sequence	

<220>
 <223> Target Specific Oligonucleotide

<400> 793
 cgtgtgatct tacgatacctt atagtaactc agtagatata gcg 43

<210> 794
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 794
 tcatacctcta cgagtctatc ttggtaactc agtagatata gcg 43

<210> 795
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 795
 tcaaagtaac ccgcgtaggc gtaactcagt agatatagcg 40

<210> 796
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 796
 ataggacgca tactgtcgca agtaactcag tagatatagc g 41

<210> 797
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 797
ttatgtccgt cgaccttgca tgtaactcag tagatatagc g 41

<210> 798
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 798
ttccaaggaa cggacttcta gggtaactca gtagatatag cg 42

<210> 799
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 799
ataggtacga acgctctcga tcgtaactca gtagatatag cg 42

<210> 800
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 800
tcttggatga tcgcatgaaa ccgtaactca gtagatatag cg 42

<210> 801
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 801

acaaccaat taacgtgaag ccgtaactca gtagatatag cg 42

<210> 802
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 802
atgcggtata acgcacgttc cgtaactcag tagatatagc g 41

<210> 803
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 803
ctcaagtcac gacgcagttc tgtaactcag tagatatagc g 41

<210> 804
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 804
gcaagtcacg aacgtgactc gtaactcagt agatatagcg 40

<210> 805
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 805
ttggcgttat actgcgccac gtaactcagt agatatagcg 40

<210> 806
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 806
agtgggtgcgt atcgtaagcg gtaactcagt agatatagcg 40

<210> 807
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 807
atccaggcga cgaaacgaga gtaactcagt agatatagcg 40

<210> 808
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 808
ttggatgaat cggcaggctg gtaactcagt agatatagcg 40

<210> 809
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 809
tcagtcaatt cgtaatgtac accgtaactc agtagatata gcg 43

<210> 810

<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 810
catcgaagac gatccactgg cgtaactcag tagatatagc g 41

<210> 811
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 811
cacggatcaa gcggcacttg taactcagta gatatagcg 39

<210> 812
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 812
tccaccgtat cgcaagctgg taactcagta gatatagcg 39

<210> 813
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 813
atgcaaagtt tcgtagggcg agtaactcag tagatatagc g 41

<210> 814
<211> 38
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 814

gcgttgccac gacgacatgt aactcagtag atatagcg

38

<210> 815

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 815

ttgcagacgg acgcccaagt aactcagtag atatagcg

38

<210> 816

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 816

agctgtatcg tcaaggcact cgtaaccttt tgaaacgcta

40

<210> 817

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 817

ctcgctccca gtccgaaatg gtaacctttt gaaacgcta

39

<210> 818

<211> 44

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 818
 acttgtacta gtatgcctta agaaagtaac cttttgaaac gcta 44

<210> 819
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 819
 gtgaccatga ctaatagcag tgggtaacct ttgaaacgc ta 42

<210> 820
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 820
 gctgtgtcga gaatatccaa gagtaacctt ttgaaacgct a 41

<210> 821
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 821
 cctactgtcg ctaatggatt gggtaacctt ttgaaacgct a 41

<210> 822
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 822

acactagcac tacctaagga ccgtaacctt ttgaaacgct a

41

<210> 823

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 823

gtctgtgaac tagttcaggc acgtaacctt ttgaaacgct a

41

<210> 824

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 824

ctaggtcagc gcaaccaaatt ggtaaccttt tgaaacgcta

40

<210> 825

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 825

cctaataagc tataactggc ccagtaacct tttgaaacgc ta

42

<210> 826

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 826
ctaaattcct atgcagtgtg actcgtaacc ttttgaaacg cta 43

<210> 827
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 827
atcttggtga gctatccaaa ctggtaacct tttgaaacgc ta 42

<210> 828
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 828
aaatagcat cgtgttatct ctggtaacct tttgaaacgc ta 42

<210> 829
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 829
tgttaagaga actagccaaa cctgtaacct tttgaaacgc ta 42

<210> 830
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 830
cataaagtag cttgatcgaa gaggtaacc ttttgaaacg cta 43

<210> 831
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 831
taagcaaaca cgcctttaca tagtaacctt ttgaaacgct a 41

<210> 832
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 832
aaggccttag taagatatta cagacgtaac cttttgaaac gcta 44

<210> 833
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 833
acaatatacg tctgctatat tcttccgtaa ctttttgaaa cgcta 45

<210> 834
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 834
tccactggat agggttctgt ctgtaacctt ttgaaacgct a 41

<210> 835
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 835
aagttatact atgaaagagc agtctgtaac cttttgaaac gcta 44

<210> 836
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 836
acatgttaat gcctaagtct atgtagtaac cttttgaaac gcta 44

<210> 837
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 837
gcctagaatg cctacttggg agtaaccttt tgaaacgcta 40

<210> 838
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 838
tcagtgggaat cgtagcaaaa cagtaacctt ttgaaacgct a 41

<210> 839
<211> 45

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 839
acaataatta ggagtagtac agttcagtaa ccttttgaaa cgcta 45

<210> 840
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 840
ttccactcgg ataagatgct gagtaactca gacatgtaga tt 42

<210> 841
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 841
aatactccac acgcaaattt ccgtaactca gacatgtaga tt 42

<210> 842
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 842
ggccagacca tcgctatctg gtaactcaga catgtagatt 40

<210> 843
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 843
 caccacacta tgtcgaaaag tggttaactca gacatgtaga tt 42

<210> 844
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 844
 cccitttcttg cggagattct ctgtaactca gacatgtaga tt 42

<210> 845
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 845
 acaaacacgc acctcaaagc gtaactcaga catgtagatt 40

<210> 846
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 846
 cccagtagat taccactgga gtgtaactca gacatgtaga tt 42

<210> 847
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 847
gcagtgctcg cttagtgctg taactcagac atgtagatt 39

<210> 848
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 848
ggctcgacgc taggatctga gtaactcaga catgtagatt 40

<210> 849
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 849
aggatgggcc tccggttcag taactcagac atgtagatt 39

<210> 850
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 850
ggaacatctc gaagcgctca gtaactcaga catgtagatt 40

<210> 851
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 851
agacggaaac cgtagctgcc gtaactcaga catgtagatt 40

<210> 852
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 852
tgttcaatat cgtccgggga cgtaactcag acatgtagat t 41

<210> 853
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 853
cattgcttgg gacggcaagg gtaactcaga catgtagatt 40

<210> 854
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 854
agtggagaat gtcagtctga gtgtaactca gacatgtaga tt 42

<210> 855
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 855

agtttttttat ggcgggaggt agagtaactc agacatgtag att 43

<210> 856
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 856
tagaaactac caaccacccg agtaactcag acatgtagat t 41

<210> 857
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 857
ttccctgggtt agtacggtga aggtaactca gacatgtaga tt 42

<210> 858
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 858
taagctggta tgtcctactc ccgtaactca gacatgtaga tt 42

<210> 859
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 859
ctgacgcaca cctattgcaa ggtaactcag acatgtagat t 41

<210> 860
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 860
tcaccgtcgt ggaaagcacg taactcagac atgtagatt 39

<210> 861
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 861
gtaaactaac ccttaactgc aagagtaact cagacatgta gatt 44

<210> 862
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 862
ttaggtact aaggttcacc aagagtaact cagacatgta gatt 44

<210> 863
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 863
tcatcatata caagagatga aatcctgtaa ctcagacatg tagatt 46

<210> 864

<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 864
ccatggtgac gatcctcacg gtaactaaca taaattcgat g 41

<210> 865
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 865
gtgaacgtct tgggttgctt cgtaactaac ataaattcga tg 42

<210> 866
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 866
ggcctggacg gcgtaagagt aactaacata aattcgatg 39

<210> 867
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 867
gaagctcatg cgggaagcgg taactaacat aaattcgatg 40

<210> 868
<211> 43
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 868

tgtcactgta cgagatgttt cggtactaa cataaattcg atg

43

<210> 869

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 869

ttgaagcttg gtatgtcagg aggtactaa cataaattcg atg

43

<210> 870

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 870

ggttcccgat acatagctgg agtaactaac ataaattcga tg

42

<210> 871

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 871

atctttgaag tcgaaagaca ggcgtaacta acataaattc gatg

44

<210> 872

<211> 44

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 872
 gcttattaac acgaagcttt gaggtaacta acataaattc gatg 44

<210> 873
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 873
 tttcattcca cgggaaggag agtaactaac ataaattcga tg 42

<210> 874
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 874
 tcagtgcctc gttggccatt gtaactaaca taaattcgat g 41

<210> 875
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 875
 ctctgcgtac caagcagtaa ttgtaactaa cataaattcg atg 43

<210> 876
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 876

tttcaaggcc tcgatttctg tcgtaactaa cataaattcg atg

43

<210> 877

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 877

tagttcacac cgtacatctc cagtaactaa cataaattcg atg

43

<210> 878

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 878

cccacatttc cggagtcac tgtaactaac ataaattcga tg

42

<210> 879

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 879

ggctctgagc tatcttcaga tattgtaact aacataaatt cgatg

45

<210> 880

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 880
tcctccgtgc gaatcgctgt aactaacata aattcgatg 39

<210> 881
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 881
gcccttttta ttccggattg cagtaactaa cataaattcg atg 43

<210> 882
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 882
gctgtctcct cagaccgcag taactaacat aaattcgatg 40

<210> 883
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 883
caccctgtc ggagttctca gtaactaaca taaattcgat g 41

<210> 884
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 884
cagatttatt accctttttg gaagcgtaac taacataaat tcgatg 46

<210> 885
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 885
tcatggg'gcgg gtacgtgggt aactaacata aattcgatg 39

<210> 886
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 886
caaaaatccc cgcttgtgaa cgtaactaac ataaattcga tg 42

<210> 887
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 887
ctggggctcgt agtcaccata cgtaactaac ataaattcga tg 42

<210> 888
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 888
cacacgatac cggcaaagaa ggtaacgtga cgattaccc 39

<210> 889
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 889
ggtgtcagtc tccgacgtga gtaacgtgac gattaccc 38

<210> 890
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 890
gtgatggtga tcatctgggc cgtaacgtga cgattaccc 39

<210> 891
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 891
ttggcctcgg gaccaagcgt aacgtgacga ttaccc 36

<210> 892
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 892
ctgtcatctt ggtcaggtgg tgtaacgtga cgattaccc 39

<210> 893
<211> 38

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 893
atcaccttgc cgaaagtgcc gtaacgtgac gattaccc 38

<210> 894
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 894
actgcacggc cgtagtcatg taacgtgacg attaccc 37

<210> 895
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 895
aggtactcag gtgtgccgcg taacgtgacg attaccc 37

<210> 896
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 896
gaaggtgcgt tcgatgacag gtaacgtgac gattaccc 38

<210> 897
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 897
 ctcctcagga gtctccacat ggtaacgtga cgattaccc 39

 <210> 898
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 898
 gtctggaaag agtacttcag gggtaacgtg acgattaccc 40

 <210> 899
 <211> 36
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 899
 caggacgcgg ttctcggtgt aacgtgacga ttaccc 36

 <210> 900
 <211> 38
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 900
 atctcagcgc catagaagcg gtaacgtgac gattaccc 38

 <210> 901
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 901
 tcgttcattg tcacgcggtg taacgtgacg attaccc 37

<210> 902
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 902
 cagcccgaag tctgtgatct tgtaacgtga cgattaccc 39

<210> 903
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 903
 tcattgtggc accgtccttg taacgtgacg attaccc 37

<210> 904
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 904
 ggtagtccag ggctgacaca gtaacgtgac gattaccc 38

<210> 905
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 905
ccatcattct tgaggaggaa gtagtaacgt gacgattacc c 41

<210> 906
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 906
acaaagcaga ggcggtcgtg taacgtgacg attaccc 37

<210> 907
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 907
cggtcctcgg agaacacacg gtaacgtgac gattaccc 38

<210> 908
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 908
gagcctcacg ttggtccacg taacgtgacg attaccc 37

<210> 909
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 909

ctccttgtag ccaatgaagg tggtaacgtg acgattaccc 40

<210> 910
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 910
ttcacaatag ccacgtcgct gtaacgtgac gattaccc 38

<210> 911
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 911
ccctcgtttg tgcagccaag taacgtgacg attaccc 37

<210> 912
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 912
agctatgtcc gctatcttca tcggtaacctc tcttctattg cag 43

<210> 913
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 913
ttggcacatc gagacatggt tgtaactctc ttctattgca g 41

<210> 914
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 914
ccatcttggt cgtactttgt gagtaactct cttctattgc ag 42

<210> 915
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 915
ccaactgagc atacgctagg agtaactctc ttctattgca g 41

<210> 916
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 916
tcacgtacta gccgttccat cgtaactctc ttctattgca g 41

<210> 917
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 917
tttctccaag tcgtctctca tctgtaactc tcttctattg cag 43

<210> 918

<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 918
tcgtaagaaa cgccactaga aagtaactct cttctattgc ag 42

<210> 919
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 919
cactggcgtg cctaaaccag taactctctt ctattgcag 39

<210> 920
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 920
acatatcata cgtggacatt agaacgtaac tctcttctat tgcag 45

<210> 921
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 921
gccgatggaa tgctccatcc gtaactctct tctattgcag 40

<210> 922
<211> 43
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 922

gattagcaat cggtcacaaa gacgtaactc tcttctattg cag

43

<210> 923

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 923

ggtgtagtag tacacattgg agcgtaactc tcttctattg cag

43

<210> 924

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 924

gatgaaactt cggttgtagc ctgtaactct cttctattgc ag

42

<210> 925

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 925

ttcttgaggc tagcaacttg tggtaactct cttctattgc ag

42

<210> 926

<211> 43

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 926
 gtcccaaac tcgattagct tccgtaactc tcttctattg cag 43

 <210> 927
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 927
 tattcgtgga acccctaaca gcgtaactct cttctattgc ag 42

 <210> 928
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 928
 caaagttgat atcgcccaaa atggtaactc tcttctattg cag 43

 <210> 929
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 929
 tagatccaag cggttccatt tcgtaactct cttctattgc ag 42

 <210> 930
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Target Specific Oligonucleotide

<400> 930

tgaccagttc ccgtaaaaca ctgtaactct cttctattgc ag

42

<210> 931

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 931

tggcacatgg tcgatacaca tgtaactctc ttctattgca g

41

<210> 932

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 932

tgacagcaca acgatcacao cgtaactctc ttctattgca g

41

<210> 933

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 933

aagctcatga actatgccag aggtaactct cttctattgc ag

42

<210> 934

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 934
cgtcatacct gaccgagtac tgtaactctc ttctattgca g 41

<210> 935
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 935
tcttgattgt cgagaaagac ttggtactc tcttctattg cag 43

<210> 936
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 936
tactgagccc tatcggaag tgtaactgat cttcatatta cg 42

<210> 937
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 937
ccaaatccct tcgcagcaat tgtaactgat cttcatatta cg 42

<210> 938
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 938
gccatgatca atcgcatcac tgtaactgat cttcatatta cg 42

<210> 939
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 939
atcatccaga ttcgaaccgt ccgtaactga tttcatatt acg 43

<210> 940
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 940
ggactacatt cgtgaagaag ctgtaactga tttcatatt acg 43

<210> 941
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 941
ggagaggatc cgtccaagaa agtaactgat cttcatatta cg 42

<210> 942
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 942
gtcccagcat tagaacctgt ggtaactgat cttcatatta cg 42

<210> 943
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 943
actctcagcc agacctttag cgtaactgat cttcatatta cg 42

<210> 944
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 944
catagtgtca tgtgcatgta gtcgtaactg atcttcatat tacg 44

<210> 945
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 945
ccctgaccag catattatct acagtaactg atcttcatat tacg 44

<210> 946
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 946
cagcgcctgt tacaagctct gtaactgata ttcattattac g 41

<210> 947
<211> 41

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 947
cgccagtctt aactgccatg gtaactgac ttcattattac g 41

<210> 948
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 948
tcttcccaac accgtaattt ttgtaactga tcttcatatt acg 43

<210> 949
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 949
gtgacttatg ttcgggtctc tcgtaactga tcttcatatt acg 43

<210> 950
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 950
tgttaggttc tagggccata gcgtaactga tcttcatatt acg 43

<210> 951
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 951
 ctggatagct ttgggcaact cgtaactgat cttcatatta cg 42

<210> 952
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 952
 tgcagacagg gtatgtatat ttgggtaact gatcttcata ttacg 45

<210> 953
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 953
 aagaaaatat agctgagctc cctgtaactg atcttcatat tacg 44

<210> 954
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 954
 gagaccggag aaacccggcg taactgatct tcatattacg 40

<210> 955
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 955
 ccgcaggaga ccgaggtctg taactgatct tcatattacg 40

<210> 956
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 956
 aggctagggc tcaagacaag ggtaactgat cttcatatta cg 42

<210> 957
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 957
 gcgtccggtg tcgccatgta actgatcttc atattacg 38

<210> 958
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 958
 actctgggtc ggcttgatcc gtaactgac ttcattattac g 41

<210> 959
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 959
catgggagga tcgagcctgg gtaactgata ttcataattac g 41

<210> 960
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 960
ggcactggaa acgattgact tgtaacggca atacatcgt 39

<210> 961
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 961
tcaggcattc gttcacctgt gtaacggcaa tacatcgt 38

<210> 962
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 962
actgtagcga ttaatgccat ccgtaacggc aatacatcgt 40

<210> 963
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 963

atagcctcca ttgcggttgg gtaacggcaa tacatcgt 38

<210> 964
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 964
cattcgggtg atcgatacac ttgtaacggc aatacatcgt 40

<210> 965
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 965
gcacactcat cgagttgctc cgtaacggca atacatcgt 39

<210> 966
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 966
tcccgcttaa tgcgcaggtg taacggcaat acatcgt 37

<210> 967
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 967
ggtcccctgt atggcgtgag taacggcaat acatcgt 37

<210> 968
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 968
aacacactgg cggttgtcaa gtaacggcaa tacatcgt 38

<210> 969
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 969
cacacatcga cgaaggtttc agtaacggca atacatcgt 39

<210> 970
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 970
ggctcttgca cgagttaact tgtaacggca atacatcgt 39

<210> 971
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 971
atgtcaatgg tacaccgctg agtaacggca atacatcgt 39

<210> 972

<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 972
gccatgctta cgcttttcgtt gtaacggcaa tacatcgt 38

<210> 973
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 973
ggtataccag taacacggac cagtaacggc aatacatcgt 40

<210> 974
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 974
gactctctca cgcataaacc tggtaacggc aatacatcgt 40

<210> 975
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 975
aggagatgcg taggtcaatt cagtaacggc aatacatcgt 40

<210> 976
<211> 39
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 976

ccaacaggac gctagtgtag agtaacggca atacatcgt

39

<210> 977

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 977

cagtaccaat taggttagct tctggtaacg gcaatacatc gt

42

<210> 978

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 978

tccatggccg tcgatcaatg gtaacggcaa tacatcgt

38

<210> 979

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 979

tagtcaggaa tatgcggtca ttgtaacggc aatacatcgt

40

<210> 980

<211> 41

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 980
 tatagcaact acttcgcatt tccgtaacgg caatacatcg t 41

<210> 981
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 981
 cgatggtgtc ctacggatgt cgtaacggca atacatcgt 39

<210> 982
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 982
 gtaaccatag taccattat tagtgggtaa cggcaataca tcgt 44

<210> 983
 <211> 37
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 983
 cagcatcagc ccgtgagtag taacggcaat acatcgt 37

<210> 984
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 984

tcagatgcta ctggccgctt agacaagtta agatcgga

39

<210> 985

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 985

cttgatcaag gcgctgaaca atagacaagt taagatcgga a

41

<210> 986

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 986

tcccttcgta tctcagcgag atagacaagt taagatcgga a

41

<210> 987

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 987

agactgttga ctggcgtgat gtagacaagt taagatcgga a

41

<210> 988

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 988
ccaacatgct cgcatagatt ctagacaagt taagatcgga a 41

<210> 989
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 989
ttccttcacc gaactgagga gtagacaagt taagatcgga a 41

<210> 990
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 990
agttccaacg agcggcttca tagacaagtt aagatcgga 40

<210> 991
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 991
ccatggctga cgagatctga tagacaagtt aagatcgga 40

<210> 992
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 992
tagcctaaga cccggagctt tagacaagtt aagatcgga 40

<210> 993
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 993
gcagatactc agcggcattg tagacaagtt aagatcggaa 40

<210> 994
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 994
catagctcac gcagaacgtg tagacaagtt aagatcggaa 40

<210> 995
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 995
gtcggccacc gttgaatgat agacaagtta agatcggaa 39

<210> 996
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 996
agaacggtca gcgagcgtat agacaagtta agatcggaa 39

<210> 997
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 997
gttatgctta gagtgttatc tccatagaca agttaagatc ggaa 44

<210> 998
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 998
tggatgatgtc cgtgcgttcc tagacaagtt aagatcggaa 40

<210> 999
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 999
ggtccagagg atcgctctct tagacaagtt aagatcggaa 40

<210> 1000
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1000
cgtggactgc aagtcccgat agacaagtta agatcggaa 39

<210> 1001
<211> 41

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1001
acaggtcaat tcccgggtaa gtagacaagt taagatcgga a 41

<210> 1002
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1002
ctgcaccagg ttaggggtgtt ttagacaagt taagatcgga a 41

<210> 1003
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1003
ggaaatggca tatacgtggg atttagacaa gttaagatcg gaa 43

<210> 1004
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1004
cttttgtctt tgcgccagg tagacaagtt aagatcgga 40

<210> 1005
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1005
tcctgccggt tgcactccta gacaagttaa gatcggaa 38

<210> 1006
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1006
atcatacagt gcaacgaaaa ggtagacaa gttaagatcg gaa 43

<210> 1007
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1007
tcccacttgt cgtagttggg tagacaagtt aagatcggaa 40

<210> 1008
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1008
agggtgtgtt ccgaacgagc tagacagccc aattaaacg 39

<210> 1009
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1009
agatccgtga gcggaatgta tagacagccc aattaaacg 39

<210> 1010
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1010
ctcactcgct ttagtggact cctagacagc ccaattaaac g 41

<210> 1011
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1011
gccaaagacc gtggcgagta gacagcccaa ttaaagc 37

<210> 1012
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1012
agagttcttg gtcgttgat cctagacagc ccaattaaac g 41

<210> 1013
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1013
ctcctttgca accgggtctg tagacagccc aattaaacg 39

<210> 1014
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1014
cttggtattg acgtcgaagg cttagacagc ccaattaaac g 41

<210> 1015
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1015
caggaacgtg taactcttgc ctagacagcc caattaaacg 40

<210> 1016
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1016
ggagtttcac acacgagttg gtagacagcc caattaaacg 40

<210> 1017
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1017

aggttccgc tctacggatg tagacagccc aattaaacg 39

<210> 1018
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1018
accgtcatgg actgccgtct agacagccca attaaacg 38

<210> 1019
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1019
tgggaccttt agacttcggt gtagacagcc caattaaacg 40

<210> 1020
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1020
gtccctgtag acgcgcgtta gacagcccaa ttaaacg 37

<210> 1021
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1021
ccagagaggg cgcatttgt agacagccca attaaacg 38

<210> 1022
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1022
tccactctgc acgctcatag ttagacagcc caattaaacg 40

<210> 1023
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1023
gtgaaactcg acgttcacgt atagacagcc caattaaacg 40

<210> 1024
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1024
acacctcttt gtcgttgacc ttagacagcc caattaaacg 40

<210> 1025
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1025
actgttgcca gttctgag tagacagccc aattaaacg 39

<210> 1026

<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1026
tggcaactcc gtagttgtcc tagacagccc aattaaacg 39

<210> 1027
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1027
tcctcggacg ctaagctcat agacagccca attaaacg 38

<210> 1028
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1028
ttaccggaag aaccctcgct agacagccca attaaacg 38

<210> 1029
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1029
tcccgaaca tgcggtaggt agacagccca attaaacg 38

<210> 1030
<211> 38
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1030

tgctcgatgt cgcccactgt agacagccca attaaacg

38

<210> 1031

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1031

tgccggtgcc gcttatggta gacagcccaa ttaaacg

37

<210> 1032

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1032

ccaaagtctg ctagcttgat ggtagacggt ataatactta tttcc

45

<210> 1033

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1033

tattaggatg gttaagctcc ttaagtagac ggtataatac ttattttcc

48

<210> 1034

<211> 45

<212> DNA

<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1034
catgggtgta agtacgaaca ggtagacggt ataatactta tttcc 45

<210> 1035
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1035
ggcagaaagc taggcctgg tagacggtat aatacttatt tcc 43

<210> 1036
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1036
gtacacaact ccgtacgtgc tagacggtat aatacttatt tcc 43

<210> 1037
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1037
atggaacgca gtatacctct cgtagacggt ataatactta tttcc 45

<210> 1038
<211> 46
<212> DNA
<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1038

cttggcttgt aatcaggcat agatagacgg tataatactt atttcc

46

<210> 1039

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1039

ctccatgaag cgccagcgta gacggtataa tacttatttc c

41

<210> 1040

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1040

ccgcttggtta gggtcgtagt tagacggtat aatacttatt tcc

43

<210> 1041

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1041

ctcgggtggag gacccgatgt agacggtata atacttattt cc

42

<210> 1042

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1042
ttactaaaat cttgccgggc ctagacggta taatacttat ttcc 44

<210> 1043
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1043
gcagcatttg cgataacaag ctagacggta taatacttat ttcc 44

<210> 1044
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1044
agaaggctat cagagtcgaa gatagacggt ataatactta ttcc 45

<210> 1045
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1045
ttcaggagct cggtaccaca tagacggtat aatacttatt tcc 43

<210> 1046
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1046
ccccagagtc cgaaagatcc gtagacggta taatacttat ttcc 44

<210> 1047
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1047
acagggccca gtaccgtggt agacggtata atacttattt cc 42

<210> 1048
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1048
tcagcaataa ctaagagaag gggtagacgg tataatactt atttcc 46

<210> 1049
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1049
gtacggcaaa tctaactgt aggtagacgg tataatactt atttcc 46

<210> 1050
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1050
tgaaacaatg ttgccgcctc ctagacggta taatacttat ttcc 44

<210> 1051
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1051
taataattat ggggcattca gagatagacg gtataatact tattttcc 47

<210> 1052
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1052
tctcacctgc ctcataaggc tagacggtat aatacttatt tcc 43

<210> 1053
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1053
atggtgaagc aatagattgg aatgtagacg gtataatact tattttcc 47

<210> 1054
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1054
cactaactag ggtataaact gattggtaga cggtataata cttattttcc 49

<210> 1055
<211> 44

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1055
agaagggaca aacaagggga ctagacggta taatacttat ttcc 44

<210> 1056
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1056
agtccgatac tcaagcgcaa atagacaata aattctaacg agc 43

<210> 1057
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1057
cttggtgcgc tcacggtatg tagacaataa attctaacga gc 42

<210> 1058
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1058
ccagagttgt agacgagcag ctagacaata aattctaacg agc 43

<210> 1059
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 1059
 ttagcatggc aacacggcgt agacaataaa ttctaacgag c 41

 <210> 1060
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 1060
 atgatgcgca cttcacgggt agacaataaa ttctaacgag c 41

 <210> 1061
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 1061
 cccaccgcta ggagggtagc tagacaataa attctaacga gc 42

 <210> 1062
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 1062
 gcagtgtggt taggccgatg tagacaataa attctaacga gc 42

 <210> 1063
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1063
 gacacggcgg tgcactatct agacaataaa ttctaacgag c 41

<210> 1064
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1064
 gcccaaagcg gcttgtagta gacaataaat tctaacgagc 40

<210> 1065
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1065
 atacacacac ggctaatact gctagacaat aaattctaac gagc 44

<210> 1066
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1066
 gtgaccgtgt acaccaaaa ctagacaata aattctaacg agc 43

<210> 1067
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1067
ctcttcatac tagcatgact gtcatagaca ataaattcta acgagc 46

<210> 1068
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1068
agaaggcttt cgtcgttccc tagacaataa attctaacga gc 42

<210> 1069
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1069
tttgctccgt gcgttcaagg tagacaataa attctaacga gc 42

<210> 1070
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1070
tccagtgcac cgtcacatc tagacaataa attctaacga gc 42

<210> 1071
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1071

gatgaacagc ggtgcgttgt agacaataaa ttctaacgag c 41

<210> 1072
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1072
cactgatacc ggctctccgt tagacaataa attctaacga gc 42

<210> 1073
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1073
gaacgcttgc gttccctagc tagacaataa attctaacga gc 42

<210> 1074
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1074
cagatagatt tccgggatac agctagacaa taaattctaa cgagc 45

<210> 1075
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1075
tctgctgcgg cgattgtgta gacaataaat tctaacgagc 40

<210> 1076
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1076
ctcggatgatc atgcgtccct agacaataaa ttctaacgag c 41

<210> 1077
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1077
tccaatttca gggcgttctc gtagacaata aattctaacg agc 43

<210> 1078
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1078
tgcgcaggtc gacgtcagta gacaataaat tctaacgagc 40

<210> 1079
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1079
gtccaggtag tatccggagg gtagacaata aattctaacg agc 43

<210> 1080

<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1080
attccccgaca gactcatcgc tagacgataa attgcgaacg 40

<210> 1081
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1081
cagttacatg ttgcgcgacg tagacgataa attgcgaacg 40

<210> 1082
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1082
acgagcacta gggtcgtcgt agacgataaa ttgcgaacg 39

<210> 1083
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1083
ttttgataat cgaatgaaaa agtcactaga cgataaattg cgaacg 46

<210> 1084
<211> 43
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1084

ctgaatactg ctagacgaga agctagacga taaattgcga acg

43

<210> 1085

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1085

ctccttgga cgaactaatc ctgtagacga taaattgcga acg

43

<210> 1086

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1086

ttcaggcggg taattggtac cctagacgat aaattgcgaa cg

42

<210> 1087

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1087

gttaggaatg gcgaacagac agtagacgat aaattgcgaa cg

42

<210> 1088

<211> 42

<212> DNA

<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1088
gatggcttta aagcgtgaag cctagacgat aaattgcgaa cg 42

<210> 1089
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1089
ctgtgcctag ccctaactta tatagacgat aaattgcgaa cg 42

<210> 1090
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1090
agagaccacc cataacaaga gttagacgat aaattgcgaa cg 42

<210> 1091
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1091
ttggagcacc gatatagata tggtagacga taaattgcga acg 43

<210> 1092
<211> 41
<212> DNA
<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1092

tcaaagacgc aaacgtccaa atagacgata aattgcgaac g

41

<210> 1093

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1093

gagagctgat taggtgctca ggtagacgat aaattgcgaa cg

42

<210> 1094

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1094

tgcttgtagc cggagaaggt tagacgataa attgcgaacg

40

<210> 1095

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1095

ctgcagacac gtgtatgtgc tagacgataa attgcgaacg

40

<210> 1096

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1096
catccaatgc aagtccggtg tagacgataa attgcgaacg 40

<210> 1097
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1097
accaagtgat aacgtgttca gatagacgat aaattgcgaa cg 42

<210> 1098
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1098
aatctgagct ttgcgaaatg gttagacgat aaattgcgaa cg 42

<210> 1099
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1099
caaagcccac ataacactat cttttagacg ataaattgcg aacg 44

<210> 1100
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1100
tgtactggac tatagacacc aatttagacg ataaattgcg aacg 44

<210> 1101
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1101
atcaatatac cacgtagta gtcactagac gataaattgc gaacg 45

<210> 1102
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1102
tgtattttta cgccaagcag gctagacgat aaattgcgaa cg 42

<210> 1103
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1103
cactgaaaac acggttatgt cctagacgat aaattgcgaa cg 42

<210> 1104
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1104
cgagacagat cggagtagct gtagacgacc gaatttacgg 40

<210> 1105
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1105
tctctcaatg acgggacaaa gatagacgac cgaatttacg g 41

<210> 1106
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1106
cagatgtggt gtatggtcca catagacgac cgaatttacg g 41

<210> 1107
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1107
ttctcctcgg ttacttcgtg atagacgacc gaatttacgg 40

<210> 1108
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1108
tgtgctaagc cgaaggaggt tagacgaccg aatttacgg 39

<210> 1109
<211> 44

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1109
gtaaacatag aacgactcat agtcatagac gaccgaattt acgg 44

<210> 1110
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1110
ttccacttca attagctctt gaattagacg accgaattta cgg 43

<210> 1111
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1111
ctggggtaga gatagctcgc ttagacgacc gaatttacgg 40

<210> 1112
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1112
gctataagct cgcctacat tctagacgac cgaatttacg g 41

<210> 1113
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1113
ttcttggggc gggtagagtg tagacgaccg aatttacgg 39

<210> 1114
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1114
aagacctcag accgtcagaa gtagacgacc gaatttacgg 40

<210> 1115
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1115
tcagatcctg acgacctgca tagacgaccg aatttacgg 39

<210> 1116
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1116
gcagaaatct cgagaggacg ctagacgacc gaatttacgg 40

<210> 1117
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1117
ctcgcagtct aggccgaaga tagacgaccg aatttacgg 39

<210> 1118
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1118
ccggtctccc tcgagaatca tagacgaccg aatttacgg 39

<210> 1119
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1119
tcctggtgag aacgtcctgc tagacgaccg aatttacgg 39

<210> 1120
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1120
tgccctttgg taaggcgctt agacgaccga atttacgg 38

<210> 1121
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1121
cacagacaca gccgaggact agacgaccga atttacgg 38

<210> 1122
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1122
tcccaaaagc taccgctgag tagacgaccg aatttacgg 39

<210> 1123
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1123
taaggtagag tcgggcgaag tagacgaccg aatttacgg 39

<210> 1124
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1124
gagtggccgg aaaaaccgt agacgaccga atttacgg 38

<210> 1125
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1125

atgcgacat ggtcgcccta gacgaccgaa tttacgg 37

<210> 1126
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1126
ggctcccaa cgccctgata gacgaccgaa tttacgg 37

<210> 1127
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1127
tccatttcac cgtcagaaag gtagacgacc gaatttacgg 40

<210> 1128
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1128
ttgcctagac agcaccgtaa tgtagacacg aatattccaa ttc 43

<210> 1129
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1129
ttcccagagc gtggttccat agacacgaat attccaattc 40

<210> 1130
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1130
taaggacatc gcttttccgg ttagacacga atattccaat tc 42

<210> 1131
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1131
ttctccacgt cgcggacact agacacgaat attccaattc 40

<210> 1132
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1132
gttctcatga tagaggttcc ttaagtagac acgaatattc caattc 46

<210> 1133
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1133
ggccacgtcg gtgcagatag acacgaatat tccaattc 38

<210> 1134

<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1134
gttgtggacg atcaacgggg tagacacgaa tattccaatt c 41

<210> 1135
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1135
tgtccccttc ggggtcatat ctagacacga atattccaat tc 42

<210> 1136
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1136
aatagaacct catccggtag tggtagacac gaatattcca attc 44

<210> 1137
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1137
cagtcagcg tatgtggtat ttagacacga atattccaat tc 42

<210> 1138
<211> 42
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1138

aaagcttgtc cgattgatg gtagacacga atattccaat tc

42

<210> 1139

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1139

aacccttgta gatcggtggt atagacacga atattccaat tc

42

<210> 1140

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1140

agtagagaac gtttccaccg ttagacacga atattccaat tc

42

<210> 1141

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1141

actgctcatt gtcgttggtt ctagacacga atattccaat tc

42

<210> 1142

<211> 41

<212> DNA

<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 1142
 aacgtattgc cgagaacca tagacacgaa tattccaatt c 41

 <210> 1143
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 1143
 acaaagtgc tatagagtg cctagacacg aatattccaa ttc 43

 <210> 1144
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 1144
 agccatccct agacactcgt ttagacacga atattccaat tc 42

 <210> 1145
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 1145
 gcgatttgga gcataccaga gtagacacga atattccaat tc 42

 <210> 1146
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Target Specific Oligonucleotide

<400> 1146

aggatccgat cgaaactcag ctagacacga atattccaat tc

42

<210> 1147

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1147

ctggaatata tcgctttag ctgtagacac gaatattcca attc

44

<210> 1148

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1148

cttcaggtca tgcgtggaca tagacacgaa tattccaatt c

41

<210> 1149

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1149

agagaagcgc acttccgtgt tagacacgaa tattccaatt c

41

<210> 1150

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1150
tgatgttatc cgtg'gcagg tagacacgaa tattccaatt c 41

<210> 1151
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1151
aaagaccgta atcggttcaca ttgtagacac gaatattcca attc 44

<210> 1152
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1152
agagatttgt ctacgtagag ccgtagactc agaaatctca cg 42

<210> 1153
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1153
tcctttgcat acggtctctt cgtagactca gaaatctcac g 41

<210> 1154
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1154
aagtttgttt acatccgatg ttactagact cagaaatctc acg 43

<210> 1155
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1155
ttcccatata gaacgtggcc tagactcaga aatctcacg 39

<210> 1156
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1156
aacagatcaa cggcaaaagc ctagactcag aaatctcacg 40

<210> 1157
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1157
catccttggg tagtaggatg aactagactc agaaatctca cg 42

<210> 1158
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1158
gaatttgcta gttgcagggc atagactcag aaatctcacg 40

<210> 1159
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1159
tgatcttaca attgatactg tcaatgtaga ctcagaaatc tcacg 45

<210> 1160
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1160
tggatgtgga ggcgaccgtt agactcagaa atctcacg 38

<210> 1161
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1161
acttctggac ctatagtagc ctgtagactc agaaatctca cg 42

<210> 1162
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1162
caacacggat agcttatcca acctagactc agaaatctca cg 42

<210> 1163
<211> 40

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1163
tgtcaaggta acgtgagcac ttagactcag aaatctcacg 40

<210> 1164
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1164
tttacagaaa tcggcatcca catagactca gaaatctcac g 41

<210> 1165
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1165
cagctactag aggtctataa ttccttagac tcagaaatct cacg 44

<210> 1166
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1166
ctggcacctc tatggaatcc ctagactcag aaatctcacg 40

<210> 1167
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1167
 attctgatat cggctattgt gagatagact cagaaatctc acg 43

<210> 1168
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1168
 gccaccagtc tagtgccaac tagactcaga aatctcacg 39

<210> 1169
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1169
 caactacccc ggacaatttg atagactcag aaatctcacg 40

<210> 1170
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1170
 aggacttaac atgggctatg cctagactca gaaatctcac g 41

<210> 1171
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1171
 ctctgcgaac gaagtgtttt tgtagactca gaaatctcac g 41

<210> 1172
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1172
 tgcagcatat taaggtgttg attttagact cagaaatctc acg 43

<210> 1173
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1173
 aagtaactaa acccatagac tgaaatagac tcagaaatct cacg 44

<210> 1174
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1174
 ctgccagggc ttaacataag gtagactcag aaatctcacg 40

<210> 1175
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1175
ataacatttg atagggccac tcctagactc agaaatctca cg 42

<210> 1176
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1176
ctgaagataa tcgcagacac cctagacgtc tcccgtatatt t 41

<210> 1177
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1177
tgactgaaca cgtgttctgt tctagacgtc tcccgtatatt t 41

<210> 1178
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1178
tttcagccat acccggatgg tagacgtctc ccgtatattt 39

<210> 1179
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1179

tgagaagagt aaccgctgaa tatagacgtc tcccgtatatt t 41

<210> 1180
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1180
acactgcaat tccgccgtct agacgtctcc cgtatattt 38

<210> 1181
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1181
ttgtcgtggc cggctactgat agacgtctcc cgtatattt 38

<210> 1182
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1182
ggcaggcgac actaccttca tagacgtctc ccgtatattt 39

<210> 1183
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1183
ctgggccagt attgaccact gtagacgtct cccgtatattt 40

<210> 1184	
<211> 40	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 1184	
tctcagatca gtgcggagaa atagacgtct cccgtatattt	40
<210> 1185	
<211> 39	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 1185	
gcccacaaat atccgtctgc tagacgtctc ccgtatattt	39
<210> 1186	
<211> 36	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 1186	
ccatgttcgc gcggcgatag acgtctcccg tatattt	36
<210> 1187	
<211> 42	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Target Specific Oligonucleotide	
<400> 1187	
atgaaaggct gctagagaag tcctagacgt ctcccgtatt tt	42
<210> 1188	

<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1188
aatcacaac ccggacttgg atagacgtct cccgtatattt 40

<210> 1189
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1189
actagcctgt cacgtttgtc ttagacgtct cccgtatattt 40

<210> 1190
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1190
atctttacaa tgcggtcggc cctagacgtc tcccgtatatt t 41

<210> 1191
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1191
tgtcctggta tgatcccaac actagacgtc tcccgtatatt t 41

<210> 1192
<211> 41
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1192

ctgatcattt cgcatacacag tgtagacgtc tcccgtattt t

41

<210> 1193

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1193

ctttccttac gtgtgtcaca catagacgtc tcccgtattt t

41

<210> 1194

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1194

tagtttgatc gcctccttaa acctagacgt ctcccgtatt tt

42

<210> 1195

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1195

aaatccctag gatagcacct ttgtagacgt ctcccgtatt tt

42

<210> 1196

<211> 42

<212> DNA

<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1196
cttacactta cgatgagcag atgtagacgt ctcccgtatt tt 42

<210> 1197
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1197
catttgctac ctagcatatg agagtagacg tctcccgtat ttt 43

<210> 1198
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1198
acagatgtca aacggtcaca tttagacgtc tcccgtat ttt 41

<210> 1199
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1199
ttctaagata cgtcactcca attctagacg tctcccgtat ttt 43

<210> 1200
<211> 42
<212> DNA
<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1200

acagtccgtc gattctttac aatagactct ataatcagc gt

42

<210> 1201

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1201

tctccacgta aatcccgatc ttagactcta taaatcagcg t

41

<210> 1202

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1202

cacgtgctga accaaccact tagactctat aaatcagcgt

40

<210> 1203

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1203

tcttgccgaa gttggccggt agactctata aatcagcgt

39

<210> 1204

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1204
agcagcagtt ggatctacag ttagactcta taaatcagcg t 41

<210> 1205
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1205
gtctagcagt aaacctgtaa acctagactc tataaatcag cgt 43

<210> 1206
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1206
gtgcattatt ggacgaacat catagactct ataaatcagc gt 42

<210> 1207
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1207
gctgttggtta atggtctata atccatagac tctataaatc agcgt 45

<210> 1208
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1208
cacacatatc ctatgttcat caatatagac tctataaatc agcgt 45

<210> 1209
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1209
ttgagtgggtc gttttcttac acatagactc tataaatcag cgt 43

<210> 1210
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1210
cataatcaaa acgaaatggt tggttttagac tctataaatc agcgt 45

<210> 1211
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1211
tttgtagcat caacgtcctg gtagactcta taaatcagcg t 41

<210> 1212
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1212
caacacattt gacctccgt ttagactcta taaatcagcg t 41

<210> 1213
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1213
ctaaccaccg aatagattcc tggtagactc tataaatcag cgt 43

<210> 1214
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1214
gcagatgttt gaccggatgt ttagactcta taaatcagc g t 41

<210> 1215
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1215
tgcttgatgt attcggccat cgtagactct ataaatcagc gt 42

<210> 1216
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1216
tgagtttact tgcacggaaa ggtagactct ataaatcagc gt 42

<210> 1217
<211> 42

<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1217
cactttatcc cgcagttcag ttttagactct ataaatcagc gt 42

<210> 1218
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1218
gcaaagcatg tagccattcc ctagactcta taaatcagcg t 41

<210> 1219
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1219
aaagacatct cgagctgcta atgtagactc tataaatcag cgt 43

<210> 1220
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1220
gtcaccaccc atagtatgag ttttagactc tataaatcag cgt 43

<210> 1221
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

 <400> 1221
 tttctaccta aggctctgat gcatagactc tataaatcag cgt 43

 <210> 1222
 <211> 41
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 1222
 tagagctgca cggaaagatt ttagactcta taaatcagcg t 41

 <210> 1223
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 1223
 gtgtagcata tgaatcgaca tcatagactc tataaatcag cgt 43

 <210> 1224
 <211> 43
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Target Specific Oligonucleotide

 <400> 1224
 tagccttgta tggcagaatc gtagacctaa attactgtga atg 43

 <210> 1225
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1225
 tgaattgccc tgggtataac tcctagacct aaattactgt gaatg 45

<210> 1226
 <211> 42
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1226
 ttcctgttgc aacgtgaggg tagacctaaa ttactgtgaa tg 42

<210> 1227
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1227
 atgaaagaca cgatcaaaat tgaatagacc taaattactg tgaatg 46

<210> 1228
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1228
 gtcagcacga agtgagttca atagacctaa attactgtga atg 43

<210> 1229
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Target Specific Oligonucleotide

<400> 1229
cagtttgcag cgtagaatct cttagaccta aattactgtg aatg 44

<210> 1230
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1230
gtgcagataa tacgtgtctt tgctagacct aaattactgt gaatg 45

<210> 1231
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1231
tccaatgagt atgacaagtc cattagacct aaattactgt gaatg 45

<210> 1232
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1232
tgtaagaaag ctcggtcttc aaatagacct aaattactgt gaatg 45

<210> 1233
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1233

ccatgtaaga tacacgtaag agaatagacc taaattactg tgaatg 46

<210> 1234
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1234
gactcaagag catttcgtaa ttgtttagacc taaattactg tgaatg 46

<210> 1235
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1235
atgtcattag tcacctcaag ttcttagacc taaattactg tgaatg 46

<210> 1236
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1236
ccgcactcgc acgcagatag acctaaatta ctgtgaatg 39

<210> 1237
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1237
tgtaacagt atcgtgaata tcacttagac ctaaattact gtgaatg 47

<210> 1238
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1238
actttgccat ctataaggga ggtagacct aaattactgt gaatg 45

<210> 1239
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1239
cttgctatct cgataattta tgaaactaga cctaaattac tgtgaatg 48

<210> 1240
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1240
ttaatgtatc aagagtgtta ctgaaataga cctaaattac tgtgaatg 48

<210> 1241
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1241
tcaaatggga taccttaaca gatctagacc taaattactg tgaatg 46

<210> 1242

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1242
ataaataagc ttcgatttat attacagcta gacctaaatt actgtgaatg 50

<210> 1243
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1243
cttgtgtggt aggattaacc tggtagacct aaattactgt gaatg 45

<210> 1244
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1244
gttgggtcaac tcgagcatct ttagacctaa attactgtga atg 43

<210> 1245
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Target Specific Oligonucleotide

<400> 1245
tttggtttgt aggcctgtag cttagacctaa aattactgtg aatg 44

<210> 1246
<211> 45
<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1246

cattaggcag taactcttgt tcctagacct aaattactgt gaatg

45

<210> 1247

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> Target Specific Oligonucleotide

<400> 1247

cttctcagat acgcttcttc ttatagacct aaattactgt gaatg

45

<210> 1248

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1248

ggctaattta ttaccttcta gctataacga t

31

<210> 1249

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1249

accttaagaa tggaattcta gctataacga t

31

<210> 1250

<211> 30

<212> DNA

<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1250
acttaacttg agtgggtctag ctataacgat 30

<210> 1251
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1251
ggctaattta ttacctcggt ctagatgga 29

<210> 1252
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1252
accttaagaa tggaatcggt ctagatgga 29

<210> 1253
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1253
acttaacttg agtggcggtc tagatgga 28

<210> 1254
<211> 32
<212> DNA
<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1254

ggctaattta ttacctgtta actccgtagt aa

32

<210> 1255

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1255

accttaagaa tggaatgtta actccgtagt aa

32

<210> 1256

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1256

acttaacttg agtgggttaa ctccgtagta a

31

<210> 1257

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1257

ggctaattta ttacctcgct atatctactg a

31

<210> 1258

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1258
accttaagaa tggaatcgct atatctactg a 31

<210> 1259
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1259
acttaacttg agtggcgcta tatctactga 30

<210> 1260
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1260
ggctaattta ttacctgttt ccgtttcgaa 30

<210> 1261
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1261
accttaagaa tggaatgttt ccgtttcgaa 30

<210> 1262
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1262
acttaacttg agtgggtttc cgtttcgaa 29

<210> 1263
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1263
ggctaattta ttaccttagc gtttcaaag 30

<210> 1264
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1264
accttaagaa tggaattagc gtttcaaag 30

<210> 1265
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1265
acttaacttg agtggtagcg tttcaaag 29

<210> 1266
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1266
ggctaattta ttaccttgat ccgacgag 28

<210> 1267
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1267
accttaagaa tggaattgat cgcacgag 28

<210> 1268
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1268
acttaacttg agtggtgatc cgacgag 27

<210> 1269
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1269
ggctaattta ttacctaadc tacatgtctg a 31

<210> 1270
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1270
accttaagaa tggaataatc tacatgtctg a 31

<210> 1271
<211> 30

<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1271
acttaacttg agtggaatct acatgtctga 30

<210> 1272
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1272
ggctaattta ttacctggac gttgaataca 30

<210> 1273
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1273
accttaagaa tggaatggac gttgaataca 30

<210> 1274
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1274
acttaacttg agtggggacg ttgaataca 29

<210> 1275
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1275
ggctaattta ttaccttaaa gtgacaattc a 31

<210> 1276
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1276
accttaagaa tggaattaaa gtgacaattc a 31

<210> 1277
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1277
acttaacttg agtggttaaag tgacaattca 30

<210> 1278
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1278
ggctaattta ttacctgatt cccataatta gg 32

<210> 1279
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1279
accttaagaa tggaatgatt cccataatta gg 32

<210> 1280
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1280
acttaacttg agtgggattc ccataattag g 31

<210> 1281
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1281
ggctaattta ttacctcgtc gtataaatct atc 33

<210> 1282
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1282
accttaagaa tggaatcgtc gtataaatct atc 33

<210> 1283
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1283
acttaacttg agtggcgtcg tataaatcta tc 32

<210> 1284
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1284
ggctaattta ttacctgatg tctatccttt ataa 34

<210> 1285
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1285
acctaagaa tggaatgatg tctatccttt ataa 34

<210> 1286
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1286
acttaacttg agtgggatgt ctatccttta taa 33

<210> 1287
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1287

ggctaattta ttaccttttc cacgataacc 30

<210> 1288
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1288
accttaagaa tggaattttc cacgataacc 30

<210> 1289
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1289
acttaacttg agtggtttcc acgataacc 29

<210> 1290
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1290
ggctaattta ttaccttagt accgaataag g 31

<210> 1291
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1291
accttaagaa tggaattagt accgaataag g 31

<210> 1292
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1292
acttaacttg agtggtagta ccgaataagg 30

<210> 1293
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1293
ggctaattta ttaccttaaa gttgtaaaat cc 32

<210> 1294
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1294
accttaagaa tggaattaaa gttgtaaaat cc 32

<210> 1295
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1295
acttaacttg agtggtaaag ttgtaaaatc c 31

<210> 1296

<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1296
ggctaattta ttacctggat aagtcggtaa tc 32

<210> 1297
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1297
accttaagaa tggaatggat aagtcggtaa tc 32

<210> 1298
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1298
acttaacttg agtggggata agtcggtaat c 31

<210> 1299
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1299
ggctaattta ttacctggta tttcactcta att 33

<210> 1300
<211> 33
<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1300

accttaagaa tggaatggta tttcactcta att

33

<210> 1301

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1301

acttaacttg agtgggggtat ttcactctaa tt

32

<210> 1302

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1302

ggctaattta ttacctagct agataaagta cc

32

<210> 1303

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1303

accttaagaa tggaatagct agataaagta cc

32

<210> 1304

<211> 31

<212> DNA

<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1304
acttaacttg agtggagcta gataaagtac c 31

<210> 1305
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1305
ggctaattta ttacctccga aactacgatt at 32

<210> 1306
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1306
acctaagaa tggaatccga aactacgatt at 32

<210> 1307
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1307
acttaacttg agtggccgaa actacgatta t 31

<210> 1308
<211> 32
<212> DNA
<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1308

ggctaattta ttacctcatc gaatttatgt ta

32

<210> 1309

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1309

accttaagaa tggaatcatc gaatttatgt ta

32

<210> 1310

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1310

acttaacttg agtggcatcg aatttatggt a

31

<210> 1311

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1311

ggctaattta ttacctccgt aattctaccg

30

<210> 1312

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1312
accttaagaa tggaatccgt aattctaccg 30

<210> 1313
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1313
acttaacttg agtggccgta attctaccg 29

<210> 1314
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1314
ggctaattta ttacctgggt aatcgtcac 29

<210> 1315
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1315
accttaagaa tggaatgggt aatcgtcac 29

<210> 1316
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1316
acttaacttg agtgggggta atcgtcac 28

<210> 1317	
<211> 31	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Decoding Oligonucleotide	
<400> 1317	
ggctaattta ttacctagtg ttatgagaag c	31
<210> 1318	
<211> 31	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Decoding Oligonucleotide	
<400> 1318	
accttaagaa tggaatagtg ttatgagaag c	31
<210> 1319	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Decoding Oligonucleotide	
<400> 1319	
acttaacttg agtggagtgt tatgagaagc	30
<210> 1320	
<211> 31	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Decoding Oligonucleotide	
<400> 1320	
ggctaattta ttacctctgc aatagaagag a	31

<210> 1321
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1321
accttaagaa tggaatctgc aatagaagag a 31

<210> 1322
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1322
acttaacttg agtggctgca atagaagaga 30

<210> 1323
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1323
ggctaattta ttacctgatt tttcagcgac 30

<210> 1324
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1324
accttaagaa tggaatgatt tttcagcgac 30

<210> 1325
<211> 29

<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1325
acttaacttg agtgggattt ttcagcgac 29

<210> 1326
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1326
ggctaattta ttacctcgta atatgaagat ca 32

<210> 1327
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1327
accttaagaa tggaatcgta atatgaagat ca 32

<210> 1328
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1328
acttaacttg agtggcgtaa tatgaagatc a 31

<210> 1329
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1329
ggctaattta ttacctgaat tggaatattc gt 32

<210> 1330
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1330
accttaagaa tggaatgaat tggaatattc gt 32

<210> 1331
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1331
acttaacttg agtgggaatt ggaatattcg t 31

<210> 1332
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1332
ggctaattta ttacctggta ttaatcttga aga 33

<210> 1333
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
 <223> Decoding Oligonucleotide

<400> 1333
 accttaagaa tggaatggta ttaatcttga aga 33

<210> 1334
 <211> 32
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Decoding Oligonucleotide

<400> 1334
 acttaacttg agtggggtat taatcttgaa ga 32

<210> 1335
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Decoding Oligonucleotide

<400> 1335
 ggctaattta ttacctacga tgtattgcc 29

<210> 1336
 <211> 29
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Decoding Oligonucleotide

<400> 1336
 accttaagaa tggaatacga tgtattgcc 29

<210> 1337
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Decoding Oligonucleotide

<400> 1337
acttaacttg agtggacgat gtattgcc 28

<210> 1338
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1338
ggctaattta ttacctcata taaaacggt ac 32

<210> 1339
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1339
acctaagaa tggaatcata taaaacggt ac 32

<210> 1340
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1340
acttaacttg agtggcatat aaaaacggt c 31

<210> 1341
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1341

ggctaattta ttacctttcc gatcttaact t 31

<210> 1342
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1342
accttaagaa tggaatttcc gatcttaact t 31

<210> 1343
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1343
acttaacttg agtggttccg atcttaactt 30

<210> 1344
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1344
ggctaattta ttacctgtgt taattcgcat c 31

<210> 1345
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1345
accttaagaa tggaatgtgt taattcgcat c 31

<210> 1346
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1346
acttaacttg agtgggtggtt aattcgcac 30

<210> 1347
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1347
ggctaattta ttacctcggtt taattgggct 30

<210> 1348
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1348
accttaagaa tggaatcggtt taattgggct 30

<210> 1349
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1349
acttaacttg agtggcggtt aattgggct 29

<210> 1350

<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1350
ggctaattta ttacctcaac attataacg g 31

<210> 1351
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1351
accttaagaa tggaatcaac attataacg g 31

<210> 1352
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1352
acttaacttg agtggcaaca cttataacgg 30

<210> 1353
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1353
ggctaattta ttacctggaa ataagtatta tacc 34

<210> 1354
<211> 34
<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1354

accttaagaa tggaatggaa ataagtatta tacc

34

<210> 1355

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1355

acttaacttg agtggggaaa taagtattat acc

33

<210> 1356

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1356

ggctaattta ttaccttta acgacggtt

29

<210> 1357

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1357

accttaagaa tggaatctta acgacggtt

29

<210> 1358

<211> 28

<212> DNA

<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1358
acttaacttg agtggcttaa cgacggtt 28

<210> 1359
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1359
ggctaattta ttacctgctc gttagaattt att 33

<210> 1360
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1360
accttaagaa tggaatgctc gttagaattt att 33

<210> 1361
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1361
acttaacttg agtgggctcg ttagaattta tt 32

<210> 1362
<211> 32
<212> DNA
<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1362

ggctaattta ttaccttctt tatcatcatt ga

32

<210> 1363

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1363

accttaagaa tggaattctt tatcatcatt ga

32

<210> 1364

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1364

acttaacttg agtggctctt atcatcattg a

31

<210> 1365

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1365

ggctaattta ttacctcggt cgcaatttat c

31

<210> 1366

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1366
accttaagaa tggaatcggt cgcaatttat c 31

<210> 1367
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1367
acttaacttg agtggcggtt gcaatttatc 30

<210> 1368
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1368
ggctaattta ttacctgat cttttgttgt a 31

<210> 1369
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1369
accttaagaa tggaatcgat cttttgttgt a 31

<210> 1370
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1370
acttaacttg agtggcgatc ttttgttgta 30

<210> 1371
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1371
ggctaattta ttacctacca ctcaatataa ga 32

<210> 1372
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1372
accttaagaa tggaatacca ctcaatataa ga 32

<210> 1373
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1373
acttaacttg agtggaccac tcaatataag a 31

<210> 1374
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1374
ggctaattta ttacctccgt aaattcggtc 30

<210> 1375
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1375
accttaagaa tggaatccgt aaattcggtc 30

<210> 1376
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1376
acttaacttg agtggccgta aattcggtc 29

<210> 1377
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1377
ggctaattta ttacctcgtg agatttctga 30

<210> 1378
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1378
accttaagaa tggaatcgtg agatttctga 30

<210> 1379
<211> 29

<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1379
acttaacttg agtggcgtga gatttctga 29

<210> 1380
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1380
ggctaattta ttacctcgaa gcatagaata g 31

<210> 1381
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1381
accttaagaa tggaatcgaa gcatagaata g 31

<210> 1382
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1382
acttaacttg agtggcgaag catagaatag 30

<210> 1383
<211> 30
<212> DNA
<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1383

ggctaattta ttacataaaa tacgggagac

30

<210> 1384

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1384

acctaagaa tggaataaaa tacgggagac

30

<210> 1385

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1385

acttaacttg agtggaaaat acgggagac

29

<210> 1386

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Decoding Oligonucleotide

<400> 1386

ggctaattta ttacctcgca tggataaca t

31

<210> 1387

<211> 31

<212> DNA

<213> Artificial Sequence

<220>
 <223> Decoding Oligonucleotide

<400> 1387
 accttaagaa tggaatcgca tggataaca t 31

<210> 1388
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Decoding Oligonucleotide

<400> 1388
 acttaacttg agtggcgcat ggtataacat 30

<210> 1389
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Decoding Oligonucleotide

<400> 1389
 ggctaattta ttacctacgc tgatttatag a 31

<210> 1390
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Decoding Oligonucleotide

<400> 1390
 accttaagaa tggaatcgca tgatttatag a 31

<210> 1391
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Decoding Oligonucleotide

<400> 1391
acttaacttg agtggacgct gatttataga 30

<210> 1392
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1392
ggctaattta ttacctcgta gggtaaatag att 33

<210> 1393
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1393
acctaagaa tggaatcgta gggtaaatag att 33

<210> 1394
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1394
acttaacttg agtggcgtag ggtaaataga tt 32

<210> 1395
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1395

ggctaattta ttacctcatt cacagtaatt tag 33

<210> 1396
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1396
accttaagaa tggaatcatt cacagtaatt tag 33

<210> 1397
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Decoding Oligonucleotide

<400> 1397
acttaacttg agtggcattc acagtaattt ag 32

<210> 1398
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Signal Oligonucleotide

<400> 1398
ccactcaagt taagt 15

<210> 1399
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Signal Oligonucleotide

<400> 1399
attccattct taaggt 16

<210> 1400
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Signal Oligonucleotide

<400> 1400
aggtaataaa ttagcc